

Prevalence of HIV, HCV and injecting and sexual behaviour
among IDU at Needle and Syringe Programs

**AUSTRALIAN NSP SURVEY
NATIONAL DATA REPORT
1995 - 2002**

Report prepared by Megan Buddle, Jialun Zhou and Margaret MacDonald

National Centre in HIV Epidemiology and Clinical Research
The University of New South Wales

July 2003

The NCHECR and the Australian NSP surveys are funded by
the Commonwealth Department of Health and Ageing.

© National Centre in HIV Epidemiology and Clinical Research 2003

ISSN 1448-5915

Suggested citation:

National Centre in HIV Epidemiology and Clinical Research. Australian NSP Survey
National Data Report 1995-2002. National Centre in HIV Epidemiology and Clinical
Research, The University of New South Wales, Sydney, NSW. 2003.

National Centre in HIV Epidemiology and Clinical Research
Level 2, 376 Victoria Street, Darlinghurst NSW 2010 Australia

Telephone: 02 9332 4648 Facsimile: 02 9332 1837 International prefix: 612 E-mail: receipt@nchecr.unsw.edu.au

Table of Contents

Summary	1
Introduction	1
Injecting behaviour	2
Sexual behaviour.....	4
HIV prevalence.....	5
HCV prevalence	5
 Tables	9
National	9
Australian Capital Territory	31
New South Wales.....	41
Northern Territory	63
Queensland.....	73
South Australia.....	95
Tasmania	113
Victoria	119
Western Australia	139
 Methodological notes.....	149
NSP survey questionnaire	150
Participating Sites.....	154
Acknowledgements	155
List of Tables	157

Summary

Key points

- **Amphetamine injection increased in 2001 and 2002 and heroin injection decreased, reflecting the reduced availability of heroin in Australia in 2001.**
- **Use of new sterile needles and syringes for all injections in the month before the survey was high, reported by two-thirds of participants.**
- **One in five participants reported reuse of someone else's syringe in the past month, a rate that has remained stable from 1997 to 2002.**
- **HIV antibody prevalence remained low, except among participants reporting homosexual identity.**
- **Hepatitis C antibody prevalence increased annually among new heroin injectors since 1998 and among new amphetamine injectors since 2000.**

Introduction

This report presents national and state and territory data from annually repeated cross-sectional surveys of clients at selected Needle and Syringe Programs (NSPs) from 1995 to 2002. Each year, NSP staff at participating sites asked all clients attending during the designated survey week, usually in October, to complete a brief questionnaire and provide a finger-prick blood sample for HIV and hepatitis C antibody testing. The purpose of the surveys was to monitor HIV and hepatitis C infection and related risk behaviours among injecting drug users (IDU) attending NSP services.

The number of participating NSP sites increased from 21 in 1995 to 46 in 2002. The annual response rate varied from 41% to 60% (Table 1, page 9). The surveys recruited more male (65% to 67%) than female (32% to 35%) participants. Median age at survey increased from 27 (1997) to 30 (2002) years and median duration of drug injection increased from 7 (1998) to 10 (2002) years. Median age of first drug injection remained stable (18 years). Around 15% to 20% of participants each year reported imprisonment in the year before the survey (Table 1, page 9). Nearly two thirds of participants reported that they had been tested for HIV and/or HCV antibody in the year before the survey (Table 6, page 13).

Injecting behaviour

Heroin was most frequently reported as the type of drug last injected in each year except 2001. Reporting of heroin injection decreased from 2000 (56%) to 2001 (30%) and 2002 (36%, Table 1, page 9), in line with the reduced availability of heroin in Australia in 2001. At the same time, reporting of amphetamine increased from 2000 (22%) to 2001 (37%) and 2002 (33%). Reporting of cocaine injection also increased in 2001. Changes in reporting of heroin and amphetamine from 2000 to 2002 were reported consistently from all states and territories (Figure 1). A concurrent change in the proportion of participants reporting daily or more frequent injection was also reported (58%, 46% and 50%, Table 1, page 9).

In 2002, buprenorphine was first reported in the “other” category for the type of drug last injected by participants in Queensland (1%), South Australia (1%), Tasmania (1%), Victoria (5%) and Western Australia (4%).




Figure 1: Reporting of amphetamine and heroin as the type of drug last injected by state and territory, 2000-2002.

Reporting of use of new sterile syringes for all injections in the past month was high nationally (65% to 72%, Table 2, page 10) and in all states and territories (Figure 2). Reporting of reuse of someone else's syringe in the past month has remained at around 20% from 1997 to 2002 (Table 2, page 10). Reuse of someone else's syringe was generally reported after only one person (10% of all participants) in 2002, usually a regular sex partner (7% of all participants) or a close friend (5% of all participants).




Figure 2: Reporting of use of new sterile syringes for all injections and reuse of someone else's syringe in the past month by year of survey and state and territory.

Over 40% of participants from ACT and Victoria reported injection on streets, parks or beaches in the past month, 20% to 40% of participants from Queensland, New South Wales and Western Australia and less than 20% from South Australia, Tasmania and Northern Territory (Figure 3).




Figure 3: Reporting of injecting on streets, parks or beaches in the past month by year of survey and state and territory.

Sexual behaviour

Condom use remained stable with one-third of participants reporting use of condoms with their last sex partners (Table 5, page 12). Reporting of consistent condom use with new sex partner(s) in the month before survey decreased from around 50% from 1996 to 2000, to around 40% in 2001 and 2002 (Figure 4). Around 20% of participants reported consistent condom use with their regular sex partners in the past month. Over half (59% in 2001 and 66% in 2002) reported more than twelve months duration of relationship with their current regular sex partner.

Less than 10% of participants reported sex work in the month before survey and around 90% of participants reporting sex work in the month before survey also reported using condoms last sex work (Table 5, page 12).




Figure 4: Reporting of consistent condom use with new sex partner(s) in the past month by year of survey and state and territory.

HIV prevalence

HIV antibody prevalence was low, decreasing from 2.1% in 1995 to 1.3% in 2002 (Table 7, page 14). HIV prevalence remained higher each year among male participants reporting homosexual identity than among males reporting bisexual or heterosexual identity or female participants (Table 8, page 14; Figure 5). HIV prevalence was around 2% among participants in New South Wales and Queensland, less than 1% in South Australia and Victoria and zero in other states and territories in 2002.




Figure 5: HIV prevalence by year of survey, sex and sexual identity.

HCV prevalence

Hepatitis C antibody prevalence increased from 1996/99 (49% to 50%) to 2000/02 (54% to 56%, Table 17, page 23). A trend of annually increasing HCV prevalence was found among participants aged less than 25 years nationally and from all states and territories since 1997 (Figure 6).




Figure 6: Hepatitis C prevalence among respondents aged less than 25 years by state and territory, 1997-2002.

HCV prevalence also increased among male and female participants reporting less than three years of drug injection, in particular among heroin injectors from 1998 to 2002 and among amphetamine injectors from 2000 to 2002 (Figure 8).




Figure 8: Hepatitis C prevalence and 95% confidence intervals among participants reporting less than three years of drug injection by type of drug injected, sex and year of survey.

HCV prevalence was significantly higher among participants reporting imprisonment in the previous year regardless of duration of drug injection (Figure 9).




Figure 9: Hepatitis C prevalence among participants by duration of drug injection and imprisonment in the previous year, 2001 and 2002.

**NATIONAL
1995-2002**

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	21	20	24	32	34	35	38	46
Response								
Nº surveyed	N = 1072	N = 1497	N = 1978	N = 2665	N = 2503	N = 2694	N = 2454	N = 2445
Response (%)	41%	54%	60%	42%	45%	50%	46%	42%
Sex (%)								
Male	703 (66)	1003 (67)	1297 (66)	1719 (65)	1616 (65)	1760 (65)	1616 (66)	1618 (66)
Female	353 (33)	477 (32)	674 (34)	935 (35)	875 (35)	918 (34)	814 (33)	806 (33)
Transgender	3 (<1)	1 (<1)	6 (<1)	6 (<1)	9 (<1)	10 (<1)	17 (1)	14 (1)
Not reported	13 (1)	16 (1)	1 (<1)	5 (<1)	3 (<1)	6 (<1)	7 (<1)	7 (<1)
Sexual identity (%)								
Heterosexual	848 (79)	1168 (78)	1564 (79)	2158 (81)	1890 (76)	2069 (77)	1893 (77)	1858 (76)
Bisexual	126 (12)	164 (11)	223 (11)	244 (9)	312 (12)	291 (11)	234 (10)	260 (11)
Gay/lesbian	69 (6)	111 (7)	118 (6)	159 (6)	132 (5)	169 (6)	136 (5)	101 (4)
Not reported	29 (3)	54 (4)	73 (4)	104 (4)	169 (7)	165 (6)	191 (8)	226 (9)
Age and duration of injection (years)								
Median age	29	28	27	28	28	28	29	30
Age range	14-54	13-59	15-58	14-63	14-69	14-61	14-62	14-63
Nº not reported	8	5	1	2	6	5	5	5
Median age 1 st IDU	18	18	18	18	18	18	18	18
Age range	9-48	9-48	7-50	7-47	7-55	9-54	6-53	7-56
Nº not reported	20	49	42	52	64	72	76	72
Median years IDU	10	8	8	7	8	8	9	10
Range	<1-33	<1-37	<1-37	<1-40	<1-36	<1-41	<1-44	<1-43
Nº not reported	23	50	43	53	66	75	79	73
Aboriginal and Torres Strait Islander Origin (%)								
Yes	52 (5)	66 (4)	101 (5)	167 (6)	182 (7)	233 (9)	188 (8)	183 (8)
No	987 (92)	1333 (89)	1844 (93)	2442 (92)	2237 (90)	2391 (88)	2196 (89)	2183 (89)
Not reported	33 (3)	98 (7)	33 (2)	56 (2)	84 (3)	7 (3)	70 (3)	79 (3)
Imprisonment last year (%)								
Yes	159 (15)	181 (12)	285 (14)	439 (16)	397 (16)	486 (18)	424 (17)	407 (17)
No	897 (84)	1261 (84)	1684 (85)	2193 (83)	2070 (83)	2142 (80)	1947 (80)	1992 (81)
Not reported	16 (1)	55 (4)	9 (1)	33 (1)	36 (1)	66 (2)	83 (3)	46 (2)
Injected in prison (%)								
N = 159	N = 181	N = 285	N = 439	N = 397	N = 486	N = 424	N = 407	
Yes	55 (35)	74 (41)	109 (38)	182 (41)	166 (42)	202 (42)	156 (37)	149 (37)
Frequency of injection last month (%)								
Not last month	80 (7)	103 (7)	139 (7)	150 (6)	174 (7)	171 (6)	223 (9)	225 (9)
Less than weekly	195 (18)	292 (19)	494 (25)	349 (13)	369 (15)	340 (13)	447 (18)	393 (16)
Weekly not daily	352 (33)	490 (33)	311 (16)	632 (24)	55 (22)	599 (22)	607 (25)	581 (24)
Daily or more	438 (41)	601 (40)	1023 (51)	1529 (57)	1388 (55)	1547 (58)	1135 (46)	1221 (50)
Not reported	7 (1)	11 (1)	11 (1)	5 (<1)	22 (1)	37 (1)	42 (2)	26 (1)
Last drug injected (%)								
Amphetamine	233 (22)	278 (18)	367 (18)	570 (21)	647 (26)	582 (22)	914 (37)	809 (33)
Anabolic steroids	11 (1)	30 (2)	34 (2)	30 (1)	40 (2)	43 (2)	31 (1)	47 (2)
Benzos	1 (<1)	3 (<1)	8 (<1)	7 (<1)	6 (<1)	6 (<1)	11 (<1)	8 (<1)
Buprenorphine	---	---	---	---	---	---	---	25 (1)
Cocaine	18 (2)	33 (2)	37 (2)	65 (2)	60 (2)	32 (1)	164 (7)	29 (1)
Heroin	470 (44)	796 (53)	1090 (55)	1369 (51)	1333 (53)	1517 (56)	745 (30)	881 (36)
Heroin + Cocaine	8 (1)	15 (1)	27 (1)	77 (3)	49 (2)	75 (3)	105 (4)	42 (2)
Methadone	204 (19)	169 (11)	211 (11)	220 (8)	84 (3)	94 (3)	127 (5)	165 (7)
Morphine	29 (3)	41 (3)	77 (4)	116 (4)	95 (4)	97 (4)	151 (6)	180 (7)
More than one	84 (8)	114 (8)	108 (5)	189 (7)	150 (6)	199 (7)	153 (6)	204 (8)
Other	8 (1)	13 (1)	8 (<1)	7 (<1)	6 (<1)	8 (<1)	15 (1)	22 (1)
Not reported	6 (1)	5 (<1)	11 (1)	15 (1)	33 (1)	40 (1)	38 (2)	33 (1)

NATIONAL

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 985	N = 1383	N = 1828	N = 2510	N = 2307	N = 2486	N = 2189	N = 2194
Places injected last month (%)*								
Own home	1539 (84)	2103 (84)	1873 (81)	2030 (82)	1751 (80)	1770 (81)		
Friend's home	903 (49)	1184 (47)	1032 (45)	1161 (47)	1003 (46)	918 (42)		
Dealer's home	336 (18)	483 (19)	447 (19)	509 (20)	442 (20)	400 (18)		
Street, park	543 (30)	744 (30)	712 (31)	843 (34)	578 (26)	576 (26)		
Car	164 (9)	836 (33)	910 (39)	1016 (41)	762 (35)	767 (35)		
Public toilet	536 (29)	649 (26)	683 (30)	795 (32)	545 (25)	560 (26)		
Shooting room	118 (6)	134 (5)	75 (3)	74 (3)	67 (3)	60 (3)		
Squat			184 (8)	260 (10)	190 (9)	176 (8)		
Use of new sterile needles & syringes last month (%)								
All injections	1215 (66)	1628 (65)	1530 (66)	1688 (67)	1568 (72)	1591 (72)		
Most of the time	494 (27)	640 (26)	600 (26)	610 (24)	492 (22)	466 (21)		
Half of the time	38 (2)	86 (3)	75 (3)	71 (3)	41 (2)	57 (3)		
Some of the time	21 (1)	84 (3)	27 (1)	38 (2)	30 (1)	28 (1)		
Not last month	11 (1)	7 (<1)	8 (<1)	13 (1)	9 (<1)	17 (1)		
Not reported	49 (3)	65 (3)	67 (3)	66 (3)	49 (2)	35 (2)		
Re-used another's syringe last month (%)								
None	677 (69)	1001 (72)	1485 (81)	2010 (80)	1734 (75)	1986 (80)	1777 (81)	1767 (80)
Once	101 (10)	155 (11)	76 (4)	151 (6)	165 (7)	155 (6)	123 (6)	112 (5)
Twice	101 (10)	116 (8)	72 (4)	126 (5)	107 (5)	113 (5)	77 (3)	102 (5)
3-5 times	71 (7)	64 (5)	70 (4)	98 (4)	94 (4)	88 (4)	69 (3)	74 (3)
>5 times	34 (3)	44 (3)	42 (2)	62 (2)	75 (3)	55 (2)	60 (3)	56 (3)
Not reported	1 (<1)	3 (<1)	83 (5)	63 (3)	132 (6)	89 (3)	85 (4)	83 (4)
Number of people syringe was re-used after last month (%)								
None	677 (69)	1001 (72)	1485 (81)	2010 (80)	1734 (75)	1986 (80)	1777 (81)	1767 (80)
One	187 (19)	242 (18)	255 (14)	354 (14)	360 (16)	315 (13)	190 (9)	209 (10)
Two	87 (9)	121 (9)	32 (2)	54 (2)	46 (2)	34 (1)	28 (1)	32 (2)
Three to five	12 (1)	6 (<1)	8 (<1)	14 (1)	31 (1)	30 (1)	20 (1)	18 (<1)
More than five	12 (1)	10 (1)	7 (<1)	10 (<1)	32 (1)	24 (1)	20 (1)	18 (<1)
Don't know	9 (1)	2 (<1)	0 (0)	5 (<1)	21 (1)	14 (1)	31 (1)	38 (2)
Not reported	1 (<1)	1 (<1)	41 (2)	63 (3)	83 (4)	83 (3)	123 (6)	112 (5)
Relationship to people syringe was re-used after last month* (%)								
Regular sex partner	175 (10)	255 (10)	271 (12)	226 (9)	177 (8)	157 (7)		
Casual sex partner	12 (1)	24 (1)	24 (1)	26 (1)	25 (1)	20 (1)		
Close friend	72 (4)	135 (5)	155 (7)	124 (5)	93 (4)	99 (5)		
Acquaintance	24 (1)	42 (2)	52 (2)	54 (2)	49 (2)	34 (2)		
Other	1 (<1)	4 (<1)	33 (1)	24 (1)	14 (1)	20 (1)		
Equipment used after someone else last month* (%)								
Spoon			926 (40)	821 (33)	626 (29)	594 (27)		
Water			651 (28)	550 (22)	457 (21)	479 (21)		
Filter			525 (23)	455 (18)	348 (16)	393 (18)		
Drug mix			425 (18)	341 (14)	303 (14)	344 (16)		
Tourniquet			381 (17)	313 (13)	295 (13)	293 (13)		
Injected by someone else who'd already injected themselves or others last month (%)								
Yes			376 (17)	409 (17)	410 (19)	379 (17)		
No			1808 (78)	1964 (79)	1689 (77)	1736 (79)		
Not reported			123 (5)	110 (4)	90 (4)	79 (4)		

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 1072	N = 1497	N = 1978	N = 2665	N = 2503	N = 2694	N = 2454	N = 2445
Any treatment/therapy for drug use (%)								
No	333 (31)	498 (33)	619 (31)	912 (34)	880 (35)	812 (30)	783 (32)	721 (29)
Yes	734 (68)	990 (66)	1354 (68)	1745 (65)	1606 (64)	1831 (68)	1651 (67)	1700 (70)
Not reported	5 (1)	9 (1)	5 (1)	8 (1)	17 (1)	51 (2)	20 (1)	20 (1)
History of methadone treatment (%)								
Currently	426 (40)	528 (35)	666 (34)	828 (31)	699 (28)	710 (26)	649 (26)	648 (27)
Previously	170 (16)	273 (18)	369 (19)	485 (18)	518 (21)	675 (25)	586 (24)	636 (26)
Never	471 (44)	687 (46)	938 (47)	1344 (50)	1272 (51)	1292 (48)	1192 (49)	1130 (46)
Not reported	5 (<1)	9 (1)	5 (<1)	8 (1)	12 (<1)	17 (1)	27 (1)	30 (1)
History of other pharmacological therapy (%)								
Currently				47 (2)	42 (2)	62 (2)	116 (5)	206 (8)
Previously				80 (3)	157 (6)	289 (11)	246 (10)	312 (13)
Never				2488 (93)	1504 (60)	2084 (77)	2035 (83)	1875 (77)
Not reported				49 (2)	798 (32)	258 (10)	57 (2)	51 (2)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 2503	N = 2694	N = 2454	N = 2445
From an NSP last month (%)								
Daily or almost daily					457 (18)	526 (20)	331 (14)	364 (15)
A couple of times each week					744 (30)	858 (32)	692 (28)	646 (26)
Less than weekly					568 (23)	576 (21)	592 (24)	615 (25)
Once last month					404 (16)	381 (14)	449 (18)	430 (18)
Not in the last month					273 (11)	298 (11)	335 (14)	325 (13)
Not reported					57 (2)	55 (2)	55 (2)	65 (3)
From a chemist last month (%)								
Daily or almost daily					147 (6)	171 (6)	122 (5)	135 (6)
A couple of times each week					333 (11)	395 (15)	271 (11)	267 (11)
Less than weekly					458 (18)	427 (16)	370 (15)	330 (13)
Once last month					480 (19)	474 (18)	461 (19)	449 (18)
Not in the last month					1002 (40)	1138 (42)	1147 (47)	1175 (48)
Not reported					83 (4)	89 (3)	83 (3)	89 (4)

NATIONAL

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 1072	N = 1497	N = 1978	N = 2665	N = 2503	N = 2694	N = 2454	N = 2445
Sex last month (%)								
Yes	762 (71)	1070 (71)	1289 (65)	1807 (68)	1687 (68)	1763 (66)	1696 (69)	1706 (70)
No	260 (24)	397 (27)	680 (34)	831 (31)	783 (31)	898 (33)	714 (29)	682 (28)
Not reported	50 (5)	30 (2)	9 (1)	27 (1)	33 (1)	33 (1)	44 (2)	57 (2)
Condom use last sex (%)								
Yes	281 (26)	351 (23)	699 (35)	904 (34)	879 (35)	964 (36)	797 (32)	813 (33)
No	602 (56)	689 (46)	1251 (64)	1691 (63)	1548 (62)	1638 (61)	1561 (64)	1577 (65)
Not reported	189 (18)	457 (31)	28 (1)	70 (3)	76 (3)	92 (3)	96 (4)	55 (2)
Condom use with regular sex partner(s) last month (%)*								
No	629 (66)	782 (66)	965 (65)	971 (68)	970 (66)	747 (65)	721 (64)	
Sometimes	115 (12)	160 (14)	193 (13)	164 (11)	164 (11)	174 (15)	144 (13)	
Always	209 (22)	243 (20)	320 (22)	301 (21)	338 (23)	235 (20)	266 (24)	
Condom use with new sex partner(s) last month (%)*								
No	130 (33)	175 (32)	141 (33)	238 (39)	192 (32)	380 (42)	356 (42)	
Sometimes	42 (11)	68 (13)	65 (15)	74 (12)	80 (14)	153 (17)	128 (15)	
Always	219 (56)	294 (55)	220 (52)	295 (49)	317 (54)	369 (41)	361 (43)	
Condom use with casual sex partner(s) last month (%)*								
No		188 (31)	260 (36)	257 (34)	323 (42)	321 (41)		
Sometimes		104 (17)	110 (15)	113 (15)	141 (18)	142 (18)		
Always		314 (52)	353 (49)	392 (51)	305 (40)	314 (40)		
Duration of regular sexual relationship (%)**								
One month					103 (9)	90 (7)		
2 - 6 months					196 (17)	174 (14)		
6 - 12 months					167 (15)	158 (13)		
>12 months					687 (59)	797 (66)		
Sex work last month (%)								
Yes	54 (5)	104 (7)	155 (8)	167 (6)	221 (9)	258 (10)	224 (9)	201 (8)
No	979 (91)	1321 (88)	1781 (90)	2435 (92)	2216 (89)	2356 (87)	2130 (87)	2171(89)
Not reported	39 (4)	72 (5)	42 (2)	63 (2)	64 (2)	78 (3)	100 (4)	73 (3)
Condom use last sex work last month (%)**								
Yes	46 (96)	90 (89)	119 (89)	138 (91)	185 (92)	204 (95)	161 (90)	153 (89)

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1996-2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 1072	N = 1497	N = 1978	N = 2665	N = 2503	N = 2694	N = 2454	N = 2445
Previous HIV test (%)								
Yes, last year	737 (69)	1029 (69)	1358 (68)	1740 (65)	1590 (64)	1770 (66)	1509 (61)	1596 (65)
> 1 year ago	225 (21)	288 (19)	389 (20)	561 (21)	555 (22)	573 (21)	604 (25)	549 (23)
Never tested	97 (9)	176 (12)	219 (11)	347 (13)	329 (13)	325 (12)	304 (12)	274 (11)
Not reported	13 (1)	4 (<1)	12 (1)	17 (1)	29 (1)	26 (1)	37 (2)	26 (1)
Self report HBV infection (%)								
Yes	318 (30)	405 (27)	394 (20)	493 (19)	428 (17)	456 (17)	411 (17)	430 (18)
No	729 (68)	1072 (72)	1352 (68)	1784 (67)	1808 (72)	1925 (72)	1720 (70)	1692 (69)
Don't know	0 (0)	0 (0)	226 (11)	353 (13)	220 (9)	270 (10)	275 (11)	279 (11)
Not reported	25 (2)	20 (1)	6 (1)	35 (1)	45 (2)	38 (1)	48 (2)	44 (2)
Self report HBV vaccination (%) *								
Yes	433 (40)	669 (45)	778 (39)	1136 (43)	1211 (49)	1395 (52)	1214 (49)	1289 (52)
No	601 (56)	784 (52)	914 (46)	1075 (40)	1001 (40)	959 (36)	848 (35)	849 (35)
Don't know	0 (0)	0 (0)	273 (14)	387 (15)	232 (9)	272 (10)	251 (10)	245 (10)
Not reported	38 (4)	44 (3)	13 (1)	67 (2)	59 (2)	64 (2)	141 (6)	62 (3)
Previous HCV test (%)								
Yes ever	825 (77)	1200 (80)	---	---	---	---	---	---
Yes, last year	---	---	1347 (68)	1730 (65)	1613 (65)	1869 (69)	1601 (65)	1612 (65)
> 1 year ago	---	---	325 (16)	477 (18)	511 (20)	508 (19)	559 (23)	526 (22)
Never tested	220 (20)	272 (18)	291 (15)	440 (16)	350 (14)	286 (11)	260 (11)	283 (13)
Not reported	27 (3)	25 (2)	15 (1)	18 (1)	29 (1)	31 (1)	34 (1)	24 (1)
Any treatment for HCV (%)								
Interferon					N = 930	N = 1105	N = 1000	N = 1072
Interferon+Ribarvarin					20 (2)	35 (3)	29 (3)	30 (3)
Other					5 (1)	11 (1)	9 (1)	14 (1)
No treatment					35 (4)	33 (3)	30 (3)	36 (3)
Not reported					854 (91)	1003 (91)	910 (91)	965 (90)
Current treatment for HCV								
Interferon				N = 20	N = 27	N = 21	N = 10	
Interferon+Ribarvarin				3	4	4	2	
Other				2	3	4	1	
				15	20	13	7	

* Number (percentage) among participants not reporting previous HBV infection

NATIONAL

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995	655	15 (2.3)	335	5 (1.5)	1004	21 (2.1)
1996	996	20 (2.0)	469	7 (1.5)	1482	27 (1.8)
1997	1187	24 (2.0)	621	4 (0.6)	1814	28 (1.5)
1998	1566	16 (1.0)	853	4 (0.5)	2430	20 (0.8)
1999	1531	26 (1.7)	840	8 (1.0)	2383	34 (1.4)
2000	1639	21 (1.3)	871	0 (0.0)	2525	22 (0.9)
2001	1540	20 (1.3)	778	1 (0.1)	2342	21 (0.9)
2002	1551	25 (1.6)	785	4 (0.5)	2357	31 (1.3)

Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.

Sexual identity	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Heterosexual	555	5 (0.9)	239	3 (1.3)	799	9 (1.1)
Bisexual	43	1 (2.3)	69	1 (1.5)	116	2 (1.7)
Homosexual	40	9 (22.5)	22	1 (4.6)	65	10 (15.4)
p value		<0.001		0.7		<0.001
1996						
Heterosexual	824	4 (0.5)	326	5 (1.5)	1159	9 (0.8)
Bisexual	68	3 (4.4)	91	0 (0.0)	160	3 (1.9)
Homosexual	70	13 (18.6)	39	1 (2.6)	109	14 (12.8)
p value		<0.001		0.4		<0.001
1997						
Heterosexual	1004	5 (0.5)	418	3 (0.7)	1426	8 (0.6)
Bisexual	77	2 (2.6)	130	1 (0.8)	208	3 (1.4)
Homosexual	54	17 (31.5)	58	0 (0.0)	112	17 (15.2)
p value		<0.001		0.8		<0.001
1998						
Heterosexual	1339	4 (0.3)	620	2 (0.3)	1963	6 (0.3)
Bisexual	88	2 (2.3)	139	2 (1.4)	228	4 (1.8)
Homosexual	69	10 (14.5)	74	0 (0.0)	144	10 (6.9)
p value		<0.001		0.2		<0.001
1999						
Heterosexual	1246	10 (0.8)	553	7 (1.3)	1799	17 (0.9)
Bisexual	104	2 (1.9)	187	1 (0.5)	297	3 (1.0)
Homosexual	71	12 (16.9)	52	0 (0.0)	125	12 (9.6)
p value		<0.001		0.5		<0.001
2000						
Heterosexual	1374	7 (0.5)	---	---	1935	7 (0.4)
Bisexual	77	2 (2.6)	---	---	275	2 (0.7)
Homosexual	84	12 (14.3)	---	---	160	13 (8.1)
p value		<0.001				<0.001
2001						
Heterosexual	1268	5 (0.4)	529	1 (0.2)	1808	6 (0.3)
Bisexual	69	2 (2.9)	154	0 (0.0)	225	2 (0.9)
Homosexual	80	13 (16.3)	47	0 (0.0)	129	13 (10.1)
p value		<0.001		0.8		<0.001
2002						
Heterosexual	1269	7 (0.6)	525	3 (0.6)	1800	10 (0.6)
Bisexual	71	2 (2.8)	171	1 (0.6)	248	4 (1.6)
Homosexual	58	14 (24.1)	32	0 (0.0)	92	15 (16.3)
p value		<0.001		0.9		<0.001

* Total includes people whose sex was not reported or reported as transgender.

Table 9: HIV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
< 20 years	36	0 (0.0)	28	0 (0.0)	66	0 (0.0)
20 – 24	131	4 (3.1)	98	1 (1.0)	234	5 (2.1)
25 – 29	137	3 (2.2)	63	1 (1.6)	202	4 (2.0)
30 + years	345	8 (2.3)	145	3 (2.1)	495	12 (2.4)
p value		0.8		0.8		0.6
1996						
< 20 years	86	0 (0.0)	60	0 (0.0)	147	0 (0.0)
20 – 24	245	2 (0.8)	116	2 (1.7)	364	4 (1.1)
25 – 29	209	3 (1.4)	100	1 (1.0)	313	4 (1.3)
30 + years	453	15 (3.3)	193	4 (2.1)	653	19 (2.9)
p value		0.05		0.7		0.04
1997						
< 20 years	96	0 (0.0)	91	0 (0.0)	187	0 (0.0)
20 – 24	306	1 (0.3)	158	0 (0.0)	465	1 (0.2)
25 – 29	250	6 (2.4)	149	1 (0.7)	402	7 (1.7)
30 + years	534	17 (3.2)	223	3 (1.4)	759	20 (2.6)
p value		0.02		0.3		0.002
1998						
< 20 years	138	0 (0.0)	117	0 (0.0)	255	0 (0.0)
20 – 24	386	0 (0.0)	235	1 (0.4)	622	1 (0.2)
25 – 29	353	3 (0.9)	176	0 (0.0)	533	3 (0.6)
30 + years	687	13 (1.9)	325	3 (0.9)	1018	16 (1.6)
p value		0.01		0.4		0.005
1999						
< 20 years	130	1 (0.8)	114	1 (0.9)	244	2 (0.8)
20 – 24	325	1 (0.3)	201	1 (0.5)	528	2 (0.4)
25 – 29	382	1 (0.3)	192	1 (0.5)	577	2 (0.4)
30 + years	692	23 (3.3)	332	5 (1.5)	1028	28 (2.7)
p value		<0.001		0.6		<0.001
2000						
< 20 years	111	0 (0.0)	---	---	222	0 (0.0)
20 – 24	330	1 (0.3)	---	---	569	1 (0.2)
25 – 29	390	6 (1.5)	---	---	581	6 (1.0)
30 + years	807	14 (1.7)	---	---	1151	15 (1.3)
p value		0.1				0.05
2001						
< 20 years	92	0 (0.0)	---	---	168	0 (0.0)
20 – 24	289	0 (0.0)	---	---	484	0 (0.0)
25 – 29	362	2 (0.6)	---	---	525	2 (0.4)
30 + years	795	18 (2.3)	---	---	1161	19 (1.6)
p value		0.006				0.002
2002						
< 20 years	72	0 (0.0)	67	0 (0.0)	140	0 (0.0)
20 – 24	271	0 (0.0)	179	1 (0.6)	452	1 (0.2)
25 – 29	370	7 (1.9)	176	1 (0.6)	587	8 (1.5)
30 + years	834	18 (2.2)	362	2 (0.6)	1212	22 (1.8)
p value		0.06		0.9		0.04

* Total includes people whose sex was not reported or reported as transgender.

NATIONAL
HIV ANTIBODY

Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
<1 to 2 years	79	1 (1.3)	53	0 (0.0)	134	1 (0.8)
3 to 5 years	105	2 (1.9)	61	0 (0.0)	168	2 (1.2)
6 to 10 years	129	3 (2.3)	84	2 (2.4)	216	5 (2.3)
10 + years	327	9 (2.8)	134	3 (2.2)	466	13 (2.8)
p value		0.9		0.4		0.4
1996						
<1 to 2 years	170	2 (1.2)	76	2 (2.6)	248	4 (1.6)
3 to 5 years	183	3 (1.6)	106	1 (0.9)	292	4 (1.4)
6 to 10 years	214	3 (1.4)	93	2 (2.2)	312	5 (1.6)
10 + years	393	11 (2.8)	183	2 (1.1)	581	13 (2.2)
p value		0.5		0.7		0.8
1997						
<1 to 2 years	193	2 (1.0)	126	0 (0.0)	320	2 (0.6)
3 to 5 years	234	2 (0.9)	132	0 (0.0)	366	2 (0.6)
6 to 10 years	250	6 (2.4)	143	1 (0.7)	393	7 (1.8)
10 + years	477	13 (2.7)	212	3 (1.4)	694	16 (2.3)
p value		0.3		0.3		0.07
1998						
<1 to 2 years	273	2 (0.7)	182	1 (0.6)	457	3 (0.7)
3 to 5 years	298	0 (0.0)	178	0 (0.0)	476	0 (0.0)
6 to 10 years	361	3 (0.8)	186	0 (0.0)	549	3 (0.6)
10 + years	598	11 (1.8)	296	3 (1.0)	899	14 (1.6)
p value		0.07		0.3		0.02
1999						
<1 to 2 years	239	2 (0.8)	154	1 (0.6)	393	3 (0.8)
3 to 5 years	297	2 (0.7)	178	4 (2.3)	476	6 (1.3)
6 to 10 years	362	5 (1.4)	211	0 (0.0)	577	5 (0.9)
10 + years	592	16 (2.7)	280	3 (1.1)	875	19 (2.2)
p value		0.08		0.2		0.1
2000						
<1 to 2 years	208	4 (1.9)	---	---	336	4 (1.2)
3 to 5 years	303	4 (1.3)	---	---	519	4 (0.8)
6 to 10 years	400	2 (0.5)	---	---	639	2 (0.3)
10 + years	691	11 (1.6)	---	---	972	12 (1.2)
p value		0.4				0.2
2001						
<1 to 2 years	169	3 (1.8)	110	0 (0.0)	282	3 (1.1)
3 to 5 years	258	4 (1.6)	151	0 (0.0)	412	4 (1.0)
6 to 10 years	383	4 (1.0)	223	0 (0.0)	607	4 (0.7)
10 + years	683	8 (1.2)	277	1 (0.4)	972	9 (0.9)
p value		0.9		0.6		0.9
2002						
<1 to 2 years	149	2 (1.3)	75	0 (0.0)	227	2 (0.8)
3 to 5 years	221	2 (0.9)	151	2 (1.3)	376	4 (1.1)
6 to 10 years	389	3 (0.8)	218	0 (0.0)	610	4 (0.7)
10 + years	751	17 (2.3)	316	2 (0.6)	1075	20 (1.9)
p value		0.2		0.3		0.2

* Total includes people whose sex was not reported or reported as transgender.

Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex.

Last drug injected	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Amphetamine	133	3 (2.2)	72	0 (0.0)	210	3 (1.4)
Heroin	295	9 (3.1)	146	2 (1.4)	443	11 (2.5)
More than one	59	2 (3.4)	24	0 (0.0)	86	3 (3.5)
Other/not reported	168	1 (0.6)	93	3 (3.2)	265	4 (1.5)
p value		0.4		0.3		0.6
1996						
Amphetamine	199	6 (3.0)	75	1 (1.3)	277	7 (2.5)
Heroin	517	10 (1.9)	263	4 (1.5)	787	14 (1.8)
More than one	92	2 (2.2)	36	1 (2.8)	129	3 (2.3)
Other/not reported	188	2 (1.1)	95	1 (1.1)	289	3 (1.0)
p value		0.6		0.9		0.6
1997						
Amphetamine	219	4 (1.8)	104	0 (0.0)	325	4 (1.2)
Heroin	647	15 (2.3)	359	1 (0.3)	1008	16 (1.6)
More than one	79	1 (1.3)	43	0 (0.0)	122	1 (0.8)
Other/not reported	242	4 (1.7)	115	3 (2.6)	359	7 (2.0)
p value		0.9		0.04		0.8
1998						
Amphetamine	354	3 (0.9)	155	2 (1.3)	510	5 (1.0)
Heroin	792	6 (0.8)	462	1 (0.2)	1257	7 (0.6)
More than one	155	2 (1.3)	88	0 (0.0)	247	2 (0.8)
Other/not reported	265	5 (1.9)	148	1 (0.7)	416	6 (1.4)
p value		0.4		0.3		0.4
1999						
Amphetamine	401	13 (3.2)	212	2 (0.9)	614	15 (2.4)
Heroin	784	6 (0.8)	477	4 (0.8)	1268	10 (0.8)
More than one	122	2 (1.6)	70	1 (1.4)	193	3 (1.6)
Other/not reported	224	5 (2.2)	81	1 (1.2)	308	6 (2.0)
p value		0.02		>0.9		0.03
2000						
Amphetamine	373	7 (1.9)	---	---	538	7 (1.3)
Heroin	893	9 (1.0)	---	---	1437	9 (0.6)
More than one	182	2 (1.1)	---	---	256	3 (1.2)
Other/not reported	191	3 (1.6)	---	---	294	3 (1.0)
p value		0.6				0.5
2001						
Amphetamine	591	13 (2.2)	263	0 (0.0)	865	13 (1.5)
Heroin	453	4 (0.9)	269	1 (0.4)	725	5 (0.7)
More than one	166	2 (1.2)	78	0 (0.0)	244	2 (0.8)
Other/not reported	330	1 (0.3)	168	0 (0.0)	508	1 (0.2)
p value		0.08		0.6		0.08
2002						
Amphetamine	507	15 (3.0)	260	0 (0.0)	772	15 (1.9)
Heroin	552	4 (0.7)	300	2 (0.7)	856	8 (0.9)
More than one	168	5 (3.0)	63	1 (1.6)	235	6 (2.6)
Other/not reported	324	1 (0.3)	162	1 (0.6)	494	2 (0.4)
p value		0.003		0.4		0.03

* Total includes people whose sex was not reported or reported as transgender.

NATIONAL
HIV ANTIBODY

Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.

Frequency of drug injection last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Not last month	53	1 (1.9)	19	0 (0.0)	73	1 (1.4)
Less than weekly	109	5 (4.6)	71	3 (4.2)	181	8 (4.4)
Weekly not daily	228	3 (1.3)	101	0 (0.0)	336	4 (1.2)
Daily or more	263	6 (2.3)	143	2 (1.4)	411	8 (2.0)
p value		0.3		0.1		0.1
1996						
Not last month	68	1 (1.5)	33	0 (0.0)	102	1 (1.0)
Less than weekly	190	5 (2.6)	98	2 (2.0)	291	7 (2.4)
Weekly not daily	321	6 (1.9)	159	1 (0.6)	485	7 (1.4)
Daily or more	409	8 (2.0)	176	4 (2.3)	593	12 (2.0)
p value		0.9		0.5		0.7
1997						
Not last month	90	5 (5.6)	34	1 (2.9)	125	6 (4.8)
Less than weekly	308	10 (3.3)	149	1 (0.7)	459	11 (2.4)
Weekly not daily	197	3 (1.5)	94	2 (2.1)	292	5 (1.7)
Daily or more	586	6 (1.0)	341	0 (0.0)	929	6 (0.7)
p value		0.01		0.04		0.001
1998						
Not last month	86	2 (2.3)	48	0 (0.0)	135	2 (1.5)
Less than weekly	223	5 (2.2)	99	1 (1.0)	324	6 (1.9)
Weekly not daily	396	4 (1.0)	184	1 (0.5)	582	5 (0.9)
Daily or more	859	5 (0.6)	521	2 (0.4)	1384	7 (0.5)
p value		0.1		0.8		0.08
1999						
Not last month	111	5 (4.5)	53	1 (1.9)	165	6 (3.6)
Less than weekly	226	5 (2.2)	127	0 (0.0)	355	5 (1.4)
Weekly not daily	336	3 (0.9)	183	2 (1.1)	520	5 (1.0)
Daily or more	844	13 (1.5)	472	5 (1.1)	1321	18 (1.4)
p value		0.07		0.6		0.09
2000						
Not last month	106	4 (3.8)	---	---	159	4 (2.5)
Less than weekly	234	3 (1.3)	---	---	323	3 (0.9)
Weekly not daily	352	6 (1.7)	---	---	522	7 (1.3)
Daily or more	933	8 (0.9)	---	---	1464	8 (0.6)
p value		0.07				0.05
2001						
Not last month	137	2 (1.5)	76	0 (0.0)	215	2 (0.9)
Less than weekly	308	6 (2.0)	115	1 (0.9)	426	7 (1.6)
Weekly not daily	373	4 (1.1)	207	0 (0.0)	584	4 (0.7)
Daily or more	698	8 (1.2)	369	0 (0.0)	1078	8 (0.7)
p value		0.7		0.1		0.4
2002						
Not last month	135	4 (2.3)	73	0 (0.0)	212	4 (1.9)
Less than weekly	251	6 (2.4)	115	1 (0.9)	374	8 (2.1)
Weekly not daily	383	7 (1.8)	177	1 (0.6)	563	9 (1.6)
Daily or more	769	7 (0.9)	410	2 (0.5)	1183	9 (0.8)
p value		0.09		0.9		0.1

* Total includes people whose sex was not reported or reported as transgender.

Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.

Reused someone else's syringe last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	429	12 (2.8)	203	4 (2.0)	638	17 (2.7)
Yes	170	2 (1.2)	112	1 (0.9)	289	3 (1.0)
p value		0.2		0.5		0.1
1996						
No	673	16 (2.4)	304	7 (2.3)	991	23 (2.3)
Yes	246	3 (1.2)	129	0 (0.0)	377	3 (0.8)
p value		0.3		0.08		0.07
1997						
No	909	17 (1.9)	456	3 (0.7)	1370	20 (1.5)
Yes	161	2 (1.2)	110	0 (0.0)	271	2 (0.7)
p value		0.6		0.4		0.3
1998						
No	1206	11 (0.9)	616	4 (0.7)	1829	15 (0.8)
Yes	236	2 (0.9)	165	0 (0.0)	402	2 (0.5)
p value		0.9		0.3		0.5
1999						
No	1065	16 (1.5)	578	6 (1.0)	1650	22 (1.3)
Yes	289	4 (1.4)	177	1 (0.6)	467	5 (1.1)
p value		0.9		0.6		0.7
2000						
No	1259	17 (1.4)	---	---	1872	18 (1.0)
Yes	218	0 (0.0)	---	---	391	0 (0.0)
p value		0.08				0.05
2001						
No	1260	16 (1.3)	633	1 (0.2)	1913	15 (0.9)
Yes	208	4 (1.9)	103	0 (0.0)	311	4 (1.3)
p value		0.5		0.7		0.5
2002						
No	1134	15 (1.3)	568	3 (0.5)	1717	20 (1.2)
Yes	234	4 (1.7)	115	1 (0.9)	349	5 (1.4)
p value		0.6		0.7		0.7

* Total includes people whose sex was not reported or reported as transgender.

NATIONAL
HIV ANITBODY

Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.

Imprisonment last year	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	533	13 (2.4)	297	5 (1.7)	841	18 (2.2)
Yes	113	2 (1.8)	34	0 (0.0)	150	2 (1.4)
p value		0.7		0.4		0.5
1996						
No	821	18 (2.2)	414	6 (1.5)	1250	24 (1.9)
Yes	141	1 (0.7)	38	1 (2.6)	179	2 (1.1)
p value		0.2		0.6		0.4
1997						
No	985	23 (2.3)	561	4 (0.7)	1552	27 (1.8)
Yes	198	1 (0.5)	58	0 (0.0)	256	1 (0.4)
p value		0.1		0.5		0.1
1998						
No	1245	16 (1.3)	751	3 (0.4)	2002	19 (1.0)
Yes	300	0 (0.0)	97	1 (1.0)	399	1 (0.3)
p value		0.05		0.4		0.2
1999						
No	1214	20 (1.7)	747	7 (0.9)	1970	27 (1.4)
Yes	297	4 (1.4)	82	1 (1.2)	380	5 (1.3)
p value		0.7		0.8		>0.9
2000						
No	1261	16 (1.3)	---	---	2008	16 (0.8)
Yes	337	4 (1.2)	---	---	460	4 (0.9)
p value		0.9				0.9
2001						
No	1189	16 (1.4)	656	1 (0.2)	1864	17 (0.9)
Yes	298	4 (1.3)	101	0 (0.0)	403	4 (1.0)
p value		>0.9		0.7		0.9
2002						
No	1229	23 (1.9)	682	4 (0.6)	1929	29 (1.5)
Yes	296	2 (0.7)	89	0 (0.0)	386	2 (0.5)
p value		0.2		0.5		0.1

* Total includes people whose sex was not reported or reported as transgender.

Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.

Condom use last sex	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	361	5 (1.4)	198	2 (1.0)	565	7 (1.4)
Yes	172	8 (4.7)	84	2 (2.4)	262	10 (3.8)
p value		0.02		0.4		0.03
1996						
No	437	3 (0.7)	241	3 (1.2)	684	6 (0.9)
Yes	232	9 (3.9)	113	1 (0.9)	348	10 (2.9)
p value		0.003		0.8		0.01
1997						
No	725	8 (1.1)	426	3 (0.7)	1152	11 (1.0)
Yes	449	15 (3.3)	186	1 (0.5)	640	16 (2.5)
p value		0.007		0.8		0.01
1998						
No	942	5 (0.5)	583	1 (0.2)	1528	6 (0.4)
Yes	584	10 (1.7)	249	3 (1.2)	838	13 (1.6)
p value		0.02		0.05		0.003
1999						
No	918	6 (0.7)	545	3 (0.6)	1469	9 (0.6)
Yes	573	19 (3.3)	264	5 (1.9)	841	24 (2.9)
p value		<0.001		0.07		<0.001
2000						
No	972	6 (0.6)	---	---	1532	6 (0.4)
Yes	610	15 (2.5)	---	---	906	15 (1.8)
p value		0.002				0.001
2001						
No	947	9 (1.0)	547	1 (0.2)	1502	10 (0.7)
Yes	535	11 (2.1)	203	0 (0.0)	750	11 (1.5)
p value		0.08		(0.5)		0.06
2002						
No	984	9 (1.0)	531	1 (0.2)	1522	10 (0.7)
Yes	536	16 (3.0)	237	3 (1.3)	784	21 (2.7)
p value		0.007		(0.1)		<0.001

* Total includes people whose sex was not reported or reported as transgender.

NATIONAL
HIV ANTIBODY

Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.

Sex work last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	614	12 (2.0)	293	3 (1.0)	917	16 (1.7)
Yes	13	3 (23.1)	36	2 (2.8)	52	4 (7.7)
p value		<0.001		0.4		0.003
1996						
No	922	17 (1.8)	376	6 (1.6)	1311	23 (1.8)
Yes	25	1 (4.0)	73	1 (1.4)	99	2 (2.0)
p value		0.4		0.9		0.8
1997						
No	1114	21 (1.9)	518	4 (0.8)	1637	25 (1.5)
Yes	46	2 (4.4)	94	0 (0.0)	141	2 (1.4)
p value		0.2		0.4		0.9
1998						
No	1486	14 (0.9)	731	2 (0.3)	2223	16 (0.7)
Yes	43	2 (4.7)	105	2 (1.9)	151	4 (2.7)
p value		0.02		0.02		0.01
1999						
No	1439	22 (1.5)	664	6 (0.9)	2109	28 (1.3)
Yes	55	2 (3.6)	152	2 (1.3)	211	4 (1.9)
p value		0.2		0.6		0.5
2000						
No	1519	19 (1.3)	---	---	2200	20 (0.9)
Yes	69	1 (1.5)	---	---	249	1 (0.4)
p value		0.9				0.4
2001						
No	1419	18 (1.3)	608	1 (0.2)	2039	19 (0.9)
Yes	61	2 (3.3)	141	0 (0.0)	212	2 (0.9)
p value		0.2		0.6		1.0
2002						
No	1445	24 (1.7)	635	4 (0.6)	2094	29 (1.4)
Yes	59	2 (1.7)	131	0 (0.0)	194	2 (1.0)
p value		0.7		0.6		0.7

* Total includes people whose sex was not reported or reported as transgender.

HCV antibody prevalence

Table 17: HCV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	639	400 (63)	327	208 (64)	979	618 (63)
1996	977	482 (49)	467	262 (56)	1460	752 (52)
1997	1189	570 (48)	622	344 (55)	1817	917 (50)
1998	1567	735 (47)	855	458 (54)	2433	1199 (49)
1999	1528	756 (49)	840	436 (52)	2379	1198 (50)
2000	1647	865 (53)	874	484 (55)	2536	1357 (54)
2001	1564	882 (56)	788	481 (61)	2376	1378 (58)
2002	1554	845 (56)	784	434 (55)	2359	1324 (56)
χ^2 trend p value		0.002		0.9		0.001

Table 18: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
< 20 years	36	7 (19)	28	10 (36)	65	18 (28)
20 – 24	127	41 (32)	94	44 (47)	226	88 (39)
25 – 29	133	80 (60)	63	43 (68)	198	125 (63)
30 + years	337	268 (80)	141	111 (79)	483	383 (79)
p value		<0.001		<0.001		<0.001
1996						
< 20 years	81	10 (12)	56	14 (25)	138	25 (18)
20 – 24	241	41 (17)	116	36 (31)	360	78 (22)
25 – 29	205	92 (45)	101	64 (63)	309	158 (51)
30 + years	447	338 (76)	194	148 (76)	648	490 (76)
p value		<0.001		<0.001		<0.001
1997						
< 20 years	96	14 (15)	91	22 (24)	187	36 (19)
20 – 24	306	54 (18)	158	53 (34)	465	107 (23)
25 – 29	250	98 (39)	149	87 (58)	402	187 (47)
30 + years	536	403 (75)	224	182 (81)	762	586 (77)
p value		<0.001		<0.001		<0.001
1998						
< 20 years	138	27 (20)	117	30 (26)	255	57 (22)
20 – 24	386	83 (22)	235	73 (31)	622	156 (25)
25 – 29	353	133 (38)	176	93 (53)	533	228 (43)
30 + years	688	492 (72)	327	262 (80)	1021	758 (74)
p value		<0.001		<0.001		<0.001
1999						
< 20 years	130	25 (19)	114	44 (39)	244	69 (28)
20 – 24	325	97 (30)	201	58 (29)	528	155 (29)
25 – 29	380	143 (38)	192	87 (45)	575	232 (40)
30 + years	691	490 (71)	332	246 (74)	1026	739 (72)
p value		<0.001		<0.001		<0.001
2000						
< 20 years	111	27 (24)	112	49 (44)	223	76 (34)
20 – 24	330	111 (34)	235	108 (46)	569	221 (39)
25 – 29	391	169 (43)	190	92 (48)	582	261 (45)
30 + years	814	558 (69)	337	235 (70)	1160	798 (69)
p value		<0.001		<0.001		<0.001
2001						
< 20 years	92	37 (40)	74	29 (39)	168	66 (39)
20 – 24	292	105 (36)	195	100 (51)	491	205 (42)
25 – 29	365	163 (45)	162	89 (55)	530	255 (48)
30 + years	813	576 (71)	356	262 (74)	1183	849 (72)
p value		<0.001		<0.001		<0.001
2002						
< 20 years	72	23 (32)	67	30 (45)	140	53 (38)
20 – 24	271	122 (45)	179	85 (47)	452	209 (46)
25 – 29	370	175 (47)	176	85 (48)	548	261 (48)
30 + years	837	553 (66)	361	234 (65)	1214	799 (66)
p value		<0.001		<0.001		<0.001

* Total includes people whose sex was not reported or reported as transgender.

**NATIONAL
HCV ANTIBODY**

Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
<1 to 2 years	77	14 (18)	53	15 (28)	131	29 (22)
3 to 5 years	103	34 (33)	60	22 (37)	165	58 (35)
6 to 10 years	126	70 (56)	81	57 (70)	210	130 (62)
10+ years	319	273 (86)	131	113 (86)	455	390 (86)
p value		<0.001		<0.001		<0.001
1996						
<1 to 2 years	162	16 (10)	74	12 (16)	238	29 (12)
3 to 5 years	178	25 (14)	104	36 (35)	285	62 (22)
6 to 10 years	211	101 (48)	91	53 (58)	306	157 (51)
10 + years	391	320 (82)	187	152 (81)	583	476 (82)
p value		<0.001		<0.001		<0.001
1997						
<1 to 2 years	193	23 (12)	126	20 (16)	320	43 (13)
3 to 5 years	234	48 (21)	132	48 (36)	366	96 (26)
6 to 10 years	250	91 (36)	143	83 (58)	393	174 (44)
10 + years	479	392 (82)	213	189 (89)	697	584 (84)
p value		<0.001		<0.001		<0.001
1998						
<1 to 2 years	273	41 (15)	182	36 (20)	457	77 (17)
3 to 5 years	298	75 (25)	178	61 (34)	476	136 (29)
6 to 10 years	362	139 (38)	186	104 (56)	550	243 (44)
10 + years	598	462 (77)	298	251 (84)	901	717 (80)
p value		<0.001		<0.001		<0.001
1999						
<1 to 2 years	238	37 (16)	154	42 (27)	392	79 (20)
3 to 5 years	298	86 (29)	178	59 (33)	477	145 (30)
6 to 10 years	360	155 (43)	211	102 (48)	575	259 (45)
10 + years	591	458 (78)	280	223 (80)	873	683 (78)
p value		<0.001		<0.001		<0.001
2000						
<1 to 2 years	208	53 (25)	128	36 (28)	336	89 (26)
3 to 5 years	304	99 (33)	214	104 (49)	520	204 (39)
6 to 10 years	401	188 (47)	235	127 (54)	640	316 (49)
10 + years	697	511 (73)	279	207 (74)	980	721 (74)
p value		<0.001		<0.001		<0.001
2001						
<1 to 2 years	171	39 (23)	112	41 (37)	286	80 (28)
3 to 5 years	259	98 (38)	152	77 (51)	414	176 (43)
6 to 10 years	390	190 (49)	227	144 (63)	618	334 (54)
10 + years	695	534 (77)	279	212 (76)	986	757 (77)
p value		<0.001		<0.001		<0.001
2002						
<1 to 2 years	149	56 (38)	74	28 (38)	226	85 (38)
3 to 5 years	221	101 (46)	151	65 (43)	376	168 (45)
6 to 10 years	390	182 (47)	218	119 (55)	611	303 (50)
10 + years	752	519 (69)	316	211 (67)	1076	738 (69)
p value		<0.001		<0.001		<0.001

* Total includes people whose sex was not reported or reported as transgender.

Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Amphetamine	66	11 (17)	138	61 (44)	206	73 (35)
Heroin	39	13 (33)	386	272 (70)	431	288 (67)
More than one	7	1 (14)	74	57 (77)	84	60 (71)
Other/not reported	19	4 (21)	232	188 (81)	258	197 (76)
p value		0.2		<0.001		<0.001
1996						
Amphetamine	99	9 (9)	169	51 (30)	273	61 (22)
Heroin	100	12 (12)	652	395 (61)	775	420 (54)
More than one	12	2 (17)	107	70 (65)	128	79 (62)
Other/not reported	27	5 (19)	246	180 (73)	284	192 (68)
p value		0.5		<0.001		<0.001
1997						
Amphetamine	120	8 (7)	199	54 (27)	326	62 (19)
Heroin	150	31 (21)	845	510 (60)	1008	549 (54)
More than one	17	1 (6)	103	71 (69)	123	74 (60)
Other/not reported	33	3 (9)	309	219 (71)	360	232 (64)
p value		0.005		<0.001		<0.001
1998						
Amphetamine	156	8 (5)	344	90 (26)	510	101 (20)
Heroin	213	51 (24)	1031	603 (58)	1259	665 (53)
More than one	47	12 (26)	197	144 (73)	247	156 (63)
Other/not reported	41	6 (15)	355	259 (73)	417	227 (66)
p value		<0.001		<0.001		<0.001
1999						
Amphetamine	167	9 (5)	441	136 (31)	614	146 (24)
Heroin	169	60 (36)	1068	681 (64)	1264	761 (60)
More than one	20	7 (35)	164	107 (65)	193	122 (63)
Other/not reported	36	3 (8)	252	163 (65)	308	169 (55)
p value		<0.001		<0.001		<0.001
2000						
Amphetamine	107	11 (10)	420	141 (34)	540	156 (29)
Heroin	168	59 (35)	1256	809 (64)	1440	880 (61)
More than one	31	15 (48)	223	144 (65)	259	162 (63)
Other/not reported	30	4 (13)	241	147 (61)	297	159 (54)
p value		<0.001		<0.001		<0.001
2001						
Amphetamine	149	30 (20)	706	327 (46)	879	364 (41)
Heroin	67	29 (43)	652	476 (73)	730	512 (70)
More than one	14	5 (36)	226	160 (71)	247	172 (70)
Other/not reported	56	16 (29)	434	304 (70)	520	330 (63)
p value		0.005		<0.001		<0.001
2002						
Amphetamine	101	36 (36)	647	272 (42)	772	319 (41)
Heroin	54	25 (46)	791	547 (69)	855	575 (67)
More than one	17	7 (41)	215	138 (64)	236	147 (62)
Other/not reported	54	17 (31)	410	252 (61)	496	283 (57)
p value		0.4		<0.001		<0.001

* Total includes people who did not report duration of drug injection.

**NATIONAL
HCV ANTIBODY**

Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Less than daily	84	19 (23)	415	286 (69)	507	311 (61)
Daily or more	34	8 (24)	356	259 (73)	399	272 (68)
p value		0.9		0.2		0.03
1996						
Less than daily	162	18 (11)	583	346 (59)	762	374 (49)
Daily or more	55	9 (16)	509	311 (61)	590	335 (57)
p value		0.3		0.6		0.005
1997						
Less than daily	159	14 (9)	583	296 (51)	752	313 (42)
Daily or more	135	26 (19)	773	500 (65)	931	542 (58)
p value		0.009		<0.001		<0.001
1998						
Less than daily	196	17 (9)	699	356 (51)	906	378 (42)
Daily or more	236	59 (25)	1126	692 (61)	1386	768 (55)
p value		<0.001		<0.001		<0.001
1999						
Less than daily	163	23 (14)	692	344 (50)	873	378 (43)
Daily or more	200	54 (27)	1097	666 (61)	1319	736 (56)
p value		0.003		<0.001		<0.001
2000						
Less than daily	121	19 (16)	737	367 (50)	879	397 (45)
Daily or more	185	68 (37)	1266	804 (64)	1472	884 (60)
p value		<0.001		<0.001		<0.001
2001						
Less than daily	141	42 (30)	866	497 (57)	1025	544 (53)
Daily or more	109	32 (29)	968	657 (68)	1096	701 (64)
p value		0.9		<0.001		<0.001
2002						
Less than daily	97	34 (35)	823	437 (53)	938	481 (51)
Daily or more	97	40 (41)	1059	676 (64)	1182	725 (61)
p value		0.4		<0.001		<0.001

* Total includes people who did not report duration of drug injection.

Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month and duration of drug injection.

Reused someone else's syringe last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
No	88	15 (17)	528	363 (69)	626	386 (62)
Yes	30	12 (40)	243	182 (75)	279	197 (71)
p value		0.01		0.08		0.009
1996						
No	168	22 (13)	779	452 (58)	974	386 (40)
Yes	49	6 (12)	312	204 (65)	377	222 (59)
p value		0.9		0.03		<0.001
1997						
No	239	31 (13)	1104	630 (57)	1372	679 (49)
Yes	47	8 (17)	221	144 (65)	272	153 (56)
p value		0.5		0.03		0.04
1998						
No	346	60 (17)	1460	827 (57)	1831	904 (49)
Yes	75	14 (19)	321	193 (60)	402	211 (52)
p value		0.8		0.3		0.3
1999						
No	271	52 (19)	1346	752 (56)	1646	824 (50)
Yes	78	22 (28)	378	221 (58)	467	250 (54)
p value		0.09		0.4		0.2
2000						
No	252	63 (25)	1594	906 (57)	1881	988 (53)
Yes	49	23 (47)	338	224 (66)	394	251 (64)
p value		0.002		0.001		<0.001
2001						
No	234	62 (27)	1665	1019 (61)	1939	1098 (57)
Yes	39	15 (38)	275	190 (69)	317	207 (65)
p value		0.1		0.01		0.004
2002						
No	152	56 (37)	1535	901 (59)	1717	967 (56)
Yes	37	17 (46)	300	183 (61)	349	207 (59)
p value		0.3		0.12		0.3

* Total includes people who did not report duration of drug injection.

NATIONAL
HCV ANTIBODY

Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection.

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
No	122	28 (23)	686	460 (67)	821	496 (60)
Yes	8	1 (13)	134	111 (83)	146	114 (78)
p value		0.5		<0.001		<0.001
1996						
No	223	25 (11)	969	547 (56)	1228	592 (48)
Yes	8	2 (25)	161	121 (75)	178	129 (72)
p value		0.2		<0.001		<0.001
1997						
No	307	40 (13)	1212	674 (56)	1555	730 (47)
Yes	11	3 (27)	240	177 (74)	256	184 (72)
p value		0.2		<0.001		<0.001
1998						
No	402	58 (14)	1563	833 (53)	2004	910 (45)
Yes	50	18 (36)	344	250 (73)	400	272 (68)
p value		<0.001		<0.001		<0.001
1999						
No	361	64 (18)	1559	811 (52)	1968	900 (46)
Yes	25	13 (52)	344	262 (76)	378	281 (74)
p value		<0.001		<0.001		<0.001
2000						
No	293	62 (21)	1681	926 (55)	2016	1004 (50)
Yes	36	25 (69)	416	293 (70)	463	326 (70)
p value		<0.001		<0.001		<0.001
2001						
No	253	62 (25)	1584	947 (60)	1892	1030 (54)
Yes	22	12 (55)	380	286 (75)	408	303 (74)
p value		0.002		<0.001		<0.001
2002						
No	185	65 (35)	1687	941 (56)	1932	1029 (53)
Yes	34	18 (53)	345	247 (72)	385	269 (70)
p value		0.05		<0.001		<0.001

* Total includes people who did not report duration of drug injection.

Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection.

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
No	120	28 (23)	757	524 (69)	894	562 (63)
Yes	4	1 (25)	47	35 (74)	51	36 (71)
p value		0.9		0.4		0.3
1996						
No	222	29 (13)	1029	601 (58)	1287	648 (50)
Yes	5	0 (0)	91	53 (58)	102	58 (57)
p value		0.4		>0.9		0.2
1997						
No	302	36 (12)	1299	759 (58)	1639	813 (50)
Yes	13	5 (38)	127	77 (61)	142	83 (58)
p value		0.005		0.6		0.04
1998						
No	428	69 (16)	1757	976 (55)	2226	1067 (48)
Yes	19	6 (32)	128	93 (73)	151	100 (66)
p value		0.08		<0.001		<0.001
1999						
No	358	68 (19)	1700	953 (56)	2105	1046 (50)
Yes	25	9 (36)	178	103 (58)	211	116 (55)
p value		0.04		0.6		0.1
2000						
No	305	77 (25)	1856	1065 (57)	2211	1163 (53)
Yes	24	12 (50)	220	146 (66)	249	162 (65)
p value		0.009		0.01		<0.001
2001						
No	254	68 (27)	1757	1083 (62)	2067	1176 (57)
Yes	20	7 (35)	191	143 (75)	216	152 (70)
p value		0.4		<0.001		<0.001
2002						
No	204	76 (37)	1833	1068 (58)	2096	1170 (56)
Yes	15	6 (40)	172	108 (63)	194	117 (60)
p value		0.9		0.5		0.4

* Total includes people who did not report duration of drug injection.

**AUSTRALIAN CAPITAL TERRITORY
AIVL 1995-1996 and ADD Inc 1997-2002**

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	1	1	1	1	1	1	1	1
Response								
Nº surveyed	N = 72	N = 125	N = 87	N = 138	N = 94	N = 163	N=44	N = 62
% response	97%	89%	49%	91%	55%	56%	40%	29%
Sex (%)								
Males	47 (65)	69 (55)	59 (68)	87 (63)	51 (54)	120 (74)	34 (77)	41 (66)
Females	24 (34)	55 (44)	28 (32)	51 (37)	43 (46)	43 (26)	10 (23)	21 (34)
Transgender	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)								
Heterosexual	59 (82)	97 (78)	64 (74)	118 (86)	69 (73)	139 (85)	39 (88)	45 (72)
Bisexual	9 (13)	15 (12)	13 (15)	13 (9)	7 (7)	12 (8)	2 (5)	6 (10)
Gay/lesbian	3 (4)	9 (7)	3 (3)	2 (1)	10 (11)	2 (1)	1 (2)	1 (2)
Not reported	1 (1)	4 (3)	7 (8)	5 (4)	8 (9)	10 (6)	2 (5)	10 (16)
Age and duration of injection (years)								
Median age	32	30	23	25	25	27	28	31
Age range	17-41	13-49	15-45	16-45	16-46	16-47	19-45	18-54
Not reported	0	1	0	0	0	1	0	0
Median age 1 st IDU	18	18	17	17	17	17	17	17
Age range	9-33	11-33	12-33	12-32	12-34	9-42	11-40	13-39
Not reported	1	5	3	1	2	4	1	2
Median years IDU	12	10	5	7	6.5	8	11	12
Age range	1-23	<1-34	<1-25	<1-31	<1-28	<1-32	1-30	1-40
Not reported	1	0	3	1	2	5	1	2
Aboriginal and Torres Strait Islander Origin (%)								
Yes	5 (7)	7 (6)	4 (5)	12 (9)	16 (17)	18 (11)	5 (11)	8 (13)
No	65 (90)	110 (88)	83 (95)	123 (89)	76 (81)	140 (87)	39 (89)	53 (85)
Not reported	2 (3)	8 (6)	0 (0)	3 (2)	2 (2)	4 (2)	0 (0)	1 (2)
Imprisonment last year (%)								
Yes	7 (10)	12 (10)	15 (17)	26 (19)	17 (18)	23 (14)	15 (34)	6 (10)
No	64 (89)	107 (85)	71 (82)	110 (80)	76 (81)	139 (85)	29 (66)	56 (90)
Not reported	1 (1)	6 (5)	1 (1)	2 (1)	1 (1)	1 (1)	0 (0)	0 (0)
Injected in prison (%)								
Yes	3 (43)	4 (33)	6 (40)	5 (19)	6 (35)	8 (35)	3 (20)	2 (33)
Frequency of injection last month (%)								
Not last month	15 (21)	13 (10)	5 (6)	6 (4)	13 (14)	9 (6)	3 (7)	7 (11)
Less than weekly	19 (26)	25 (20)	21 (24)	14 (10)	19 (20)	25 (15)	10 (23)	9 (15)
Weekly not daily	23 (32)	40 (32)	13 (15)	34 (25)	11 (12)	27 (16)	19 (43)	16 (26)
Daily or more	15 (21)	45 (36)	47 (54)	84 (61)	51 (54)	101 (62)	11 (25)	30 (48)
Not reported	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)
Last drug injected (%)								
Amphetamine	10 (14)	9 (7)	8 (9)	8 (6)	15 (16)	10 (6)	18 (41)	10 (16)
Anabolic steroids	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)
Benzos	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Buprenorphine							---	
Cocaine	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Heroin	43 (61)	89 (71)	69 (79)	117 (85)	72 (77)	130 (79)	13 (30)	41 (67)
Heroin + Cocaine	1 (1)	2 (2)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	2 (3)
Methadone	7 (10)	11 (9)	5 (6)	4 (3)	1 (1)	3 (2)	9 (20)	5 (8)
Morphine	3 (4)	0 (0)	0 (0)	2 (1)	0 (0)	3 (2)	1 (2)	0 (0)
More than one	4 (6)	13 (10)	4 (5)	7 (5)	4 (4)	13 (8)	2 (5)	4 (6)
Other drug	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)

ACT

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 57	N = 110	N = 81	N = 132	N = 81	N = 153	N = 40	N = 55
Places injected last month (%)*								
Own home	63 (78)	103 (78)	62 (76)	124 (81)	29 (73)	43 (78)		
Friend's home	59 (73)	87 (66)	40 (49)	80 (52)	18 (45)	37 (67)		
Dealer's home	36 (44)	40 (30)	17 (21)	45 (29)	10 (25)	21 (38)		
Street, park, beach	40 (49)	64 (48)	43 (53)	65 (42)	15 (38)	28 (51)		
Car	5 (6)	77 (58)	47 (58)	73 (48)	18 (45)	27 (49)		
Public toilet	55 (68)	76 (58)	49 (60)	78 (51)	19 (48)	25 (45)		
"Shooting" room	7 (9)	2 (2)	2 (2)	2 (1)	1 (3)	0 (0)		
Squat			11 (14)	19 (12)	2 (5)	6 (11)		
Use of new sterile needles & syringes last month (%)								
All injections	55 (68)	84 (64)	56 (69)	114 (74)	26 (65)	39 (71)		
Most of the time	23 (29)	38 (29)	19 (24)	36 (23)	13 (33)	15 (27)		
Half of the time	2 (2)	3 (2)	2 (2)	1 (1)	1 (3)	1 (2)		
Some of the time	1 (1)	3 (2)	2 (2)	0 (0)	0 (0)	0 (0)		
Not last month	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)		
Not reported	0 (0)	4 (3)	1 (1)	1 (1)	0 (0)	0 (0)		
Re-used another's syringe last month (%)								
None	34 (60)	83 (75)	67 (83)	100 (76)	56 (69)	121 (79)	28 (70)	38 (70)
Once	10 (18)	16 (14)	1 (1)	12 (9)	10 (13)	15 (10)	8 (20)	4 (7)
Twice	3 (5)	6 (5)	4 (5)	8 (6)	5 (6)	5 (3)	2 (5)	4 (7)
3-5 times	6 (10)	1 (1)	7 (9)	6 (4)	9 (11)	4 (3)	0 (0)	2 (4)
>5 times	4 (7)	4 (4)	0 (0)	2 (2)	0 (0)	7 (4)	1 (3)	3 (5)
Not reported	0 (0)	0 (0)	2 (2)	4 (3)	1 (1)	1 (1)	1 (3)	4 (7)
Number of people syringe was re-used after last month (%)								
None	34 (60)	83 (76)	67 (83)	100 (76)	56 (69)	121 (79)	28 (70)	38 (68)
One	11 (19)	10 (9)	12 (15)	23 (17)	17 (21)	21 (14)	9 (21)	6 (11)
Two	3 (5)	17 (15)	1 (1)	3 (2)	3 (4)	0 (0)	1 (3)	2 (4)
Three to five	1 (2)	0 (0)	1 (1)	2 (1)	1 (1)	3 (2)	0 (0)	0 (0)
More than five	1 (2)	0 (0)	0 (0)	0 (0)	2 (3)	2 (1)	1 (3)	2 (4)
Don't know	7 (12)	0 (0)	0 (0)	0 (0)	1 (1)	5 (3)	0 (0)	2 (4)
Not reported	0 (0)	0 (0)	0 (0)	4 (3)	1 (1)	1 (1)	1 (3)	5 (9)
Relationship to people syringe was re-used after last month (%)*								
Regular sex partner	8 (10)	13 (10)	10 (12)	15 (10)	5 (13)	6 (11)		
Casual sex partner	2 (2)	2 (2)	0 (0)	3 (2)	0 (0)	1 (2)		
Close friend	5 (6)	14 (11)	10 (12)	6 (4)	3 (8)	5 (9)		
Acquaintance	3 (4)	1 (1)	3 (4)	8 (5)	2 (5)	2 (4)		
Other	0 (0)	2 (2)	2 (2)	3 (2)	1 (3)	3 (5)		
Equipment used after someone else last month (%)*								
Spoon			31 (38)	61 (40)	14 (35)	25 (45)		
Water			20 (25)	31 (20)	4 (10)	15 (27)		
Filter			22 (27)	35 (23)	3 (8)	15 (27)		
Tourniquet			15 (19)	16 (10)	4 (10)	10 (18)		
Drug mix			14 (17)	21 (14)	4 (10)	11 (20)		
Injected by someone else who'd already injected themselves or others last month (%)								
Yes			18 (22)	25 (17)	2 (4)	13 (24)		
No			60 (74)	126 (82)	37 (94)	42 (76)		
Not reported			3 (4)	2 (1)	1 (2)	0 (0)		

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 72	N = 125	N = 87	N = 138	N = 94	N = 163	N = 44	N = 62
Any treatment/therapy for drug use (%)								
No	13 (18)	20 (16)	20 (23)	33 (24)	24 (26)	29 (18)	4 (9)	11 (18)
Yes	57 (79)	104 (83)	67 (77)	105 (76)	69 (73)	133 (81)	40 (91)	51 (82)
Not reported	2 (3)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
History of methadone treatment (%)								
Currently	30 (41)	50 (40)	16 (18)	38 (28)	30 (32)	46 (28)	14 (32)	18 (29)
Previously	15 (21)	34 (27)	19 (22)	32 (23)	18 (19)	52 (32)	14 (32)	26 (42)
Never	25 (35)	40 (32)	52 (60)	68 (49)	22 (23)	63 (39)	16 (36)	17 (27)
Not reported	2 (3)	1 (1)	0 (0)	0 (0)	24 (26)	1 (1)	0 (0)	1 (2)
History of other pharmacological therapy (%)								
Currently					0 (0)	2 (1)	0 (0)	8 (13)
Previously					5 (5)	14 (9)	5 (11)	7 (11)
Never					65 (69)	143 (88)	39 (89)	47 (76)
Not reported					24 (26)	4 (2)	0 (0)	0 (0)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 94	N = 163	N = 44	N = 62
From an NSP last month (%)								
Daily or almost daily					34 (36)	64 (39)	4 (9)	15 (24)
A couple of times each week					26 (28)	53 (33)	13 (30)	22 (35)
Less than weekly					12 (13)	20 (12)	15 (34)	9 (15)
Once last month					6 (6)	13 (8)	7 (16)	9 (15)
Not in the last month					14 (15)	9 (6)	3 (7)	7 (11)
Not reported					2 (2)	4 (2)	2 (4)	0 (0)
From a chemist last month (%)								
Daily or almost daily					4 (4)	10 (6)	0 (0)	5 (8)
A couple of times each week					6 (7)	16 (10)	4 (9)	6 (10)
Less than weekly					18 (19)	20 (12)	6 (14)	10 (16)
Once last month					15 (16)	27 (17)	9 (20)	7 (11)
Not in the last month					49 (52)	86 (53)	23 (52)	32 (52)
Not reported					2 (2)	4 (2)	2 (5)	2 (3)

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 72	N = 125	N = 87	N = 138	N = 94	N = 163	N = 44	N = 62
Sex last month (%)								
No	18 (25)	42 (34)	29 (33)	53 (38)	42 (45)	56 (34)	15 (34)	23 (37)
Yes	49 (68)	80 (64)	58 (67)	85 (62)	51 (54)	106 (65)	29 (66)	38 (61)
Not reported	5 (7)	3 (2)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	1 (2)
Condom use last sex (%)								
Yes	15 (21)	22 (18)	30 (34)	41 (30)	38 (41)	66 (41)	13 (30)	22 (35)
No	41 (57)	57 (45)	55 (64)	91 (66)	53 (56)	95 (58)	30 (68)	39 (63)
Not reported	16 (22)	46 (37)	2 (2)	6 (4)	3 (3)	2 (1)	1 (2)	1 (2)
Condom use with regular sex partner(s) last month (%)*								
No	50 (67)	36 (70)	42 (60)	33 (81)	58 (63)	16 (67)	10 (44)	
Sometimes	13 (18)	8 (15)	14 (20)	3 (7)	15 (16)	6 (25)	6 (26)	
Always	11 915)	8 (15)	14 (20)	5 (12)	19 (21)	2 (8)	7 (30)	
Condom use with new sex partner(s) last month (%)*								
No	14 (48)	12 (34)	8 (30)	6 (35)	8 (25)	3 (25)	12 (57)	
Sometimes	1 (3)	5 (14)	4 (15)	2 (12)	5 (16)	5 (42)	3 (14)	
Always	14 (48)	18 (51)	25 (56)	9 (53)	19 (59)	4 (33)	6 (29)	
Condom use with casual sex partner(s) last month (%)*								
No		12 (32)	9 (39)	11 (28)	5 (46)	7 (42)		
Sometimes		10 (27)	2 (9)	14 (35)	2 (18)	5 (29)		
Always		15 (41)	12 (52)	15 (37)	4 (36)	5 (29)		
Duration of regular sexual relationship (%)**								
One month					2 (10)	3 (11)		
2 - 6 months					2 (10)	1 (4)		
6 - 12 months					5 (24)	3 (12)		
>12 months					12 (56)	19 (73)		
Sex work last month (%)								
Yes	2 (3)	10 (8)	7 (8)	8 (6)	7 (7)	11 (7)	1 (2)	3 (5)
No	68 (94)	105 (84)	78 (90)	126 (91)	86 (91)	148 (91)	43 (98)	58 (94)
Not reported	2 (3)	10 (8)	2 (2)	4 (3)	1 (1)	4 (2)	0 (0)	1 (1)
Condom use last sex work last month (%)**								
Yes	2 (100)	8 (80)	6 (86)	7 (100)	7 (100)	9 (100)	1 (100)	3 (100)

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1996-2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
N° surveyed	N = 72	N = 125	N = 87	N = 138	N = 94	N = 163	N = 44	N = 62
Previous HIV test (%)								
Last year	43 (58)	73 (58)	60 (69)	92 (67)	55 (59)	101 (62)	24 (54)	41 (65)
> 1 year ago	17 (24)	35 (28)	14 (16)	29 (21)	22 (23)	42 (26)	14 (32)	16 (26)
Never tested	4 (6)	6 (5)	0 (0)	3 (2)	17 (18)	20 (12)	6 (14)	4 (7)
Not reported	9 (12)	11 (9)	13 (15)	14 (10)	0 (0)	0 (0)	0 (0)	1 (2)
Self report HBV infection (%)								
Yes	19 (26)	39 (31)	19 (22)	28 (20)	16 (17)	19 (12)	9 (20)	18 (29)
No	50 (70)	84 (67)	53 (61)	98 (71)	70 (75)	119 (73)	33 (75)	36 (58)
Don't know	0 (0)	0 (0)	15 (17)	12 (9)	7 (7)	23 (14)	2 (5)	8 (13)
Not reported	3 (4)	2 (2)	0 (0)	0 (0)	1 (1)	2 (1)	0 (0)	0 (0)
Self report HBV vaccination (%)*								
Yes	22 (42)	48 (56)	33 (34)	47 (46)	43 (56)	71 (49)	19 (54)	25 (57)
No	30 (56)	35 (41)	21 (31)	44 (36)	29 (37)	53 (37)	13 (37)	13 (30)
Don't know	0 (0)	0 (0)	24 (35)	18 (16)	5 (6)	18 (13)	1 (3)	6 (14)
Not reported	1 (2)	3 (3)	0 (0)	1 (2)	1 (1)	2 (1)	2 (6)	0 (0)
Previous HCV test (%)								
Yes ever	59 (82)	106 (84)	---	---	---	---	---	---
Last year	---	---	59 (68)	102 (74)	61 (65)	109 (67)	26 (59)	40 (65)
> 1 year ago	---	---	16 (18)	20 (15)	17 (18)	38 (23)	13 (30)	19 (31)
Never tested	9 (13)	17 (14)	1 (1)	2 (1)	16 (17)	16 (10)	5 (11)	2 (3)
Not reported	4 (5)	2 (2)	11 (13)	14 (10)	0 (0)	0 (0)	0 (0)	1 (2)
Any treatment for HCV (%)								
No					N = 45	N = 83	N = 25	N = 38
Interferon					44 (98)	77 (94)	24 (96)	34 (89)
Interferon + Ribavirin					0 (0)	2 (2)	0 (0)	1 (3)
Other					0 (0)	2 (2)	0 (0)	0 (0)
Not reported					1 (2)	1 (1)	0 (0)	2 (5)
Current treatment for HCV								
Interferon					N = 1	N = 4	N = 0	N = 3
Interferon+Ribarvirin					---	2	---	---
Other					---	1	---	---

* Number (percentage) among participants not reporting HBV infection.

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995	38	2 (5.3)	23	0 (0.0)	62	2 (3.2)
1996	69	1 (1.5)	55	0 (0.0)	125	1 (0.8)
1997	53	0 (0.0)	27	0 (0.0)	80	0 (0.0)
1998	87	0 (0.0)	50	0 (0.0)	137	0 (0.0)
1999	50	0 (0.0)	42	1 (2.4)	92	1 (1.1)
2000	120	0 (0.0)	42	0 (0.0)	162	0 (0.0)
2001	33	0 (0.0)	8	0 (0.0)	41	0 (0.0)
2002	33	0 (0.0)	21	0 (0.0)	61	0 (0.0)

* Total includes people whose sex was not reported or reported as transgender.

Table 8: HIV antibody prevalence according to sexual identity, 1995-2002.

Sexual identity	Nº tested	Nº with HIV (%)
Heterosexual	611	4 (0.7)
Bisexual	74	0 (0.0)
Homosexual	29	0 (0.0)
p value		0.7

Table 9: HIV antibody prevalence according to age group, 1995-2002.

Age group	Nº tested	Nº with HIV (%)
<20 years	109	0 (0.0)
20 – 24	180	0 (0.0)
25 – 29	157	0 (0.0)
30 + years	313	4 (1.3)
p value		0.1

Table 10: HIV antibody prevalence according to duration of drug injection, 1995-2002.

Duration of drug injection	Nº tested	Nº with HIV (%)
<1 to 2 years	120	0 (0.0)
3 to 5 years	150	0 (0.0)
6 to 10 years	166	0 (0.0)
10 + years	305	4 (1.3)
p value		0.1

Table 11: HIV antibody prevalence according to last drug injected, 1995-2002.

Last drug injected	Nº tested	Nº with HIV (%)
Amphetamine	84	0 (0.0)
Heroin	557	3 (0.5)
More than one	57	1 (1.8)
Other/not reported	62	0 (0.0)
p value		0.5

Table 12: HIV antibody prevalence according to frequency of drug injection last month, 1995-2002.

Frequency of drug injection last month	Nº tested	Nº with HIV (%)
Less than daily	315	1 (0.3)
More than daily	371	1 (0.3)
No injection last month	69	2 (2.9)
p value		0.02

Table 13: HIV antibody prevalence according to reuse of someone else's syringe last month, 1995-2002.

Reused someone else's syringe last month	Nº tested	Nº with HIV (%)
No	513	2 (0.4)
Yes	167	0 (0.0)
No injection last month	80	2 (2.5)
p value		0.03

Table 14: HIV antibody prevalence according to imprisonment last year, 1995-2002.

Imprisonment last year	Nº tested	Nº with HIV (%)
No	631	4 (0.6)
Yes	117	0 (0.0)
p value		0.4

Table 15: HIV antibody prevalence according to condom use last sex, 1995-2002.

Condom use last sex	Nº tested	Nº with HIV (%)
No	444	2 (0.5)
Yes	240	2 (0.9)
p value		0.5

Table 16: HIV antibody prevalence according to sex work last month, 1995-2002.

Sex work last month	Nº tested	Nº with HIV (%)
No	688	4 (0.6)
Yes	48	0 (0.0)
p value		0.6

HCV antibody prevalence

Table 17: HCV antibody prevalence according to year of survey and sex.

Year of survey	Males		Females		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	32	18 (56)	21	14 (67)	54	33 (61)
1996	69	45 (65)	55	32 (62)	125	80 (64)
1997	53	21 (40)	27	11 (41)	80	32 (40)
1998	87	46 (53)	50	22 (44)	137	68 (50)
1999	48	30 (63)	42	24 (57)	90	54 (60)
2000	120	65 (54)	42	27 (64)	162	92 (57)
2001	33	20 (61)	8	5 (63)	41	25 (61)
2002	40	30 (75)	21	18 (86)	61	48 (79)
χ^2 trend p value		0.2		0.2		0.1

Table 18: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995 – 1996						
< 25 years	23	8 (35)	21	10 (48)	44	18 (41)
25 + years	77	55 (71)	55	38 (69)	134	95 (71)
Total	100	63 (63)	76	48 (63)	178	113 (63)
p value		0.001		0.08		<0.001
1997 – 1998						
< 25 years	68	15 (22)	43	11 (26)	111	26 (23)
25 + years	72	52 (72)	34	22 (65)	106	74 (70)
Total	140	67 (48)	77	33 (43)	217	100 (46)
p value		<0.001		0.001		<0.001
1999 – 2000						
< 25 years	65	18 (28)	40	19 (48)	105	37 (35)
25 + years	103	77 (75)	44	32 (73)	47	109 (74)
Total	168	95 (57)	84	51 (61)	252	146 (58)
p value		<0.001		0.02		<0.001
2001 – 2002						
< 25 years	13	5 (38)	13	7 (54)	26	12 (46)
25 + years	60	45 (75)	16	16(100)	76	61 (80)
Total	73	50 (68)	29	23 (79)	102	73 (72)
p value		0.01		0.002		0.001

* Total includes people whose sex was not reported or reported as transgender.

ACT
HCV ANTIBODY

Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995 - 1996						
< 3 years	1	0 (0)	11	3 (27)	12	4 (33)
3 to 5 years	18	4 (22)	13	3 (23)	31	7 (23)
6 to 10 years	29	19 (66)	14	11 (79)	43	30 (70)
10 + years	50	37 (74)	36	29 (81)	88	68 (77)
p value		0.001		<0.001		<0.001
1997 - 1998						
< 3 years	23	5 (22)	28	4 (14)	51	9 (18)
3 to 5 years	36	8 (22)	19	7 (37)	55	15 (27)
6 to 10 years	27	8 (30)	8	2 (25)	35	10 (29)
10 + years	50	43 (86)	22	20 (91)	72	63 (88)
p value		<0.001		<0.001		<0.001
1999 - 2000						
< 3 years	34	5 (15)	14	4 (29)	48	9 (19)
3 to 5 years	31	11 (35)	24	14 (58)	55	25 (45)
6 to 10 years	38	27 (71)	15	8 (53)	53	35 (66)
10 + years	62	50 (81)	28	23 (82)	90	73 (81)
p value		<0.001		0.008		<0.001
2001 - 2002						
< 3 years	5	3 (60)	2	2 (100)	7	5 (71)
3 to 5 years	4	2 (50)	4	3 (75)	8	5 (63)
6 to 10 years	20	11 (55)	14	9 (64)	34	20 (59)
10 + years	41	34 (83)	9	9 (100)	50	43 (86)
p value		0.09		0.2		0.04

* Total includes people whose sex was not reported or reported as transgender.

Table 20: HCV antibody prevalence according to year of survey and last drug injected.

Last drug injected	Nº tested	Nº with HCV (%)
1995-1996		
Amphetamine	15	7 (47)
Heroin	123	79 (64)
More than one	18	12 (67)
Other/not reported	23	15 (65)
p value		0.6
1997-1998		
Amphetamine	16	8 (50)
Heroin	180	79 (44)
More than one	11	7 (64)
Other/not reported	10	6 (60)
p value		0.5
1999-2000		
Amphetamine	25	9 (36)
Heroin	197	118 (60)
More than one	19	13 (68)
Other/not reported	11	6 (55)
p value		0.1
2001-2002		
Amphetamine	26	15 (58)
Heroin	52	38 (73)
More than one	8	6 (75)
Other/not reported	16	14 (88)
p value		0.2

Table 21: HCV antibody prevalence according to year of survey and frequency of drug injection last month.

Frequency of drug injection last month	Nº tested	Nº with HCV (%)
1995-1996		
Less than daily	97	64 (66)
Daily or more	56	36 (64)
p value		0.8
1997-1998		
Less than daily	79	42 (53)
Daily or more	126	48 (38)
p value		0.03
1999-2000		
Less than daily	79	50 (63)
Daily or more	150	83 (55)
p value		0.2
2001-2002		
Less than daily	53	37 (70)
Daily or more	38	28 (74)
p value		0.7

Table 22: HCV antibody prevalence according to year of survey and re-use of someone else's syringe last month.

Reused of someone else's syringe last month	Nº tested	Nº with HCV (%)
1995-1996		
Yes	44	33 (75)
No	109	67 (61)
p value		0.1
1997-1998		
Yes	42	12 (29)
No	159	77 (48)
p value		0.02
1999-2000		
Yes	54	31 (57)
No	173	101 (58)
p value		0.9
2001-2002		
Yes	25	15 (60)
No	63	48 (76)
p value		0.1

Table 23: HCV antibody prevalence according to year of survey and imprisonment last year.

Imprisonment last year	Nº tested	Nº with HCV (%)
1995-1996		
Yes	18	13 (72)
No	155	97 (63)
p value		0.4
1997-1998		
Yes	39	23 (59)
No	175	76 (43)
p value		0.08
1999-2000		
Yes	38	23 (61)
No	212	122 (58)
p value		0.7
2001-2002		
Yes	20	16 (80)
No	82	57 (70)
p value		0.4

ACT
HCV ANTIBODY

Table 24: HCV antibody prevalence according to year of survey and sex work last month.

Sex work last month	Nº tested	Nº with HCV (%)
1995-1996		
Yes	12	6 (50)
No	156	97 (62)
p value		0.4
1997-1998		
Yes	14	5 (36)
No	197	93 (47)
p value		0.4
1999-2000		
Yes	18	14 (78)
No	229	128 (56)
p value		0.07
2001-2002		
Yes	4	3 (75)
No	97	69 (71)
p value		0.9

NEW SOUTH WALES
1995-2002

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	4	4	7	11	14	13	14	18
Response								
Nº surveyed	N = 433	N = 499	N = 682	N = 1001	N = 907	N = 911	N = 691	N = 760
% response	40%	47%	66%	37%	41%	43%	40%	29%
Sex (%)								
Male	267 (62)	324 (65)	414 (61)	597 (60)	575 (63)	570 (63)	430 (62)	485 (64)
Female	159 (37)	170 (34)	267 (39)	398 (40)	326 (36)	336 (37)	252 (36)	267 (35)
Transgender	2 (<1)	1 (<1)	11 (<1)	3 (<1)	5 (1)	2 (<1)	5 (1)	6 (1)
Not reported	5 (1)	4 (1)	0 (0)	3 (<1)	1 (<1)	3 (<1)	4 (1)	2 (<1)
Sexual identity (%)								
Heterosexual	352 (81)	380 (76)	529 (78)	808 (81)	671 (74)	693 (76)	536 (78)	578 (76)
Bisexual	44 (10)	53 (11)	78 (11)	92 (9)	116 (13)	93 (10)	77 (11)	83 (11)
Gay/lesbian	24 (6)	39 (8)	47 (7)	44 (4)	38 (4)	54 (6)	31 (4)	38 (5)
Not reported	13 (3)	27 (5)	28 (4)	57 (6)	82 (9)	71 (8)	47 (7)	61 (8)
Age and duration of injection (years)								
Median age	31	31	31	30	30	30	30	30
Age range	17 – 54	15 – 59	15 – 58	15 – 63	16 – 69	15 – 61	16 – 62	16 – 63
Not reported	5	1	0	1	1	10	2	2
Median age 1 st IDU	17	17	18	18	18	18	18	18
Age range	10 – 40	9 – 48	7 – 49	9 – 46	8 – 55	10 – 54	8 – 52	9 – 529
Not reported	6	18	20	24	19	23	22	26
Median years IDU	13	12	11	10	10	9	10	10
Range	<1 – 33	<1 – 34	<1 – 37	<1 – 37	<1 – 35	<1 – 41	<1 – 44	<1 – 43
Not reported	9	18	20	24	19	36	23	26
Aboriginal and Torres Strait Islander Origin (%)								
Yes	28 (6)	34 (7)	46 (7)	80 (8)	80 (9)	93 (10)	63 (9)	76 (10)
No	390 (91)	417 (83)	620 (91)	888 (89)	793 (87)	798 (88)	606 (88)	652 (86)
Not reported	15 (3)	48 (10)	16 (2)	33 (3)	34 (4)	20 (2)	22 (3)	32 (4)
Imprisonment last year (%)								
Yes	93 (21)	94 (19)	137 (20)	240 (24)	170 (19)	211 (23)	147 (21)	160 (21)
No	335 (78)	384 (77)	543 (80)	746 (74)	721 (79)	671 (74)	520 (75)	582 (77)
Not reported	5 (1)	21 (4)	2 (<1)	15 (2)	16 (2)	29 (3)	24 (4)	18 (2)
Injected in prison	N = 93	N = 94	N = 137	N = 240	N = 170	N = 211	N = 147	N = 160
Yes	33(35)	40(43)	49(36)	110(46)	80(47)	99(47)	58 (39)	61 (38)
Frequency of injection last month (%)								
Not last month	23 (5)	28 (6)	44 (6)	52 (5)	60 (7)	45 (5)	83 (12)	86 (11)
Less than weekly	71 (16)	83 (17)	169 (25)	90 (9)	115 (13)	85 (9)	107 (15)	108 (14)
Weekly not daily	146 (34)	165 (33)	93 (14)	197 (20)	178 (20)	182 (20)	150 (22)	162 (21)
Daily or more	191 (45)	219 (44)	369 (54)	660 (66)	548 (60)	585 (64)	336 (49)	393 (53)
Not reported	2 (<1)	4 (1)	7 (1)	2 (<1)	6 (1)	14 (2)	15 (2)	11 (1)
Last drug injected (%)								
Amphetamine	35 (8)	44 (9)	59 (9)	74 (7)	110 (12)	113 (12)	115 (16)	173 (23)
Anabolic steroids	3 (1)	8 (2)	11 (2)	16 (2)	24 (3)	12 (1)	14 (2)	17 (2)
Benzos	0 (0)	1 (<1)	0 (0)	4 (<1)	1 (<1)	2 (<1)	6 (1)	3 (<1)
Buprenorphine	---	---	---	---	---	---	---	0 (0.0)
Cocaine	15 (3)	26 (5)	31 (5)	55 (5)	52 (6)	25 (3)	146 (21)	26 (3)
Heroin	136 (31)	196 (39)	318 (46)	483 (48)	534 (59)	534 (59)	221 (32)	367 (48)
Heroin + Cocaine	6 (1)	11 (2)	23 (3)	75 (7)	45 (5)	61 (7)	71 (10)	21 (3)
Methadone	183 (42)	141 (28)	168 (24)	182 (18)	54 (6)	65 (7)	56 (8)	66 (9)
Morphine	3 (1)	8 (2)	1 (<1)	5 (1)	3 (<1)	5 (1)	4 (1)	14 (2)
More than one	50 (12)	61 (12)	62 (9)	99 (10)	75 (8)	77 (8)	39 (6)	61 (8)
Other	0 (0)	5 (1)	4 (1)	1 (<1)	3 (<1)	7 (1)	5 (1)	2 (<1)
Not reported	2 (<1)	1 (<1)	5 (1)	7 (1)	8 (1)	11 (1)	14 (2)	10 (1)

NEW SOUTH WALES

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 408	N = 467	N = 631	N = 947	N = 841	N = 852	N = 593	N = 667
Places injected last month (%)*								
Own home	539 (85)	800 (84)	676 (80)	676 (79)	457 (77)	530 (80)		
Friend's home	257 (41)	363 (38)	331 (39)	352 (41)	243 (41)	236 (36)		
Dealer's home	85 (13)	157 (17)	141 (17)	141 (17)	81 (14)	85 (13)		
Street, park, beach	177 (28)	305 (32)	296 (35)	346 (41)	191 (32)	195 (29)		
Car	---	---	291 (35)	303 (36)	175 (30)	174 (26)		
Public toilet	158 (25)	241 (25)	265 (32)	307 (36)	177 (30)	171 (26)		
"Shooting" room	85 (13)	111 (12)	64 (8)	50 (6)	58 (10)	46 (7)		
Squat	---	---	76 (9)	120 (14)	73 (12)	57 (9)		
MSIC	---	---	---	---	64 (11)	73 (11)		
Use of new sterile needles & syringes last month (%)								
All injections	412 (61)	593 (59)	527 (58)	537 (59)	393 (66)	453 (68)		
Most of the time	175 (26)	249 (25)	234 (26)	248 (27)	157 (27)	148 (23)		
Half of the time	16 (2)	26 (3)	36 (4)	31 (3)	16 (3)	22 (3)		
Some of the time	9 (1)	44 (4)	13 (1)	19 (2)	12 (2)	14 (2)		
Not last month	0 (0)	2 (<1)	3 (<1)	6 (1)	2 (<1)	12 (2)		
Not reported	70 (10)	87 (9)	94 (10)	70 (8)	13 (2)	14 (2)		
Re-used another's syringe last month (%)								
None	266 (65)	319 (68)	510 (81)	736 (78)	623 (74)	667 (78)	481 (81)	519 (78)
Once	39 (10)	54 (12)	27 (4)	56 (6)	60 (7)	60 (7)	33 (6)	39 (6)
Twice	52 (13)	52 (11)	24 (3)	54 (6)	38 (5)	37 (5)	12 (2)	30 (5)
3-5 times	29 (7)	22 (5)	16 (3)	49 (5)	28 (3)	43 (5)	26 (4)	20 (3)
>5 times	22 (5)	18 (4)	16 (3)	20 (2)	27 (3)	16 (2)	19 (3)	17 (3)
Not reported	0 (0)	2 (1)	38 (6)	32 (3)	65 (8)	29 (3)	22 (4)	37 (6)
Number of people syringe was re-used after last month (%)								
None	266 (65)	319 (68)	510 (81)	736 (78)	623 (74)	667 (78)	481 (81)	519 (78)
One	99 (24)	102 (22)	83 (13)	136 (14)	139 (17)	119 (14)	52 (9)	65 (10)
Two	34 (8)	38 (8)	14 (2)	30 (3)	23 (3)	16 (2)	10 (2)	12 (2)
Three to five	3 (1)	0 (0)	2 (<1)	8 (1)	11 (1)	8 (1)	5 (1)	5 (1)
More than five	5 (1)	6 (1)	4 (1)	4 (1)	10 (1)	9 (1)	8 (1)	8 (1)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	4 (<1)	4 (1)	4 (1)	19 (3)
Not reported	1 (1)	2 (1)	18 (3)	32 (3)	31 (4)	29 (3)	33 (5)	35 (5)
Relationship to people syringe was re-used after last month*								
Regular sex partner	60 (10)	88 (9)	101 (12)	81 (10)	45 (8)	53 (8)		
Casual sex partner	4 (1)	10 (1)	12 (1)	6 (1)	8 (1)	4 (1)		
Close friend	23 (4)	60 (6)	70 (8)	50 (6)	23 (4)	36 (5)		
Acquaintance	7 (1)	25 (3)	16 (2)	19 (2)	12 (2)	11 (2)		
Other	3 (<1)	8 (1)	11 (1)	11 (1)	2 (<1)	8 (1)		
Equipment used after someone else last month (%)*								
Spoon				352 (42)	293 (34)	192 (32)	174 (26)	
Water				223 (27)	193 (23)	140 (24)	138 (21)	
Filter				172 (20)	147 (17)	98 (17)	102 (15)	
Tourniquet				135 (16)	87 (10)	85 (14)	72 (11)	
Drug mix				120 (14)	110 (13)	79 (13)	95 (14)	
Injected by someone else who'd already injected themselves or others last month (%)								
Yes				124 (15)	146 (17)	122 (21)	123 (19)	
No				676 (80)	666 (78)	444 (75)	511 (77)	
Not reported				41 (5)	40 (5)	27 (4)	29 (4)	

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 433	N = 499	N = 682	N = 1001	N = 907	N = 911	N = 691	N = 760
Any treatment/therapy for drug use (%)								
No	45 (10)	77 (15)	111 (16)	200 (20)	238 (26)	211 (23)	165 (24)	189 (25)
Yes	387 (89)	419 (84)	569 (83)	798 (80)	667 (74)	666 (73)	520 (75)	559 (73)
Not reported	1 (1)	3 (1)	2 (1)	3 (<1)	2 (<1)	34 (4)	6 (1)	12 (2)
History of methadone treatment (%)								
Currently	300 (69)	279 (56)	382 (56)	500 (50)	369 (40)	304 (33)	294 (43)	266 (35)
Previously	55 (13)	110 (22)	120 (18)	190 (19)	178 (20)	253 (28)	134 (19)	199 (26)
Never	77 (18)	107 (21)	178 (26)	308 (31)	359 (40)	347 (38)	256 (37)	280 (37)
Not reported	1 (<1)	3 (1)	2 (<1)	3 (<1)	1 (<1)	7 (1)	7 (1)	5 (2)
History of other pharmacological therapy (%)								
Currently					16 (2)	8 (1)	31 (4)	29 (4)
Previously					53 (6)	79 (9)	50 (7)	82 (11)
Never					603 (66)	592 (65)	598 (87)	627 (82)
Not reported					235 (26)	232 (25)	12 (2)	22 (3)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 907	N = 911	N = 691	N = 760
From an NSP last month (%)								
Daily or almost daily				220 (24)	271 (30)	157 (23)	154 (20)	
A couple of times each week				289 (32)	290 (32)	197 (29)	199 (26)	
Less than weekly				171 (19)	147 (16)	125 (18)	175 (23)	
Once last month				120 (13)	101 (11)	92 (13)	98 (13)	
Not in the last month				89 (10)	86 (9)	104 (15)	111 (15)	
Not reported				18 (2)	16 (2)	16 (2)	23 (3)	
From a chemist last month (%)								
Daily or almost daily				76 (8)	105 (12)	72 (10)	69 (9)	
A couple of times each week				150 (16)	184 (20)	101 (15)	107 (14)	
Less than weekly				134 (15)	128 (14)	98 (14)	100 (13)	
Once last month				137 (15)	131 (14)	114 (17)	103 (14)	
Not in the last month				378 (42)	322 (35)	285 (41)	357 (47)	
Not reported				32 (4)	40 (5)	21 (3)	24 (3)	

NEW SOUTH WALES

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 433	N = 499	N = 682	N = 1001	N = 907	N = 911	N = 691	N = 760
Sex last month (%)								
No	97 (22)	128 (26)	250 (37)	352 (35)	291 (32)	347 (38)	231 (33)	224 (30)
Yes	307 (71)	357 (71)	431 (63)	637 (64)	609 (67)	553 (61)	448 (65)	515 (67)
Not reported	29 (7)	14 (3)	1 (<1)	12 (1)	7 (1)	11 (1)	12 (2)	21 (3)
Condoms last sex (%)								
No	259 (60)	236 (48)	441 (65)	658 (66)	531 (58)	525 (58)	435 (63)	459 (60)
Yes	107 (25)	107 (21)	225 (33)	315 (31)	344 (38)	350 (38)	235 (34)	279 (37)
Not reported	67 (15)	156 (31)	16 (2)	28 (3)	32 (4)	36 (4)	21 (3)	22 (3)
Condom use with regular sex partner(s) last month (%)*								
No	233 (73)	257 (64)	357 (66)	333 (64)	296 (64)	189 (62)	209 (59)	
Sometimes	26 (8)	46 (12)	71 (13)	58 (11)	43 (9)	49 (16)	54 (15)	
Always	60 (19)	95 (24)	113 (21)	127 (25)	124 (27)	69 (22)	90 (26)	
Condom use with new sex partner(s) last month (%)*								
No	43 (33)	57 (31)	51 (31)	85 (33)	66 (32)	95 (39)	93 (36)	
Sometimes	14 (11)	23 (12)	26 (16)	37 (14)	23 (11)	46 (19)	36 (14)	
Always	72 (56)	107 (57)	86 (53)	134 (53)	117 (57)	105 (42)	129 (50)	
Condom use with casual sex partner(s) last month (%)*								
No				58 (28)	83 (29)	71 (29)	93 (42)	86 (36)
Sometimes				34 (17)	60 (21)	31 (13)	47 (21)	54 (23)
Always				114 (55)	147 (50)	142 (58)	83 (37)	100 (41)
Duration of regular sexual relationship (%)**								
One month						35 (11)	31 (9)	
2 - 6 months						56 (19)	56 (16)	
6 - 12 months						38 (13)	52 (14)	
>12 months						173 (57)	222 (61)	
Sex work last month (%)								
Yes	27 (6)	52 (10)	74 (11)	84 (8)	110 (12)	105 (12)	85 (12)	85 (11)
No	393 (91)	414 (83)	592 (87)	890 (89)	771 (85)	775 (85)	577 (84)	647 (85)
Not reported	13 (3)	33 (7)	16 (2)	27 (3)	26 (3)	31 (3)	29 (4)	28 (4)
Condom use last sex work last month (%)**								
Yes	23 (100)	46 (94)	59 (95)	73 (94)	98 (93)	72 (94)	53 (91)	57 (95)

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1996-2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
N ^o surveyed	N = 433	N = 499	N = 682	N = 1001	N = 907	N = 911	N = 691	N = 761
Previous HIV test (%)								
Yes, last year	319 (74)	398 (80)	536 (79)	797 (80)	604 (67)	618 (68)	437 (63)	491 (65)
> 1 year ago	79 (18)	85 (17)	118 (17)	185 (18)	197 (22)	182 (20)	163 (24)	168 (22)
Never tested	30 (7)	14 (3)	23 (3)	9 (1)	92 (10)	98 (11)	78 (11)	90 (12)
Not reported	5 (1)	2 (<1)	5 (1)	10 (1)	14 (1)	13 (1)	13 (2)	11 (1)
Self report HBV infection (%)								
Yes	176 (41)	194 (39)	192 (28)	253 (25)	193 (21)	201 (22)	153 (22)	161 (21)
No	252 (58)	300 (60)	399 (59)	573 (57)	633 (70)	595 (65)	426 (62)	493 (65)
Don't know	0 (0)	0 (0)	88 (13)	154 (15)	65 (7)	101 (11)	98 (14)	94 (12)
Not reported	5 (1)	5 (1)	3 (<1)	21 (2)	16 (2)	14 (2)	14 (2)	12 (2)
Self report HBV vaccination (%)*								
Yes	121 (47)	144 (47)	200 (41)	305 (41)	336 (46)	337 (47)	249 (46)	315 (53)
No	125 (49)	152 (50)	205 (42)	281 (38)	286 (43)	266 (38)	167 (31)	200 (33)
Don't know	0 (0)	0 (0)	81 (16)	138 (18)	76 (9)	86 (12)	80 (15)	67 (11)
Not reported	11 (4)	9 (3)	4 (1)	24 (3)	16 (2)	19 (3)	42 (8)	17 (3)
Previous HCV test (%)								
Yes ever	365 (84)	443 (89)	---	---	---	---	---	---
Yes, last year	---	---	528 (77)	694 (69)	610 (67)	667 (73)	479 (69)	510 (68)
> 1 year ago	---	---	94 (14)	161 (16)	187 (21)	148 (16)	147 (21)	163 (21)
Never tested	59 (14)	48 (10)	55 (8)	139 (14)	97 (11)	83 (9)	55 (8)	79 (10)
Not reported	9 (2)	8 (2)	5 (1)	7 (1)	13 (1)	13 (1)	10 (2)	9 (1)
Any treatment for HCV (%)								
Interferon					N = 401	N = 451	N = 337	N = 390
Interferon+Ribavarin					7 (2)	20 (4)	8 (2)	13 (3)
Other					3 (1)	4 (1)	3 (1)	3 (1)
No treatment					17 (4)	17 (4)	6 (2)	9 (2)
Not reported					367 (92)	402 (89)	315 (93)	356 (92)
Current treatment for HCV								
Interferon					N = 8	N = 13	N = 5	N = 4
Interferon+Ribavarin					3	2	2	1
Other					1	2	1	1
					4	9	2	2

* Number (percentage) among participants not reporting HBV infection

NEW SOUTH WALES

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Nº tested	Male		Female		Nº tested	Total *
		Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested		
1995	259	6 (2.3)	155	4 (2.6)	420	11 (2.6)	
1996	317	8 (2.5)	162	5 (3.1)	484	13 (2.7)	
1997	384	6 (1.6)	254	1 (0.4)	639	7 (1.1)	
1998	542	5 (0.9)	368	1 (0.3)	916	6 (0.7)	
1999	536	8 (1.5)	312	1 (0.3)	854	9 (1.1)	
2000	535	11 (2.1)	326	0 (0.0)	866	11 (1.3)	
2001	406	6 (1.5)	241	0 (0.0)	656	6 (0.9)	
2002	469	13 (2.8)	261	1 (0.4)	738	15 (2.0)	
χ^2 trend p value		0.7		<0.001			0.02

Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.

Sexual identity	Nº tested	Male		Female		Nº tested	Total *
		Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested		
1995							
Heterosexual	225	1 (0.4)	113	2 (1.7)	341	4 (1.2)	
Bisexual	11	0 (0.0)	31	1 (3.2)	43	1 (2.3)	
Homosexual	14	5 (35.7)	9	1 (11.1)	24	6 (25.0)	
p value		<0.001		0.2		<0.001	
1996							
Heterosexual	256	0 (0.0)	113	3 (2.7)	371	3 (0.8)	
Bisexual	23	2 (8.7)	26	0 (0.0)	49	2 (4.1)	
Homosexual	23	6 (26.1)	14	1 (7.1)	37	7 (18.9)	
p value		<0.001		0.4		<0.001	
1997							
Heterosexual	319	1 (0.3)	173	1 (0.6)	492	2 (0.4)	
Bisexual	30	0 (0.0)	44	0 (0.0)	74	0 (0.0)	
Homosexual	17	5 (29.4)	28	0 (0.0)	45	5 (11.1)	
p value		<0.001		0.8		<0.001	
1998							
Heterosexual	459	2 (0.4)	274	0 (0.0)	735	2 (0.3)	
Bisexual	30	2 (6.7)	60	1 (1.7)	90	3 (3.3)	
Homosexual	14	1 (7.1)	23	0 (0.0)	37	1 (2.7)	
p value		<0.001		0.08		0.001	
1999							
Heterosexual	424	3 (0.7)	208	1 (0.5)	632	4 (0.6)	
Bisexual	34	0 (0.0)	69	0 (0.0)	107	0 (0.0)	
Homosexual	26	5 (19.2)	11	0 (0.0)	37	5 (13.5)	
p value		<0.001		0.8		<0.001	
2000							
Heterosexual	451	6 (1.3)	---	---	656	6 (0.9)	
Bisexual	18	1 (5.6)	---	---	88	1 (1.1)	
Homosexual	22	4 (18.2)	---	---	53	4 (7.6)	
p value		<0.001				<0.001	
2001							
Heterosexual	342	1 (0.3)	---	---	512	1 (0.2)	
Bisexual	21	1 (4.8)	---	---	72	1 (1.4)	
Homosexual	15	4 (26.7)	---	---	29	4 (13.8)	
p value		<0.001				<0.001	
2002							
Heterosexual	388	3 (0.8)	175	1 (0.6)	566	4 (0.7)	
Bisexual	24	1 (4.2)	51	0 (0.0)	79	2 (2.5)	
Homosexual	20	8 (40.0)	14	0 (0.0)	34	8 (23.5)	
p value		<0.001		0.8		<0.001	

* Total includes people whose sex was not reported or reported transgender.

Table 9: HIV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
< 20 years	5	0 (0.0)	8	0 (0.0)	14	0 (0.0)
20 – 24	32	3 (9.4)	33	1 (3.0)	67	4 (6.0)
25 – 29	55	1 (1.8)	34	1 (2.9)	89	2 (2.3)
30 + years	163	2 (1.2)	79	2 (2.5)	245	5 (2.0)
p value		0.05		>0.9		0.3
1996						
< 20 years	9	0 (0.0)	9	0 (0.0)	19	0 (0.0)
20 – 24	46	0 (0.0)	27	2 (7.4)	73	2 (2.7)
25 – 29	71	1 (1.4)	45	0 (0.0)	117	1 (0.9)
30 + years	190	7 (3.7)	81	3 (3.7)	274	10 (3.7)
p value		0.4		0.3		0.4
1997						
< 20 years	9	0 (0.0)	20	0 (0.0)	29	0 (0.0)
20 – 24	68	0 (0.0)	45	0 (0.0)	113	0 (0.0)
25 – 29	75	3 (4.0)	66	0 (0.0)	141	3 (2.1)
30 + years	232	3 (1.3)	123	1 (0.8)	356	4 (1.2)
p value		0.2		0.8		0.4
1998						
< 20 years	45	0 (0.0)	35	0 (0.0)	80	0 (0.0)
20 – 24	99	0 (0.0)	83	0 (0.0)	183	0 (0.0)
25 – 29	105	1 (1.0)	79	0 (0.0)	188	1 (0.5)
30 + years	292	4 (1.4)	171	1 (0.6)	464	5 (1.1)
p value		0.6		0.8		0.4
1999						
< 20 years	32	0 (0.0)	23	1 (4.4)	55	1 (1.8)
20 – 24	95	0 (0.0)	60	0 (0.0)	155	0 (0.0)
25 – 29	122	1 (0.8)	78	0 (0.0)	202	1 (0.5)
30 + years	287	7 (2.4)	151	0 (0.0)	441	7 (1.6)
p value		0.3		0.006		0.3
2000						
< 20 years	32	0 (0.0)	---	---	73	0 (0.0)
20 – 24	95	0 (0.0)	---	---	167	0 (0.0)
25 – 29	117	3 (2.6)	---	---	191	3 (1.6)
30 + years	291	8 (2.8)	---	---	435	8 (1.8)
p value		0.3				0.2
2001						
< 20 years	23	0 (0.0)	---	---	41	0 (0.0)
20 – 24	59	0 (0.0)	---	---	116	0 (0.0)
25 – 29	87	1 (1.2)	---	---	138	1 (0.7)
30 + years	237	5 (2.1)	---	---	359	5 (1.4)
p value		0.6				0.5
2002						
< 20 years	18	0 (0.0)	14	0 (0.0)	32	0 (0.0)
20 – 24	72	0 (0.0)	62	0 (0.0)	135	0 (0.0)
25 – 29	111	4 (3.6)	60	1 (1.7)	171	5 (0.7)
30 + years	266	9 (3.4)	125	0 (0.0)	398	10 (1.4)
p value		0.4		0.3		0.2

* Total includes people whose sex was not reported or reported transgender.

NEW SOUTH WALES
HIV ANTIBODY

Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
<1 to 2 years	9	1 (11.1)	13	0 (0.0)	23	1 (4.4)
3 to 5 years	20	2 (10.0)	17	0 (0.0)	38	2 (5.3)
6 to 10 years	56	1 (1.8)	40	2 (5.0)	97	3 (3.1)
10 + years	169	2 (1.2)	83	2 (2.4)	254	5 (2.0)
p value		0.03		0.6		0.6
1996						
<1 to 2 years	29	1 (3.5)	14	2 (14.3)	44	3 (6.8)
3 to 5 years	26	0 (0.0)	17	1 (5.9)	43	1 (2.3)
6 to 10 years	66	2 (3.3)	42	1 (2.4)	108	3 (2.8)
10 + years	184	5 (2.7)	84	1 (1.2)	272	6 (2.2)
p value		0.8		0.07		0.4
1997						
<1 to 2 years	30	2 (6.7)	24	0 (0.0)	54	2 (3.7)
3 to 5 years	49	0 (0.0)	36	0 (0.0)	85	0 (0.0)
6 to 10 years	80	3 (3.8)	64	0 (0.0)	144	3 (2.1)
10 + years	211	1 (0.5)	124	1 (0.8)	336	2 (0.6)
p value		0.02		0.8		0.1
1998						
<1 to 2 years	71	1 (1.4)	52	0 (0.0)	124	1 (0.8)
3 to 5 years	76	0 (0.0)	65	0 (0.0)	141	0 (0.0)
6 to 10 years	111	0 (0.0)	79	0 (0.0)	191	0 (0.0)
10 + years	266	4 (1.5)	167	1 (0.6)	436	5 (1.2)
p value		0.4		0.8		0.3
1999						
<1 to 2 years	74	0 (0.0)	43	0 (0.0)	117	0 (0.0)
3 to 5 years	88	2 (2.3)	56	1 (1.8)	144	3 (2.1)
6 to 10 years	114	1 (0.9)	71	0 (0.0)	186	1 (0.5)
10 + years	239	5 (2.1)	136	0 (0.0)	378	5 (1.3)
p value		0.5		0.2		0.3
2000						
<1 to 2 years	70	1 (1.4)	---	---	116	1 (0.9)
3 to 5 years	79	3 (3.8)	---	---	140	3 (2.1)
6 to 10 years	120	1 (0.8)	---	---	213	1 (0.5)
10 + years	245	6 (2.5)	---	---	364	6 (1.7)
p value		0.5				0.5
2001						
<1 to 2 years	55	2 (3.6)	---	---	86	2 (2.3)
3 to 5 years	62	0 (0.0)	---	---	104	0 (0.0)
6 to 10 years	77	1 (1.3)	---	---	142	1 (0.7)
10 + years	201	3 (1.5)	---	---	306	3 (1.0)
p value		0.5				0.4
2002						
<1 to 2 years	54	0 (0.0)	20	0 (0.0)	75	0 (0.0)
3 to 5 years	62	0 (0.0)	54	1 (1.9)	118	1 (0.9)
6 to 10 years	108	3 (2.8)	66	0 (0.0)	175	4 (2.3)
10 + years	230	9 (3.9)	113	0 (0.0)	346	9 (2.6)
p value		0.2		0.3		0.4

* Total includes people whose sex was not reported or reported transgender.

Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex.

Last drug injected	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Amphetamine	22	2 (9.1)	12	0 (0.0)	35	2 (5.7)
Heroin	83	2 (2.4)	48	1 (2.1)	131	3 (2.3)
More than one	38	2 (5.3)	16	0 (0.0)	56	3 (5.4)
Other/not reported	116	0 (0.0)	79	3 (3.8)	198	3 (1.5)
p value		0.03		0.7		0.3
1996						
Amphetamine	28	3 (10.7)	15	0 (0.0)	43	3 (7.0)
Heroin	129	5 (3.9)	58	3 (5.2)	187	8 (4.3)
More than one	50	0 (0.0)	22	1 (4.6)	72	1 (1.4)
Other/not reported	110	0 (0.0)	67	1 (1.5)	182	1 (0.6)
p value		0.005		0.6		0.04
1997						
Amphetamine	33	1 (3.0)	25	0 (0.0)	58	1 (1.7)
Heroin	175	4 (2.3)	118	0 (0.0)	294	4 (1.4)
More than one	47	1 (2.1)	29	0 (0.0)	76	1 (1.3)
Other/not reported	129	0 (0.0)	82	1 (1.2)	211	1 (0.5)
p value		0.4		0.6		0.8
1998						
Amphetamine	36	1 (2.8)	27	0 (0.0)	63	1 (1.6)
Heroin	266	3 (1.1)	167	0 (0.0)	435	3 (0.7)
More than one	95	0 (0.0)	66	0 (0.0)	164	0 (0.0)
Other/not reported	145	1 (0.7)	108	1 (0.9)	254	2 (0.8)
p value		0.5		0.5		0.6
1999						
Amphetamine	65	4 (6.2)	38	0 (0.0)	103	4 (3.9)
Heroin	311	2 (0.6)	181	1 (0.6)	496	3 (0.6)
More than one	68	1 (1.5)	48	0 (0.0)	117	1 (0.9)
Other/not reported	92	1 (1.1)	45	0 (0.0)	138	1 (0.7)
p value		0.01		0.9		0.03
2000						
Amphetamine	75	3 (4.0)	---	---	105	3 (2.9)
Heroin	309	5 (1.6)	---	---	504	5 (1.0)
More than one	85	1 (1.2)	---	---	136	1 (0.7)
Other/not reported	66	2 (3.0)	---	---	121	2 (1.7)
p value		0.5				0.4
2001						
Amphetamine	64	4 (6.3)	---	---	105	4 (3.8)
Heroin	141	1 (0.7)	---	---	212	1 (0.5)
More than one	66	0 (0.0)	---	---	105	0 (0.0)
Other/not reported	135	1 (0.7)	---	---	234	1 (0.4)
p value		0.007				0.008
2002						
Amphetamine	103	8 (7.8)	60	0 (0.0)	164	8 (4.9)
Heroin	227	3 (1.3)	129	1 (0.8)	359	5 (1.4)
More than one	50	2 (4.0)	28	0 (0.0)	80	2 (2.5)
Other/not reported	89	0 (0.7)	44	0 (0.0)	135	0 (0.0)
p value		0.003		0.8		0.02

* Total includes people whose sex was not reported or reported transgender.

NEW SOUTH WALES
HIV ANTIBODY

Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.

Frequency of drug injection last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Not last month	14	0 (0.0)	9	0 (0.0)	23	0 (0.0)
Less than weekly	42	4 (10.0)	28	2 (7.1)	70	6 (8.6)
Weekly not daily	94	1 (1.1)	44	0 (0.0)	142	2 (1.4)
Daily or more	108	1 (0.9)	74	2 (2.7)	184	3 (1.6)
p value		0.009		0.3		0.008
1996						
Not last month	17	0 (0.0)	10	0 (0.0)	27	0 (0.0)
Less than weekly	61	2 (3.3)	20	1 (5.0)	82	3 (3.7)
Weekly not daily	101	2 (2.0)	56	1 (1.8)	160	3 (1.9)
Daily or more	136	4 (2.9)	74	3 (4.1)	211	7 (3.3)
p value		0.9		0.8		0.6
1997						
Not last month	25	1 (4.0)	17	0 (0.0)	42	1 (2.4)
Less than weekly	98	2 (2.0)	63	1 (1.6)	162	3 (1.9)
Weekly not daily	63	1 (1.6)	26	0 (0.0)	89	1 (1.1)
Daily or more	194	2 (1.0)	145	0 (0.0)	339	2 (0.6)
p value		0.7		0.4		0.5
1998						
Not last month	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
Less than weekly	55	2 (3.6)	29	0 (0.0)	85	2 (2.4)
Weekly not daily	108	1 (0.9)	69	1 (1.5)	178	2 (1.1)
Daily or more	350	1 (0.3)	250	0 (0.0)	603	1 (0.2)
p value		0.05		0.2		0.05
1999						
Not last month	40	3 (7.5)	16	0 (0.0)	57	3 (5.3)
Less than weekly	63	1 (1.6)	44	0 (0.0)	109	1 (0.9)
Weekly not daily	108	1 (0.9)	57	0 (0.0)	165	1 (0.6)
Daily or more	322	3 (0.9)	193	1 (0.5)	517	4 (0.8)
p value		0.01		0.9		0.02
2000						
Not last month	30	2 (6.7)	---	---	43	2 (4.7)
Less than weekly	56	2 (3.6)	---	---	80	2 (2.5)
Weekly not daily	106	1 (0.9)	---	---	169	1 (0.6)
Daily or more	336	6 (1.8)	---	---	561	6 (1.1)
p value		0.2				0.1
2001						
Not last month	50	0 (0.0)	---	---	81	0 (0.0)
Less than weekly	60	3 (5.0)	---	---	98	3 (3.1)
Weekly not daily	85	1 (1.2)	---	---	143	1 (0.7)
Daily or more	202	2 (1.0)	---	---	319	2 (0.6)
p value		0.1				0.1
2002						
Not last month	47	1 (2.1)	33	0 (0.0)	81	1 (1.2)
Less than weekly	66	3 (4.6)	33	0 (0.0)	103	3 (2.9)
Weekly not daily	109	5 (4.6)	47	0 (0.0)	157	6 (3.8)
Daily or more	244	4 (1.6)	142	1 (0.7)	387	5 (1.3)
p value		0.3		0.9		0.2

* Total includes people whose sex was not reported or reported transgender.

Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.

Reused someone else's syringe last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	159	5 (3.1)	87	3 (3.3)	258	9 (3.9)
Yes	79	1 (1.3)	55	1 (1.8)	138	2 (1.5)
p value		0.4		0.6		0.2
1996						
No	202	6 (2.9)	91	5 (5.2)	309	11 (3.6)
Yes	88	2 (2.2)	54	0 (0.0)	144	2 (1.4)
p value		0.7		0.09		0.2
1997						
No	294	4 (1.3)	180	1 (0.6)	480	5 (1.0)
Yes	52	1 (1.9)	41	0 (0.0)	94	1 (1.1)
p value		0.8		0.6		>0.9
1998						
No	390	3 (0.8)	271	1 (0.4)	669	4 (0.6)
Yes	103	1 (1.0)	61	0 (0.0)	166	1 (0.6)
p value		0.8		0.6		>0.9
1999						
No	365	5 (1.4)	213	1 (0.5)	588	6 (1.0)
Yes	104	0 (0.0)	70	0 (0.0)	174	0 (0.0)
p value		0.2		0.6		0.2
2000						
No	396	9 (2.2)	---	---	635	9 (1.4)
Yes	82	0 (0.0)	---	---	150	0 (0.0)
p value		0.2				0.1
2001						
No	285	6 (2.1)	---	---	454	6 (1.3)
Yes	54	0 (0.0)	---	---	86	0 (0.0)
p value		0.3				0.3
2002						
No	324	9 (2.8)	181	1 (0.6)	511	11 (2.2)
Yes	83	3 (3.6)	35	0 (0.0)	118	3 (2.5)
p value		0.7		0.7		0.8

* Total includes people whose sex was not reported or reported transgender.

NEW SOUTH WALES
HIV ANITBODY

Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.

Imprisonment last year	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	194	4 (2.1)	130	4 (3.1)	329	9 (2.7)
Yes	63	2 (3.2)	24	0 (0.0)	88	2 (2.3)
p value		0.6		0.4		0.8
1996						
No	238	7 (2.9)	130	4 (3.1)	373	11 (3.0)
Yes	67	0 (0.0)	25	1 (4.0)	92	1 (1.1)
p value		0.2		0.8		0.3
1997						
No	289	6 (2.1)	219	1 (0.5)	509	7 (1.4)
Yes	94	0 (0.0)	34	0 (0.0)	128	0 (0.0)
p value		0.2		0.7		0.2
1998						
No	379	5 (1.3)	297	1 (0.3)	680	6 (0.9)
Yes	155	0 (0.0)	67	0 (0.0)	222	0 (0.0)
p value		0.2		0.6		0.2
1999						
No	407	6 (1.5)	265	0 (0.0)	677	6 (0.9)
Yes	120	1 (0.8)	42	1 (2.4)	163	2 (1.2)
p value		0.6		0.01		0.7
2000						
No	385	6 (1.6)	---	---	639	6 (0.9)
Yes	133	4 (3.0)	---	---	203	4 (2.0)
p value		0.3				0.2
2001						
No	298	6 (2.0)	---	---	494	6 (1.2)
Yes	95	0 (0.0)	---	---	140	0 (0.0)
p value		0.2				0.2
2002						
No	345	12 (3.5)	214	1 (0.5)	566	14 (2.5)
Yes	116	1 (0.9)	39	0 (0.0)	155	1 (0.7)
p value		0.1		0.7		0.2

* Total includes people whose sex was not reported or reported transgender.

Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.

Condom use last sex	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	151	3 (2.0)	99	2 (2.0)	252	6 (2.4)
Yes	70	3 (4.3)	32	1 (3.1)	104	4 (3.9)
p value		0.3		0.7		0.4
1996						
No	148	2 (1.4)	81	3 (3.7)	231	5 (2.2)
Yes	63	3 (4.8)	40	0 (0.0)	104	3 (2.9)
p value		0.1		0.2		0.7
1997						
No	240	3 (1.3)	176	1 (0.6)	416	4 (1.0)
Yes	140	2 (1.4)	69	0 (0.0)	210	2 (1.0)
p value		0.9		0.5		>0.9
1998						
No	339	2 (0.6)	258	1 (0.4)	598	3 (0.5)
Yes	189	3 (1.6)	100	0 (0.0)	292	3 (1.0)
p value		0.3		0.5		0.4
1999						
No	295	3 (1.0)	201	1 (0.5)	500	4 (0.8)
Yes	221	4 (1.8)	100	0 (0.0)	323	4 (1.2)
p value		0.4		0.5		0.5
2000						
No	302	2 (0.7)	---	---	499	2 (0.4)
Yes	213	9 (4.2)	---	---	334	9 (2.7)
p value		0.006				0.004
2001						
No	250	5 (2.0)	---	---	417	5 (1.2)
Yes	143	1 (0.7)	---	---	220	1 (0.5)
p value		0.5				0.6
2002						
No	281	6 (2.1)	165	1 (0.6)	447	7 (1.6)
Yes	176	7 (4.0)	90	0 (0.0)	271	8 (3.0)
p value		0.7		0.7		0.4

* Total includes people whose sex was not reported or reported transgender.

NEW SOUTH WALES
HIV ANTIBODY

Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.

Sex work last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	243	5 (2.1)	136	2 (1.5)	383	8 (2.1)
Yes	5	1 (20.0)	18	1 (5.6)	25	2 (8.0)
p value				0.2		0.06
1996						
No	282	7 (2.5)	118	5 (4.2)	404	12 (3.0)
Yes	10	0 (0.0)	37	0 (0.0)	47	0 (0.0)
p value		0.6		0.2		0.2
1997						
No	350	4 (1.1)	205	1 (0.5)	556	5 (0.9)
Yes	26	1 (3.9)	43	0 (0.0)	69	1 (1.5)
p value		0.2		0.6		0.7
1998						
No	503	5 (1.0)	308	1 (0.3)	813	6 (0.7)
Yes	22	0 (0.0)	54	0 (0.0)	79	0 (0.0)
p value		0.6		0.7		0.4
1999						
No	491	7 (1.4)	231	1 (0.4)	726	8 (1.1)
Yes	27	1 (3.7)	74	0 (0.0)	103	1 (1.0)
p value		0.4		0.6		0.9
2000						
No	493	10 (2.0)	---	---	736	10 (1.4)
Yes	23	0 (0.0)	---	---	102	0 (0.0)
p value		0.5				0.2
2001						
No	371	4 (1.1)	---	---	552	4 (0.7)
Yes	19	2 (10.5)	---	---	78	2 (2.6)
p value		0.001				0.1
2002						
No	431	12 (2.8)	193	1 (0.5)	630	13 (2.1)
Yes	19	1 (5.3)	62	0 (0.0)	82	2 (2.4)
p value		0.5		0.6		0.8

* Total includes people whose sex was not reported or reported transgender.

HCV antibody prevalence

Table 17: HCV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	254	219 (86)	152	124 (82)	412	348 (84)
1996	323	233 (72)	169	117 (69)	497	355 (71)
1997	386	260 (67)	254	176 (69)	641	437 (68)
1998	543	369 (68)	369	265 (72)	918	637 (69)
1999	537	322 (60)	312	198 (63)	854	524 (61)
2000	538	350 (65)	327	225 (69)	870	579 (67)
2001	412	321 (71)	244	183 (75)	655	476 (73)
2002	473	335 (71)	261	181 (69)	741	523 (71)
χ^2 trend p value		0.007		0.2		0.005

* Total includes people whose sex was not reported or reported transgender.

NEW SOUTH WALES
HCV ANTIBODY

Table 18: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
< 20 years	5	1 (20)	8	4 (50)	14	6 (43)
20 – 24	31	19 (61)	32	24 (75)	65	44 (68)
25 – 29	54	47 (87)	34	30 (88)	88	77 (88)
30 + years	160	148 (93)	77	66 (86)	240	217 (90)
p value		<0.001		0.04		<0.001
1996						
< 20 years	9	1 (11)	9	4 (44)	19	5 (26)
20 – 24	48	23 (48)	29	14 (48)	77	37 (48)
25 – 29	73	49 (67)	47	35 (77)	121	85 (70)
30 + years	192	159 (83)	84	65 (77)	279	227 (81)
p value		<0.001		0.006		<0.001
1997						
< 20 years	9	3 (33)	20	7 (35)	29	10 (34)
20 – 24	68	21 (31)	45	22 (49)	113	43 (38)
25 – 29	75	39 (52)	66	41 (62)	141	80 (57)
30 + years	234	197 (84)	123	106 (86)	358	304 (85)
p value		<0.001		<0.001		<0.001
1998						
< 20 years	45	15 (33)	35	15 (43)	80	30 (38)
20 – 24	99	39 (39)	83	48 (58)	183	87 (48)
25 – 29	105	70 (67)	79	54 (68)	188	126 (67)
30 + years	293	245 (84)	172	148 (86)	466	394 (85)
p value		<0.001		<0.001		<0.001
1999						
< 20 years	32	13 (41)	23	14 (61)	55	27 (49)
20 – 24	96	39 (41)	60	23 (38)	156	62 (40)
25 – 29	122	59 (48)	78	41 (53)	202	102 (51)
30 + years	287	211 (74)	151	120 (79)	440	333 (76)
p value		<0.001		<0.001		<0.001
2000						
< 20 years	32	32 (50)	41	24 (59)	73	40 (55)
20 – 24	93	47 (49)	71	46 (65)	167	93 (56)
25 – 29	116	62 (53)	74	42 (57)	191	104 (54)
30 + years	291	225 (77)	141	113 (80)	439	342 (78)
p value		<0.001		<0.001		<0.001
2001						
< 20 years	23	14 (61)	17	11 (65)	41	25 (61)
20 – 24	59	31 (53)	58	40 (69)	118	71 (60)
25 – 29	88	49 (56)	51	32 (63)	139	81 (58)
30 + years	242	193 (80)	117	99 (85)	365	297 (81)
p value		<0.001		0.008		<0.001
2002						
< 20 years	18	8 (44)	14	8 (57)	32	16 (50)
20 – 24	72	45 (63)	62	40 (65)	135	86 (64)
25 – 29	112	72 (64)	60	37 (62)	172	109 (63)
30 + years	268	209 (78)	125	96 (77)	400	311 (78)
p value		<0.001		0.09		<0.001

* Total includes people whose sex was not reported or reported transgender.

Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
<1 to 2 years	9	5 (56)	13	6 (46)	23	11 (48)
3 to 5 years	20	10 (50)	17	10 (59)	38	21 (55)
6 to 10 years	53	42 (79)	38	31 (82)	92	74 (80)
10 + years	167	157 (94)	82	76 (93)	251	235 (94)
p value		<0.001		<0.001		<0.001
1996						
<1 to 2 years	29	8 (28)	14	3 (21)	44	11 (25)
3 to 5 years	29	6 (21)	18	11 (61)	47	17 (36)
6 to 10 years	68	41 (60)	41	29 (71)	109	60 (64)
10 + years	184	168 (91)	90	71 (79)	279	242 (87)
p value		<0.001		<0.001		<0.001
1997						
<1 to 2 years	30	6 (20)	24	4 (17)	54	10 (19)
3 to 5 years	49	20 (41)	36	17 (47)	85	37 (44)
6 to 10 years	80	40 (50)	64	37 (58)	144	77 (53)
10 + years	213	185 (87)	124	114 (92)	338	300 (89)
p value		<0.001		<0.001		<0.001
1998						
<1 to 2 years	71	13 (18)	52	19 (37)	124	32 (26)
3 to 5 years	76	37 (49)	65	38 (58)	141	75 (53)
6 to 10 years	112	75 (67)	79	60 (76)	192	135 (70)
10 + years	266	232 (87)	168	144 (86)	437	378 (87)
p value		<0.001		<0.001		<0.001
1999						
<1 to 2 years	74	21 (28)	43	16 (37)	117	37 (32)
3 to 5 years	89	32 (36)	56	24 (43)	145	56 (39)
6 to 10 years	114	61 (54)	71	42 (59)	186	104 (56)
10 + years	239	195 (82)	136	112 (82)	377	309 (82)
p value		<0.001		<0.001		<0.001
2000						
<1 to 2 years	70	27 (38)	47	16 (34)	117	43 (37)
3 to 5 years	79	40 (51)	62	41 (66)	141	81 (57)
6 to 10 years	121	71 (59)	92	63 (68)	213	134 (63)
10 + years	248	201 (81)	118	99 (84)	368	302 (82)
p value		<0.001		<0.001		<0.001
2001						
<1 to 2 years	55	21 (38)	29	16 (55)	86	37 (43)
3 to 5 years	62	36 (58)	42	27 (64)	104	63 (61)
6 to 10 years	78	53 (68)	67	54 (81)	145	107 (74)
10 + years	205	171 (83)	101	83 (82)	310	258 (83)
p value		<0.001		<0.001		<0.001
2002						
<1 to 2 years	54	24 (44)	20	10 (50)	75	35 (47)
3 to 5 years	62	40 (65)	54	35 (65)	118	76 (64)
6 to 10 years	109	76 (70)	66	44 (67)	176	121 (69)
10 + years	232	188 (81)	113	89 (79)	348	280 (80)
p value		<0.001		0.03		<0.001

* Total includes people whose sex was not reported or reported transgender.

NEW SOUTH WALES
HCV ANTIBODY

Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Amphetamine	9	6 (67)	26	20 (77)	35	26 (74)
Heroin	8	3 (38)	120	107 (89)	129	111 (86)
More than one	2	0 (0)	51	44 (86)	55	46 (84)
Other/not reported	4	2 (50)	184	159 (86)	193	165 (85)
p value		0.3		0.4		0.4
1996						
Amphetamine	10	3 (30)	32	21 (66)	44	25 (57)
Heroin	18	3 (17)	172	119 (69)	194	126 (65)
More than one	6	1 (17)	60	47 (78)	72	53 (74)
Other/not reported	10	5 (50)	171	142 (83)	187	152 (81)
p value		0.3		0.01		0.001
1997						
Amphetamine	12	2 (17)	45	19 (42)	58	21 (36)
Heroin	28	6 (21)	262	189 (72)	294	199 (68)
More than one	7	1 (14)	67	50 (75)	77	53 (69)
Other/not reported	7	1 (14)	193	156 (81)	212	164 (77)
p value		>0.9		<0.001		<0.001
1998						
Amphetamine	12	3 (25)	50	33 (66)	63	37 (59)
Heroin	74	18 (24)	355	249 (70)	437	274 (63)
More than one	25	8 (32)	138	113 (82)	164	121 (74)
Other/not reported	13	3 (23)	227	193 (85)	254	205 (81)
p value		0.9		<0.001		<0.001
1999						
Amphetamine	16	0 (0)	86	33 (38)	103	33 (32)
Heroin	72	30 (42)	407	278 (68)	496	320 (65)
More than one	11	5 (45)	101	76 (75)	117	86 (74)
Other/not reported	18	2 (11)	114	82 (72)	130	85 (62)
p value		0.002		<0.001		<0.001
2000						
Amphetamine	16	1 (6)	84	44 (52)	106	48 (45)
Heroin	72	28 (38)	422	310 (73)	506	346 (68)
More than one	19	11 (58)	114	91 (80)	136	105 (77)
Other/not reported	10	3 (30)	102	72 (71)	122	80 (66)
p value		0.02		<0.001		<0.001
2001						
Amphetamine	16	6 (38)	88	62 (70)	107	70 (65)
Heroin	28	14 (50)	181	142 (78)	212	159 (75)
More than one	6	3 (50)	97	78 (80)	107	85 (79)
Other/not reported	36	14 (39)	193	146 (76)	239	162 (68)
p value		0.8		<0.001		<0.001
2002						
Amphetamine	17	7 (41)	143	85 (59)	166	96 (58)
Heroin	36	18 (50)	319	256 (80)	359	275 (77)
More than one	5	2 (40)	74	52 (70)	80	54 (68)
Other/not reported	17	8 (47)	105	84 (79)	136	98 (72)
p value		0.9		<0.001		<0.001

* Total includes people who did not report duration of drug injection.

Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Less than daily	11	6 (55)	194	171 (88)	208	180 (87)
Daily or more	12	5 (42)	163	141 (87)	180	150 (83)
p value		0.5		0.6		0.4
1996						
Less than daily	28	7 (25)	211	167 (79)	247	180 (73)
Daily or more	9	4 (44)	200	146 (73)	218	159 (73)
p value		0.3		0.1		>0.9
1997						
Less than daily	22	2 (9)	227	155 (68)	252	157 (62)
Daily or more	27	7 (26)	299	229 (77)	340	249 (73)
p value		0.1		0.03		0.005
1998						
Less than daily	29	4 (14)	228	175 (77)	263	183 (70)
Daily or more	86	27 (31)	506	388 (77)	604	425 (70)
p value		0.07		>0.9		0.8
1999						
Less than daily	32	6 (19)	234	143 (61)	274	155 (57)
Daily or more	76	30 (39)	428	298 (70)	517	338 (65)
p value		0.04		0.03		0.02
2000						
Less than daily	25	6 (24)	215	137 (64)	251	149 (59)
Daily or more	86	36 (42)	465	351 (75)	564	397 (70)
p value		0.1		0.002		0.002
2001						
Less than daily	32	16 (50)	210	158 (75)	246	176 (72)
Daily or more	39	16 (41)	281	215 (77)	323	233 (72)
p value		0.5		0.7		0.9
2002						
Less than daily	28	11 (39)	226	161 (71)	261	176 (67)
Daily or more	36	20 (56)	343	264 (77)	387	288 (74)
p value		0.3		0.3		0.05

* Total includes people who did not report duration of drug injection.

NEW SOUTH WALES
HCV ANTIBODY

Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month and duration of drug injection.

Reused someone else's syringe last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
No	15	5 (33)	236	206 (87)	256	216 (84)
Yes	8	6 (75)	121	106 (88)	132	114 (86)
p value		0.06		>0.9		0.6
1996						
No	30	7 (23)	280	212 (76)	317	224 (71)
Yes	7	3 (43)	131	101 (77)	148	114 (77)
p value		0.3		0.8		0.2
1997						
No	35	6 (17)	431	306 (71)	481	324 (67)
Yes	10	2 (18)	82	67 (82)	95	70 (74)
p value		>0.9		0.05		0.2
1998						
No	87	23 (26)	571	433 (76)	670	467 (69)
Yes	24	7 (29)	139	114 (82)	166	123 (74)
p value		0.8		0.1		0.3
1999						
No	77	25 (32)	496	325 (66)	587	361 (62)
Yes	27	9 (33)	141	100 (70)	175	114 (65)
p value		>0.9		0.2		0.4
2000						
No	83	29 (35)	538	379 (70)	639	420 (66)
Yes	26	13 (50)	119	91 (76)	151	108 (72)
p value		0.2		0.2		0.2
2001						
No	60	28 (47)	397	299 (75)	463	330 (71)
Yes	8	2 (25)	77	59 (77)	86	62 (72)
p value		0.4		0.5		0.9
2002						
No	46	19 (41)	456	342 (75)	512	365 (71)
Yes	16	11 (69)	98	73 (74)	118	87 (74)
p value		0.1		0.9		0.6

* Total includes people who did not report duration of drug injection.

Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection.

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
No	20	11 (55)	297	253 (85)	323	269 (83)
Yes	2	0 (0)	82	75 (91)	86	77 (90)
p value		0.1		0.1		0.2
1996						
No	37	8 (22)	334	248 (74)	383	264 (69)
Yes	5	2 (40)	83	67 (81)	93	74 (80)
p value		0.4		0.2		0.04
1997						
No	50	8 (16)	445	317 (71)	511	334 (65)
Yes	4	2 (50)	120	96 (80)	128	102 (80)
p value		0.09		0.06		0.002
1998						
No	97	23 (24)	567	419 (74)	682	455 (67)
Yes	26	9 (35)	192	160 (83)	222	172 (77)
p value		0.3		0.008		0.003
1999						
No	99	27 (27)	556	339 (61)	677	380 (56)
Yes	14	9 (64)	143	124 (87)	163	137 (84)
p value		0.005		<0.001		<0.001
2000						
No	89	26 (29)	533	366 (69)	641	403 (63)
Yes	25	17 (68)	172	140 (81)	205	164 (80)
p value		<0.001		0.001		<0.001
2001						
No	68	24 (35)	419	310 (74)	502	341 (68)
Yes	14	10 (71)	126	108 (86)	141	119 (84)
p value		0.01		0.007		<0.001
2002						
No	55	21 (38)	494	352 (71)	569	380 (67)
Yes	18	13 (72)	134	114 (85)	155	129 (83)
p value		0.04		0.004		<0.001

* Total includes people who did not report duration of drug injection.

NEW SOUTH WALES
HCV ANTIBODY

Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection.

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
No	20	11 (55)	348	302 (87)	375	319 (85)
Yes	2	0 (0)	23	20 (87)	25	20 (80)
p value		0.1		>0.9		0.5
1996						
No	37	11 (30)	365	281 (77)	412	300 (73)
Yes	3	0 (0)	44	26 (59)	52	30 (58)
p value		0.3		0.01		0.02
1997						
No	49	7 (14)	490	365 (74)	557	383 (69)
Yes	4	2 (50)	65	39 (60)	70	42 (60)
p value		0.07		0.01		0.1
1998						
No	110	27 (25)	685	518 (76)	815	560 (69)
Yes	9	4 (44)	69	57 (83)	79	61 (77)
p value		0.2		0.2		0.1
1999						
No	100	31 (31)	606	401 (66)	726	445 (61)
Yes	13	5 (38)	84	54 (64)	103	62 (60)
p value		0.6		0.7		0.8
2000						
No	102	39 (38)	614	442 (72)	740	495 (67)
Yes	11	4 (36)	87	64 (74)	102	72 (71)
p value		0.9		0.8		0.5
2001						
No	82	36 (44)	460	354 (77)	558	398 (71)
Yes	4	1 (25)	75	56 (75)	80	58 (73)
2002						
No	64	32 (50)	550	415 (75)	633	455 (72)
Yes	8	1 (13)	69	42 (61)	82	45 (55)
p value		0.1		0.006		0.002

* Total includes people who did not report duration of drug injection.

**NORTHERN TERRITORY
1995-2002**

Table 1: Number (percent) and age of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	2	2	2	2	1	2	2	1
Response								
Nº surveyed response	N = 30 42%	N = 19 17%	N = 102 70%	N = 102 58%	N = 93 55%	N = 95 65%	N = 94 57%	N = 47 42%
Sex (%)								
Male	20 (67)	13 (68)	76 (74)	77 (75)	73 (78)	75 (79)	75 (80)	35 (75)
Female	10 (33)	6 (32)	24 (24)	25 (25)	20 (22)	19 (20)	18 (19)	11 (23)
Transgender	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Sexual identity (%)								
Heterosexual	23 (77)	19 (100)	85 (83)	80 (78)	83 (89)	69 (73)	69 (73)	41 (88)
Bisexual	3 (10)	0 (0)	7 (7)	11 (11)	7 (8)	10 (11)	8 (9)	1 (2)
Gay/lesbian	3 (10)	0 (0)	8 (8)	6 (6)	2 (2)	9 (9)	4 (4)	2 (4)
Not reported	1 (3)	0 (0)	2 (2)	5 (5)	1 (1)	7 (7)	13 (14)	3 (6)
Age and duration of injection (years)								
Median age	34	30	30.5	31	33	34	35	37
Age range	21-48	21-43	16-50	16-56	16-57	18-58	16-52	19-55
Not reported	0	0	0	0	0	0	0	0
Median age 1 st IDU	20	18	17	18	18	18	18.5	18
Age range	13-41	11-36	12-41	12-47	10-41	9-45	13-48	12-37
Not reported	2	0	1	1	0	2	4	0
Median years IDU	8	7	10	10	11	12	11	17
Range	1-28	1-27	<1-30	<1-35	<1-34	<1-35	<1-34	<1-36
Not reported	2	0	1	1	0	2	4	0
Aboriginal and Torres Strait Islander Origin (%)								
Yes	1 (3)	1 (5)	10 (10)	13 (13)	10 (11)	7 (7)	11 (12)	3 (6)
No	27 (90)	18 (95)	92 (90)	89 (87)	83 (89)	87 (92)	81 (86)	44 (94)
Not reported	2 (7)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)
Imprisonment last year (%)								
Yes	1 (3)	2 (11)	10 (10)	11 (11)	9 (10)	11 (12)	17 (18)	4 (9)
No	29 (97)	16 (84)	92 (90)	90 (88)	84 (90)	81 (85)	72 (77)	41 (87)
Not reported	0 (0)	1 (5)	0 (0)	1 (1)	0 (0)	3 (3)	5 (5)	2 (4)
Injected in prison (%)								
Yes	0 (0)	1 (50)	4 (40)	5 (45)	1 (11)	5 (45)	2 (12)	2 (50)
Frequency of injection last month (%)								
Not last month	1 (3)	1 (5)	8 (8)	2 (2)	1 (1)	8 (8)	4 (4)	0 (0)
Less than weekly	7 (23)	6 (32)	24 (24)	12 (12)	10 (11)	14 (15)	7 (7)	6 (13)
Weekly not daily	5 (17)	1 (5)	13 (13)	14 (14)	11 (12)	15 (16)	13 (14)	8 (17)
Daily or more	17 (57)	11 (58)	57 (55)	74 (72)	71 (76)	55 (58)	69 (74)	33 (70)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	0 (0)
Last drug injected (%)								
Amphetamine	6 (20)	4 (21)	11 (11)	19 (19)	21 (22)	26 (27)	34 (36)	7 (15)
Anabolic steroids	1 (3)	2 (10)	3 (3)	1 (1)	1 (1)	2 (2)	1 (1)	0 (0)
Benzos	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Heroin	6 (20)	7 (37)	19 (19)	10 (10)	11 (12)	12 (13)	5 (5)	2 (4)
Heroin + Cocaine	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Methadone	4 (13)	3 (16)	6 (6)	1 (1)	3 (3)	0 (0)	8 (9)	0 (0)
Morphine	10 (34)	3 (16)	59 (57)	71 (69)	56 (61)	43 (46)	40 (43)	37 (79)
More than one	3 (10)	0 (0)	2 (2)	0 (0)	0 (0)	8 (8)	5 (5)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	0 (0)	0 (0)

NORTHERN TERRITORY

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 29	N = 18	N = 94	N = 100	N = 92	N = 84	N = 89	N = 47
Places injected last month (%)*								
Own home	79 (84)	88 (88)	86 (93)	69 (82)	73 (82)	44 (94)		
Friend's home	46 (49)	56 (56)	22 (24)	38 (45)	35 (39)	19 (40)		
Dealer's home	16 (17)	19 (19)	3 (3)	20 (24)	22 (25)	11 (23)		
Street, park, beach	25 (27)	18 (18)	6 (7)	17 (20)	8 (9)	4 (9)		
Car	12 (13)	29 (29)	19 (21)	27 (32)	17 (19)	17 (15)		
Public toilet	19 (20)	11 (11)	13 (14)	20 (24)	9 (10)	8 (17)		
"Shooting" room	0 (0)	0 (0)	1 (1)	3 (4)	0 (0)	0 (0)		
Squat			2 (2)	9 (11)	4 (4)	4 (9)		
Use of new sterile needles & syringes last month (%)								
All injections	62 (66)	78 (78)	82 (89)	64 (77)	67 (75)	41 (87)		
Most of the time	30 (32)	18 (18)	9 (10)	15 (18)	13 (15)	6 (13)		
Half of the time	2 (2)	4 (4)	1 (1)	2 (2)	3 (3)	0 (0)		
Some of the time	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)		
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)		
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	4 (5)	0 (0)		
Re-used another's syringe last month (%)								
None	21 (72)	13 (72)	85 (91)	94 (94)	73 (80)	70 (84)	73 (82)	46 (98)
Once	3 (10)	1 (6)	0 (0)	5 (5)	3 (3)	1 (1)	1 (1)	1 (2)
Twice	3 (10)	3 (16)	2 (2)	0 (0)	3 (3)	10 (12)	1 (1)	0 (0)
3-5 times	1 (4)	1 (6)	3 (3)	1 (1)	0 (0)	1 (1)	4 (5)	0 (0)
>5 times	1 (4)	0 (0)	4 (4)	0 (0)	0 (0)	1 (1)	4 (5)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	13 (14)	1 (1)	6 (6)	0 (0)
Number of people syringe was re-used after last month (%)								
None	21 (72)	13 (72)	85 (91)	94 (94)	73 (80)	70 (84)	73 (82)	46 (98)
One	6 (21)	4 (22)	9 (9)	6 (6)	5 (5)	5 (5)	5 (6)	0 (0)
Two	2 (7)	1 (6)	0 (0)	0 (0)	1 (1)	4 (5)	1 (1)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (5)	2 (2)	1 (2)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	13 (14)	1 (1)	7 (8)	0 (0)
Relationship to people syringe was re-used after last month (%)*								
Regular sex partner	5 (5)	5 (5)	0 (0)	6 (7)	5 (6)	0 (0)		
Casual sex partner	1 (1)	0 (0)	2 (2)	1 (1)	1 (1)	0 (0)		
Close friend	1 (1)	1 (1)	2 (2)	3 (4)	3 (3)	1 (2)		
Acquaintance	0 (0)	0 (0)	2 (2)	1 (1)	2 (2)	1 (2)		
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)		
Equipment used after someone else last month (%)*								
Spoon			4 (4)	29 (35)	21 (24)	7 (15)		
Water			11 (12)	11 (13)	11 (12)	0 (0)		
Filter			2 (2)	15 (18)	11 (12)	3 (6)		
Tourniquet			7 (8)	17 (20)	11 (12)	5 (11)		
Drug mix			2 (2)	11 (13)	6 (7)	2 (4)		
Injected by someone else who'd already injected themselves or others last month (%)								
Yes			1 (2)	9 (11)	9 (10)	6 (13)		
No			74 (80)	73 (87)	75 (84)	39 (83)		
Not reported			17 (18)	2 (2)	5 (6)	2 (4)		

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 30	N = 19	N = 102	N = 102	N = 93	N = 95	N = 94	N = 47
Any treatment/therapy for drug use (%)								
No	15 (50)	6 (32)	48 (47)	49 (48)	44 (47)	47 (50)	44 (47)	15 (32)
Yes	15 (50)	13 (68)	54 (53)	53 (52)	49 (53)	45 (47)	49 (52)	32 (68)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	0 (0)
History of methadone treatment (%)								
Currently	1 (3)	2 (10)	4 (4)	2 (2)	6 (7)	8 (8)	8 (9)	5 (11)
Previously	9 (30)	2 (10)	29 (28)	29 (28)	18 (19)	18 (19)	22 (23)	14 (30)
Never	20 (67)	15 (80)	69 (68)	71 (70)	69 (74)	67 (71)	63 (67)	28 (59)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)
History of other pharmacological therapy (%)								
Currently			0 (0)	0 (0)	0 (0)	2 (2)	2 (2)	2 (4)
Previously			3 (3)	0 (0)	5 (5)	6 (6)	9 (19)	
Never			99 (97)	93 (100)	88 (93)	84 (90)	36 (77)	
Not reported			0 (0)	0 (0)	2 (2)	2 (2)	0 (0)	

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 93	N = 95	N = 94	N = 47
From an NSP last month (%)								
Daily or almost daily				1 (1)	5 (5)	6 (6)	2 (4)	
A couple of times each week			17 (18)	18 (19)	18 (19)	9 (19)		
Less than weekly			50 (54)	25 (27)	21 (23)	19 (41)		
Once last month			16 (17)	24 (25)	33 (35)	16 (34)		
Not in the last month			9 (10)	20 (21)	13 (14)	1 (2)		
Not reported			0 (0)	3 (3)	3 (3)	0 (0)		
From a chemist last month (%)								
Daily or almost daily				0 (0)	3 (3)	3 (3)	0 (0)	
A couple of times each week			4 (5)	3 (3)	4 (4)	2 (4)		
Less than weekly			17 (18)	8 (9)	9 (10)	5 (11)		
Once last month			15 (16)	14 (15)	18 (19)	7 (15)		
Not in the last month			57 (61)	65 (68)	51 (54)	32 (68)		
Not reported			0 (0)	2 (2)	9 (10)	1 (2)		

NORTHERN TERRITORY

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 30	N = 19	N = 102	N = 102	N = 93	N = 95	N = 94	N = 47
Sex last month (%)								
Yes	21 (70)	13 (68)	61 (60)	61 (60)	46 (49)	56 (59)	55 (59)	25 (53)
No	9 (30)	6 (32)	40 (39)	39 (38)	47 (51)	33 (35)	38 (40)	21 (45)
Not reported	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)	6 (6)	1 (1)	1 (2)
Condom use last sex (%)								
Yes	3 (10)	6 (32)	38 (37)	39 (38)	29 (31)	35 (37)	42 (45)	15 (32)
No	18 (60)	6 (32)	64 (63)	59 (58)	64 (69)	52 (55)	46 (49)	32 (68)
Not reported	9 (30)	7 (36)	0 (0)	4 (4)	0 (0)	8 (8)	6 (6)	0 (6)
Condom use with regular sex partner(s) last month (%)*								
No	8 (67)	43 (86)	33 (94)	27 (84)	28 (64)	18 (53)	13 (81)	
Sometimes	0 (0)	1 (2)	0 (0)	1 (3)	4 (9)	4 (12)	2 (13)	
Always	4 (33)	6 (12)	2 (6)	4 (13)	12 (27)	12 (35)	1 (6)	
Condom use with new sex partner(s) last month (%)*								
No	1 (33)	6 (29)	0 (0)	0 (0)	3 (16)	11 (33)	2 (17)	
Sometimes	0 (0)	0 (0)	0 (0)	0 (0)	9 (47)	6 (18)	1 (8)	
Always	2 (67)	15 (71)	2 (100)	1 (100)	7 (37)	16 (49)	9 (75)	
Condom use with casual sex partner(s) last month (%)*								
No		10 (40)	7 (50)	7 (27)	10 (36)	2 (20)		
Sometimes		3 (12)	1 (7)	7 (27)	3 (11)	0 (0)		
Always		12 (48)	6 (43)	12 (46)	15 (53)	8 (80)		
Duration of regular sexual relationship (%)**								
One month					3 (9)	1 (6)		
2 - 6 months					4 (12)	3 (17)		
6 - 12 months					4 (12)	2 (11)		
>12 months					22 (67)	12 (66)		
Sex work last month (%)								
Yes	1 (3)	1 (5)	4 (4)	3 (3)	2 (2)	9 (10)	6 (6)	3 (6)
No	28 (94)	18 (95)	93 (91)	99 (97)	91 (98)	80 (84)	82 (88)	44 (94)
Not reported	1 (3)	0 (0)	5 (5)	0 (0)	0 (0)	6 (6)	6 (6)	0 (0)
Condom use last sex work last month (%)**								
Yes	1 (100)	1 (100)	3 (75)	1 (50)	1 (100)	8 (89)	5 (100)	2 (67)

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1996-2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 30	N = 19	N = 102	N = 102	N = 93	N = 95	N = 94	N = 47
Previous HIV test (%)								
Yes, last year	17 (57)	11 (58)	45 (44)	52 (51)	61 (66)	44 (46)	55 (58)	27 (57)
> 1 year ago	8 (27)	5 (26)	40 (39)	39 (38)	26 (28)	29 (31)	26 (28)	12 (26)
Never tested	3 (10)	3 (16)	17 (17)	11 (11)	6 (6)	20 (21)	10 (11)	7 (15)
Not reported	2 (6)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	3 (3)	1 (2)
Self report HBV infection (%)								
Yes	6 (20)	1 (5)	20 (20)	14 (14)	11 (12)	16 (17)	16 (17)	13 (28)
No	23 (77)	18 (95)	77 (75)	79 (77)	76 (81)	62 (65)	68 (72)	30 (64)
Don't know	0 (0)	0 (0)	5 (5)	9 (9)	6 (7)	16 (17)	10 (11)	4 (9)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Self report HBV vaccination (%)*								
Yes	6 (27)	8 (44)	34 (42)	34 (38)	34 (41)	34 (43)	24 (31)	18 (53)
No	18 (73)	9 (50)	37 (45)	35 (40)	42 (52)	27 (34)	38 (48)	13 (39)
Don't know	0 (0)	0 (0)	11 (13)	19 (22)	5 (6)	15 (19)	9 (12)	3 (9)
Not reported	0 (0)	1 (6)	0 (0)	0 (0)	1 (1)	3 (4)	7 (9)	0 (0)
Previous HCV test (%)								
Yes ever	16 (53)	13 (68)	---	---	---	---	---	---
Yes, last year	---	---	50 (49)	40 (39)	47 (50)	52 (55)	65 (69)	28 (61)
> 1 year ago	---	---	37 (36)	47 (46)	35 (38)	19 (20)	20 (21)	13 (28)
Never tested	14 (47)	6 (32)	15 (15)	15 (15)	11 (12)	22 (23)	7 (8)	5 (11)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (2)	1 (2)
Any treatment for HCV (%)								
Interferon					N = 33	N = 27	N = 31	N = 22
Interferon+Ribavarin					1 (3)	0 (0)	3 (10)	0 (0)
Other					0 (0)	1 (4)	0 (0)	1 (4)
No treatment					0 (0)	0 (0)	0 (0)	0 (0)
Not reported					30 (91)	25 (92)	28 (90)	22 (96)
Current treatment for HCV (%)								
Interferon					N = 0	N = 1	N = 0	N = 0
Interferon+Ribavarin					---	0	---	---
Other					---	0	---	---

* Number (percentage) among participants not reporting HBV infection.

NORTHERN TERRITORY

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
1996	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)
1997	76	5 (6.6)	24	0 (0.0)	102	5 (4.9)
1998	65	4 (6.2)	22	0 (0.0)	87	4 (4.6)
1999	64	3 (4.7)	15	0 (0.0)	79	3 (3.8)
2000	70	1 (1.4)	19	0 (0.0)	90	1 (1.1)
2001	60	0 (0.0)	18	0 (0.0)	79	0 (0.0)
2002	35	0 (0.0)	11	0 (0.0)	47	0 (0.0)

* Total includes people whose sex was not reported and reported as transgender.

Table 8: HIV antibody prevalence according to sexual identity among males, 1995-2002.

Sexual identity	Nº tested	Nº with HIV (%)
Heterosexual	339	4 (1.1)
Bisexual	15	2 (13.3)
Homosexual	27	7 (25.9)
p value		<0.001

Table 9: HIV antibody prevalence according to age group among males, 1995-2002.

Age group	Nº tested	Nº with HIV (%)
< 20 years	15	0 (0.0)
20 – 24	48	0 (0.0)
25 – 29	64	0 (0.0)
30 + years	276	13 (4.7)
p value		0.1

Table 10: HIV antibody prevalence according to duration of drug injection among males, 1995-2002.

Duration of drug injection	Nº tested	Nº with HIV (%)
<1 to 2 years	34	0 (0.0)
3 to 5 years	59	1 (1.7)
6 to 10 years	68	3 (4.4)
10 + years	236	9 (3.8)
p value		0.6

Table 11: HIV antibody prevalence according to last drug injected among males, 1995-2002.

Last drug injected	Nº tested	Nº with HIV (%)
Amphetamine	76	3 (4.0)
Heroin	49	4 (8.1)
Morphine	231	6 (2.6)
Other/not reported	47	0 (0.0)
p value		0.7

Table 12: HIV antibody prevalence according to frequency of drug injection last month among males, 1995-2002.

Frequency of drug injection last month	Nº tested	Nº with HIV (%)
Less than daily	111	7 (6.3)
Daily or more	272	4 (1.5)
Not injected last month	18	2 (11.1)
p value		0.01

Table 13: HIV antibody prevalence according to reuse of someone else's syringe last month among males, 1995-2002.

Reused someone else's syringe last month	Nº tested	Nº with HIV (%)
Yes	37	0 (0.0)
No	334	10 (3.0)
Not injected last month	32	3 (9.4)
p value		0.08

Table 14: HIV antibody prevalence according to imprisonment last year among males, 1995-2002.

Imprisonment last year	Nº tested	Nº with HIV (%)
Yes	49	0 (0.0)
No	348	13 (3.7)
p value		0.2

Table 15: HIV antibody prevalence according to condom use last sex among males, 1995-2002.

Condom use last sex	Nº tested	Nº with HIV (%)
Yes	153	11 (7.2)
No	226	1 (0.4)
Not reported	24	1 (4.1)
p value		0.001

HCV antibody prevalence

Table 16: HCV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	19	14 (74)	8	3 (38)	27	17 (63)
1996	13	5 (38)	6	2 (33)	19	6 (32)
1997	76	41 (54)	24	10 (42)	102	52 (51)
1998	65	28 (43)	23	7 (30)	88	35 (40)
1999	64	36 (56)	15	3 (20)	79	39 (49)
2000	71	32 (45)	19	6 (32)	91	38 (42)
2001	65	41 (63)	18	8 (44)	84	50 (60)
2002	35	24 (69)	11	5 (45)	47	29 (62)
χ^2 trend p value		0.2		0.8		0.2

Table 17: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1997						
< 25 years	19	2 (11)	14	2 (14)	33	4 (12)
25 – 29	16	8 (50)	12	3 (25)	30	12 (40)
35 + years	68	48 (71)	12	10 (83)	85	59 (69)
Total	103	58 (56)	38	15 (39)	148	75 (51)
p value		<0.001		0.002		<0.001
1998-1999						
< 25 years	20	1 (5)	21	0 (0)	42	1 (2)
25 – 29	29	9 (31)	6	1 (17)	35	10 (29)
35 + years	80	54 (68)	11	9 (82)	91	63 (69)
Total	129	64 (50)	38	10 (26)	167	74 (44)
p value		<0.001		<0.001		<0.001
2000-2002						
< 25 years	24	4 (17)	17	7 (41)	41	11 (27)
25 – 29	19	7 (37)	7	4 (57)	26	11 (42)
35 + years	128	86 (67)	24	8 (33)	155	95 (61)
Total	171	97 (57)	48	19 (40)	222	117 (53)
p value		<0.001		0.7		0.001

* Total includes people whose sex was not reported and reported as transgender.

NORTHERN TERRITORY
HCV ANTIBODY

Table 18: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1997						
<1 to 2 years	13	3 (23)	8	1 (13)	21	4 (19)
3 to 5 years	17	5 (29)	12	4 (33)	29	9 (31)
6 to 10 years	16	3 (19)	12	5 (42)	28	8 (29)
10 + years	60	48 (80)	6	5 (83)	68	54 (79)
p value		<0.001		0.06		<0.001
1998-1999						
<1 to 2 years	10	0 (0)	14	1 (7)	24	1 (4)
3 to 5 years	15	2 (13)	7	1 (14)	22	3 (14)
6 to 10 years	33	11 (33)	5	0 (0)	38	11 (29)
10 + years	70	50 (71)	12	8 (67)	82	58 (71)
p value		<0.001		0.002		<0.001
2000-2002						
<1 to 2 years	11	2 (18)	9	5 (56)	21	7 (33)
3 to 5 years	27	2 (7)	9	2 (22)	36	4 (11)
6 to 10 years	20	8 (40)	12	6 (50)	32	14 (44)
10 + years	109	82 (75)	18	6 (33)	128	89 (70)
p value		<0.001		0.4		<0.001

* Total includes people whose sex was not reported and reported as transgender.

Table 19: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1997						
Amphetamine	5	0 (0)	16	4 (25)	21	4 (19)
Heroin	3	1 (33)	26	14 (54)	29	15 (52)
Morphine	7	2 (29)	65	43 (66)	72	45 (63)
Other/not reported	6	1 (17) 0.6	18	10 (56) 0.03	26	12 (46) 0.005
1998-1999						
Amphetamine	12	0 (0)	24	3 (13)	37	4 (11)
Heroin	2	0 (0)	17	7 (41)	19	7 (37)
Morphine	10	1 (10)	96	62 (65)	106	63 (59)
Other/not reported	0	---	5	0 (0)	5	0 (0)
p value		0.5		<0.001		<0.001
2000-2002						
Amphetamine	14	6 (43)	45	13 (29)	60	20 (33)
Heroin	0	---	18	9 (50)	18	9 (50)
Morphine	5	1 (20)	110	75 (62)	117	75 (64)
Other/not reported	2	0 (0) 0.6	23	13 (57) 0.002	27	13 (48) 0.03

* Total includes people who did not report duration of drug injection.

Table 20: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1997						
Less than daily	10	1 (10)	44	15 (34)	55	17 (31)
Daily or more	7	3 (43)	75	52 (69)	83	55 (66)
p value		0.1		<0.001		<0.001
1998-1999						
Less than daily	10	0 (0)	31	6 (19)	41	6 (15)
Daily or more	14	1 (7)	109	66 (61)	124	68 (55)
p value		0.4		<0.001		<0.001
2000-2002						
Less than daily	8	4 (50)	48	22 (46)	57	27 (47)
Daily or more	10	3 (30)	139	83 (60)	151	88 (58)
p value		0.4		0.1		0.2

Table 21: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month.

Reused someone else's syringe last month	Nº tested	Nº with HCV (%)
1995-1997		
No	117	66 (56)
Yes	21	6 (29)
p value		0.02
1998-1999		
No	140	67 (48)
Yes	12	1 (8)
p value		0.008
2000-2002		
No	178	100 (56)
Yes	23	15 (65)
p value		0.4

Table 23: HCV antibody prevalence according to year of survey, sex work last month.

Sex work last month	Nº tested	Nº with HCV (%)
1995-1997		
No	136	70 (51)
Yes	6	1 (17)
p value		0.1
1998-1999		
No	162	74 (46)
Yes	5	0 (0)
p value		0.04
2000-2001		
No	194	104 (54)
Yes	17	11 (65)
p value		0.4

Table 22: HCV antibody prevalence according to year of survey, imprisonment last year.

Imprisonment last year	Nº tested	Nº with HCV (%)
1995-1997		
No	134	66 (49)
Yes	13	9 (69)
p value		0.2
1998-1999		
No	148	60 (41)
Yes	18	13 (72)
p value		0.01
2000-2002		
No	186	97 (52)
Yes	27	16 (59)
p value		0.5

QUEENSLAND
1995-2002

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	4	5	5	5	6	6	6	9
Response								
Nº surveyed	N = 344	N = 513	N = 520	N = 694	N = 834	N = 750	N = 817	N = 715
% response	56	69	74	50	51	57	50	48
Sex (%)								
Males	247 (72)	374 (73)	358 (69)	490 (71)	552 (66)	487 (65)	562 (69)	504 (70)
Females	92 (27)	132 (26)	160 (31)	202 (29)	227 (33)	257 (34)	247 (30)	205 (29)
Transgender	0 (0)	0 (0)	2 (<1)	2 (<1)	4 (<1)	4 (<1)	6 (1)	5 (1)
Not reported	5 (1)	7 (1)	0 (0)	0 (0)	1 (<1)	2 (<1)	2 (<1)	1 (<1)
Sexual identity (%)								
Heterosexual	264 (77)	395 (77)	419 (81)	561 (81)	621 (74)	573 (76)	626 (76)	529 (74)
Bisexual	42 (12)	65 (13)	55 (10)	67 (10)	106 (13)	80 (11)	71 (9)	71 (10)
Gay/lesbian	27 (8)	38 (7)	26 (5)	50 (7)	51 (6)	45 (6)	48 (6)	36 (5)
Not reported	11 (3)	15 (3)	20 (4)	16 (2)	56 (7)	52 (7)	72 (9)	79 (11)
Age and duration of injection (years)								
Median age	25	24	24	25	26	28	28	29
Age range	16-49	15-51	16-55	16-57	14-52	15-56	16-57	14-58
Not reported	2	2	0	1	2	5	3	3
Median age 1 st IDU	18	18	18	19	18	18	18	18
Age range	10-48	10-47	10-50	12-47	7-47	9-51	6-52	10-56
Not reported	10	17	11	14	26	18	32	24
Median years IDU	5	4	5	5	6	7	8	9
Range	0-31	0-28	0-30	0-40	0-36	0-37	<1-38	<1-38
Not reported	10	17	11	15	27	21	34	25
Aboriginal and Torres Strait Islander Origin (%)								
Yes	10 (3)	16 (3)	22 (4)	23 (3)	41 (5)	49 (6)	51 (6)	49 (7)
No	322 (94)	465 (91)	489 (94)	662 (95)	755 (91)	669 (90)	735 (90)	636 (89)
Not reported	12 (3)	32 (6)	9 (2)	9 (1)	38 (4)	32 (4)	31 (4)	30 (4)
Imprisonment last year (%)								
Yes	31 (9)	37 (7)	36 (7)	63 (9)	107 (13)	98 (13)	115 (14)	109 (15)
No	306 (89)	462 (90)	482 (93)	624 (90)	713 (85)	639 (85)	670 (82)	595 (83)
Not reported	7 (2)	14 (3)	2 (<1)	7 (1)	14 (2)	13 (2)	32 (4)	11 (2)
Injected in prison (%)								
Yes	7 (23)	16 (43)	23 (64)	26 (41)	43 (40)	39 (40)	41 (36)	43 (39)
Frequency of injection last month (%)								
Not last month	29 (9)	39 (8)	53 (10)	53 (8)	70 (8)	67 (9)	84 (10)	85 (12)
Less than weekly	63 (18)	124 (24)	157 (30)	144 (17)	145 (18)	132 (18)	180 (22)	120 (17)
Weekly not daily	111 (32)	164 (32)	92 (18)	204 (29)	203 (24)	202 (27)	207 (25)	165 (23)
Daily or more	137 (40)	183 (35)	217 (42)	292 (42)	402 (48)	343 (46)	333 (41)	339 (47)
Not reported	4 (1)	3 (1)	1 (<1)	1 (<1)	14 (2)	6 (1)	13 (2)	6 (1)
Last drug injected (%)								
Amphetamine	126 (37)	173 (34)	212 (41)	318 (46)	361 (43)	283 (38)	422 (52)	361 (43)
Anabolic steroids	5 (1)	15 (3)	17 (3)	12 (2)	14 (2)	22 (3)	14 (2)	14 (2)
Benzos	1 (<1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0 (0)	4 (<1)
Buprenorphine	---	---	---	---	---	---	---	2 (<1)
Cocaine	1 (<1)	5 (1)	2 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)	2 (<1)
Heroin	169 (49)	264 (51)	238 (46)	290 (42)	360 (43)	337 (45)	217 (26)	360 (43)
Heroin + Cocaine	1 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (<1)	6 (1)	19 (2)	2 (<1)
Methadone	9 (3)	5 (1)	14 (3)	7 (1)	10 (1)	12 (1)	32 (4)	10 (1)
Morphine	4 (1)	15 (3)	5 (1)	13 (2)	13 (2)	18 (2)	50 (6)	13 (2)
More than one	22 (6)	30 (6)	26 (5)	45 (5)	51 (6)	55 (7)	47 (6)	51 (6)
Other	5 (1)	4 (1)	1 (<1)	3 (<1)	4 (1)	1 (<1)	6 (1)	2 (<1)
Not reported	1 (<1)	0 (0)	3 (<1)	1 (<1)	15 (2)	10 (1)	8 (1)	15 (2)

QUEENSLAND

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 311	N = 471	N = 466	N = 640	N = 750	N = 677	N = 720	N = 624
Places injected last month (%)*								
Own home	386 (83)	517 (81)	602 (80)	576 (85)	578 (80)	495 (79)		
Friend's home	241 (52)	315 (49)	371 (49)	337 (50)	336 (47)	292 (47)		
Dealer's home	96 (21)	125 (20)	197 (26)	141 (21)	156 (22)	142 (23)		
Street, park, beach	96 (20)	117 (18)	189 (25)	154 (23)	157 (22)	166 (27)		
Car	---	201 (31)	293 (39)	250 (37)	241 (33)	237 (38)		
Public toilet	91 (20)	107 (17)	186 (25)	163 (24)	164 (23)	166 (27)		
"Shooting" room	11 (2)	7 (1)	6 (1)	8 (1)	6 (1)	11 (2)		
Squat	---	---	42 (6)	34 (5)	56 (8)	51 (8)		
Use of new sterile needles & syringes last month (%)								
All injections	328 (71)	455 (71)	534 (71)	506 (75)	535 (74)	469 (75)		
Most of the time	103 (22)	127 (20)	170 (23)	134 (20)	154 (21)	130 (21)		
Half of the time	10 (2)	21 (3)	16 (2)	12 (2)	10 (1)	8 (1)		
Some of the time	5 (1)	15 (2)	4 (<1)	5 (1)	2 (<1)	8 (1)		
Not last month	5 (1)	4 (1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)		
Not reported	15 (3)	18 (3)	25 (3)	18 (3)	16 (3)	8 (1)		
Re-used another's syringe last month (%)								
None	220 (71)	340 (72)	367 (79)	523 (82)	562 (75)	560 (83)	578 (80)	500 (80)
One	31 (10)	56 (12)	18 (4)	39 (6)	61 (8)	34 (5)	40 (6)	36 (6)
Twice	30 (9)	39 (8)	21 (5)	22 (3)	35 (5)	30 (4)	31 (4)	31 (5)
3-5 times	24 (8)	26 (6)	20 (4)	22 (3)	36 (4)	16 (2)	22 (3)	25 (4)
>5 times	5 (1)	9 (2)	14 (3)	17 (3)	25 (4)	12 (2)	20 (3)	18 (3)
Don't know	0 (0)	0 (0)	10 (2)	0 (0)	6 (1)	1 (<1)	0 (0)	2 (<1)
Not reported	1 (1)	1 (<1)	16 (3)	17 (3)	25 (3)	24 (4)	29 (4)	12 (2)
Number of people syringe was re-used after last month (%)								
None	220 (71)	340 (72)	367 (79)	523 (82)	562 (75)	560 (83)	578 (80)	500 (80)
One	49 (16)	91 (19)	68 (15)	79 (12)	119 (16)	72 (11)	66 (9)	65 (10)
Two	32 (10)	34 (7)	9 (2)	10 (1)	8 (1)	5 (1)	8 (1)	10 (2)
Three to five	3 (1)	1 (<1)	3 (<1)	3 (<1)	10 (1)	8 (1)	5 (1)	8 (1)
More than five	6 (2)	4 (1)	3 (<1)	4 (1)	13 (2)	5 (1)	5 (1)	5 (1)
Don't know	0 (0)	0 (0)	1 (<1)	4 (1)	13 (2)	1 (<1)	14 (2)	10 (2)
Not reported	1 (<1)	1 (<1)	15 (3)	17 (3)	25 (3)	24 (3)	44 (6)	26 (4)
Relationship to people syringe was re-used after last month (%)*								
Regular sex partner	51 (11)	65 (10)	91 (12)	62 (9)	64 (9)	47 (8)		
Casual sex partner	2 (<1)	6 (1)	8 (1)	11 (2)	8 (1)	10 (2)		
Close friend	18 (4)	28 (4)	43 (6)	32 (5)	34 (5)	28 (4)		
Acquaintance	8 (1)	6 (1)	14 (2)	14 (2)	10 (1)	11 (2)		
Other	2 (<1)	2 (<1)	10 (1)	11 (2)	6 (1)	5 (1)		
Equipment used after someone else last month (%)*								
Spoon			281 (38)	188 (28)	177 (25)	179 (29)		
Water			220 (30)	134 (20)	143 (20)	151 (24)		
Filter			165 (22)	111 (16)	98 (14)	125 (20)		
Tourniquet			119 (16)	92 (14)	95 (13)	84 (13)		
Drug mix			119 (16)	86 (13)	84 (12)	97 (16)		
Injected by someone else who'd already injected themselves or others last month (%)								
Yes			127 (18)	106 (16)	141 (20)	87 (14)		
No			566 (76)	535 (79)	549 (76)	519 (83)		
Not reported			48 (6)	36 (5)	30 (4)	18 (3)		

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 344	N = 513	N = 520	N = 694	N = 834	N = 750	N = 817	N = 715
Any treatment/therapy for drug use (%)								
No	182 (53)	269 (52)	261 (50)	359 (52)	376 (45)	303 (40)	321 (39)	271 (38)
Yes	161 (47)	241 (47)	258 (50)	332 (47)	446 (54)	440 (59)	485 (59)	433 (60)
Not reported	1 (<1)	3 (1)	1 (<1)	3 (1)	12 (1)	7 (1)	11 (1)	11 (2)
History of methadone treatment (%)								
Currently	59 (17)	110 (21)	112 (21)	144 (21)	159 (19)	191 (25)	164 (20)	142 (20)
Previously	53 (15)	63 (12)	76 (15)	79 (11)	173 (21)	153 (20)	177 (22)	143 (20)
Never	231 (67)	337 (66)	331 (64)	468 (67)	502 (60)	403 (54)	461 (56)	418 (58)
Not reported	1 (1)	3 (1)	1 (<1)	3 (1)	0 (0)	3 (<1)	15 (2)	12 (2)
History of other pharmacological therapy (%)								
Currently				15 (2)	14 (2)	18 (2)	24 (3)	54 (8)
Previously				15 (2)	48 (6)	81 (11)	74 (9)	86 (12)
Never				652 (94)	397 (47)	638 (85)	686 (84)	557 (77)
Not reported				12 (2)	374 (45)	12 (2)	22 (4)	18 (3)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 834	N = 750	N = 817	N = 715
From an NSP last month (%)								
Daily or almost daily					101 (12)	72 (10)	86 (10)	92 (13)
A couple of times each week					268 (32)	251 (33)	244 (30)	183 (25)
Less than weekly					200 (24)	184 (25)	187 (23)	171 (24)
Once last month					134 (16)	123 (16)	151 (18)	134 (19)
Not in the last month					102 (12)	102 (14)	127 (16)	110 (15)
Not reported					29 (4)	18 (2)	22 (3)	25 (4)
From a chemist last month (%)								
Daily or almost daily					42 (5)	27 (4)	23 (3)	34 (5)
A couple of times each week					111 (14)	103 (14)	92 (11)	78 (11)
Less than weekly					154 (19)	117 (15)	128 (16)	108 (15)
Once last month					199 (24)	172 (23)	167 (20)	167 (23)
Not in the last month					293 (35)	309 (41)	378 (46)	288 (40)
Not reported					35 (4)	22 (3)	29 (4)	40 (6)

QUEENSLAND

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 344	N = 513	N = 520	N = 694	N = 834	N = 750	N = 817	N = 715
Sex last month (%)								
No	81 (23)	131 (25)	175 (34)	191 (27)	232 (28)	207 (28)	214 (26)	194 (27)
Yes	260 (76)	379 (74)	341 (65)	499 (72)	585 (70)	536 (72)	584 (72)	502 (70)
Not reported	3 (1)	3 (1)	4 (1)	4 (1)	17 (2)	5 (1)	19 (2)	19 (3)
Condoms last sex (%)								
Yes	110 (32)	138 (27)	196 (38)	272 (39)	288 (34)	243 (33)	271 (33)	246 (34)
No	181 (53)	227 (44)	319 (61)	411 (59)	516 (62)	481 (64)	503 (62)	459 (65)
Not reported	53 (15)	148 (29)	5 (1)	11 (2)	30 (4)	26 (3)	43 (5)	10 (1)
Condom use with regular sex partner(s) last month (%)*								
No	191 (57)	196 (61)	247 (59)	337 (67)	316 (67)	239 (61)	212 (61)	
Sometimes	57 (17)	56 (17)	56 (13)	68 (14)	57 (12)	61 (16)	41 (12)	
Always	86 (26)	71 (22)	115 (28)	95 (19)	98 (21)	90 (23)	92 (27)	
Condom use with new sex partner(s) last month (%)*								
No	46 (31)	47 (34)	41 (34)	92 (47)	77 (43)	162 (48)	127 (46)	
Sometimes	20 (13)	27 (20)	13 (11)	23 (12)	21 (12)	55 (16)	428 (15)	
Always	84 (56)	63 (46)	67 (55)	81 (41)	80 (45)	124 (36)	109 (39)	
Condom use with casual sex partner(s) last month (%)*								
No			48 (29)	95 (43)	108 (47)	115 (44)	116 (46)	
Sometimes			28 (17)	32 (14)	23 (10)	52 (20)	40 (16)	
Always			91 (54)	96 (43)	100 (43)	96 (36)	94 (38)	
Duration of regular sexual relationship (%)**								
One month						40 (10)	26 (7)	
2 - 6 months						74 (18)	52 (15)	
6 - 12 months						57 (14)	53 (15)	
>12 months						235 (58)	225 (63)	
Sex work last month (%)								
Yes	12 (3)	15 (3)	25 (5)	23 (3)	51 (6)	38 (5)	54 (7)	44 (6)
No	323 (93)	485 (94)	484 (93)	660 (95)	755 (91)	682 (91)	724 (89)	658 (92)
Not reported	9 (3)	13 (2)	11 (2)	11 (2)	28 (3)	29 (4)	39 (4)	8 (3)
Condom use last sex work last month (%)**								
Yes	10 (83)	12 (80)	16 (76)	18 (90)	38 (88)	32 (94)	41 (89)	36 (83)

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1996-2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 344	N = 513	N = 520	N = 694	N = 834	N = 750	N = 817	N = 715
Previous HIV test (%)								
Yes, last year	197 (57)	331 (66)	327 (64)	436 (63)	517 (62)	490 (65)	496 (61)	476 (67)
> 1 year ago	74 (22)	93 (18)	95 (18)	137 (20)	170 (20)	151 (20)	187 (23)	141 (20)
Never tested	70 (20)	88 (16)	95 (17)	117 (17)	133 (16)	96 (13)	120 (14)	89 (12)
Not reported	3 (1)	1 (<1)	3 (1)	4 (<1)	14 (2)	12 (2)	14 (2)	9 (1)
Self report HBV infection (%)								
Yes	73 (21)	88 (17)	68 (13)	90 (13)	110 (13)	105 (14)	117 (14)	101 (14)
No	259 (75)	415 (81)	383 (74)	480 (69)	624 (75)	569 (76)	595 (73)	515 (72)
Don't know	---	---	68 (13)	115 (16)	79 (9)	55 (7)	81 (10)	84 (12)
Not reported	12 (3)	10 (2)	1 (1)	9 (1)	21 (3)	18 (2)	24 (3)	15 (2)
Self report HBV vaccination (%)*								
Yes	134 (49)	220 (52)	218 (48)	290 (48)	404 (56)	400 (62)	384 (55)	362 (59)
No	130 (48)	192 (45)	161 (36)	215 (36)	223 (31)	162 (25)	200 (28)	165 (27)
Don't know	---	---	71 (16)	87 (14)	72 (10)	61 (10)	68 (10)	68 (11)
Not reported	7 (3)	13 (3)	2 (<1)	12 (2)	24 (3)	21 (3)	48 (7)	19 (3)
Previous HCV test (%)								
Yes ever	240 (70)	380 (74)	-	-	-	-	-	-
Yes, last year	-	-	317 (71)	403 (58)	527 (63)	507 (68)	522 (64)	470 (66)
> 1 year ago	-	-	71 (14)	118 (17)	141 (17)	145 (19)	165 (20)	128 (18)
Never tested	95 (28)	126 (25)	127 (24)	166 (24)	153 (18)	87 (12)	112 (14)	109 (15)
Not reported	9 (2)	7 (1)	5 (1)	7 (1)	13 (2)	11 (1)	18 (2)	8 (1)
Any treatment for HCV (%)								
Interferon					N = 246	N = 233	N = 281	N = 275
Interferon+Ribavarin					7 (3)	6 (3)	9 (3)	7 (3)
Other					1 (<1)	2 (1)	2 (1)	5 (2)
No treatment					10 (4)	7 (3)	10 (4)	11 (4)
Not reported					226 (92)	211 (90)	253 (90)	245 (88)
Current treatment for HCV								
Interferon					N = 6	N = 4	N = 7	N = 1
Interferon+Ribavarin					0	1	0	0
Other					0	0	1	1
					6	3	6	0

* Number (percentage) among participants not reporting HBV infection.

QUEENSLAND

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995	225	4 (1.8)	84	1 (1.2)	314	5 (1.6)
1996	374	7 (1.9)	132	1 (0.8)	513	8 (1.6)
1997	327	7 (2.1)	150	2 (1.3)	479	9 (1.9)
1998	472	4 (0.9)	196	1 (0.5)	670	5 (0.8)
1999	531	11 (2.1)	268	2 (0.8)	804	13 (1.6)
2000	464	7 (1.5)	250	0 (0.0)	720	8 (1.1)
2001	550	8 (1.5)	240	0 (0.0)	798	8 (1.0)
2002	479	10 (2.1)	200	2 (1.0)	685	13 (1.9)
χ^2 trend p value		1.0		0.3		0.8

Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.

Sexual identity	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Heterosexual	184	1 (0.5)	59	1 (1.7)	244	2 (0.8)
Bisexual	19	0 (0.0)	17	0 (0.0)	38	0 (0.0)
Homosexual	17	3 (17.7)	6	0 (0.0)	24	3 (12.5)
p value		<0.001		0.8		<0.001
1996						
Heterosexual	303	0 (0.0)	88	2 (1.1)	395	1 (0.3)
Bisexual	32	1 (3.1)	32	0 (0.0)	65	1 (1.5)
Homosexual	26	6 (23.0)	12	0 (0.0)	38	6 (15.8)
p value		<0.001		0.8		<0.001
1997						
Heterosexual	278	1 (0.4)	105	1 (1.0)	384	2 (0.5)
Bisexual	18	0 (0.0)	34	1 (2.9)	52	1 (1.9)
Homosexual	16	6 (37.5)	10	0 (0.0)	26	6 (23.1)
p value		<0.001		0.6		<0.001
1998						
Heterosexual	401	0 (0.0)	142	0 (0.0)	544	0 (0.0)
Bisexual	29	0 (0.0)	35	1 (2.9)	64	1 (1.6)
Homosexual	29	4 (13.8)	17	0 (0.0)	47	4 (8.5)
p value		<0.001		0.1		<0.001
1999						
Heterosexual	422	4 (1.0)	177	2 (1.1)	599	6 (1.0)
Bisexual	42	0 (0.0)	59	0 (0.0)	103	0 (0.0)
Homosexual	29	5 (17.2)	17	0 (0.0)	48	5 (10.4)
p value		<0.001		0.6		<0.001
2000						
Heterosexual	378	1 (0.3)	---	---	547	1 (0.2)
Bisexual	26	1 (3.9)	---	---	79	1 (1.3)
Homosexual	26	5 (19.2)	---	---	44	6 (13.6)
p value		<0.001				<0.001
2001						
Heterosexual	440	2 (0.5)	---	---	611	2 (0.3)
Bisexual	25	0 (0.0)	---	---	70	0 (0.0)
Homosexual	33	6 (18.2)	---	---	47	6 (12.8)
p value		<0.001				<0.001
2002						
Heterosexual	337	3 (0.8)	129	1 (0.8)	507	4 (0.8)
Bisexual	19	1 (5.3)	47	1 (2.1)	68	2 (2.9)
Homosexual	24	6 (25.0)	8	0 (0.0)	34	7 (20.6)
p value		<0.001		0.7		<0.001

* Total includes people whose sex was not reported or reported as transgender.

Table 9: HIV antibody prevalence according to year of survey, age group and sex.

Age group	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
< 20 years	22	0 (0.0)	8	0 (0.0)	31	0 (0.0)
20 – 24	77	1 (1.3)	36	0 (0.0)	116	1 (0.9)
25 – 29	43	1 (2.3)	13	0 (0.0)	56	1 (1.8)
30 + years	81	2 (2.5)	26	1 (3.9)	108	3 (2.8)
p value		0.9		0.5		0.6
1996						
< 20 years	49	0 (0.0)	30	0 (0.0)	79	0 (0.0)
20 – 24	141	2 (1.4)	40	0 (0.0)	184	2 (1.1)
25 – 29	74	1 (1.3)	17	0 (0.0)	92	1 (1.1)
30 + years	110	4 (3.6)	45	1 (2.2)	156	5 (3.2)
p value		0.4		0.6		0.2
1997						
< 20 years	40	0 (0.0)	29	0 (0.0)	69	0 (0.0)
20 – 24	119	1 (0.8)	60	0 (0.0)	180	1 (0.6)
25 – 29	63	1 (1.6)	24	0 (0.0)	88	1 (1.1)
30 + years	105	5 (4.8)	37	2 (5.4)	142	7 (4.9)
p value		0.1		0.1		0.02
1998						
< 20 years	45	0 (0.0)	31	0 (0.0)	76	0 (0.0)
20 – 24	156	0 (0.0)	64	0 (0.0)	220	0 (0.0)
25 – 29	119	2 (1.7)	37	0 (0.0)	156	2 (1.3)
30 + years	151	2 (1.3)	64	1 (1.6)	217	3 (1.4)
p value		0.4		0.6		0.3
1999						
< 20 years	65	1 (1.5)	45	0 (0.0)	110	1 (0.9)
20 – 24	129	1 (0.8)	78	0 (0.0)	209	1 (0.5)
25 – 29	152	0 (0.0)	56	0 (0.0)	209	0 (0.0)
30 + years	184	9 (4.9)	89	2 (2.3)	274	11 (4.0)
p value		0.009		0.3		0.002
2000						
< 20 years	40	0 (0.0)	---	---	76	0 (0.0)
20 – 24	98	1 (1.0)	---	---	175	1 (0.6)
25 – 29	114	2 (1.8)	---	---	161	2 (1.2)
30 + years	211	4 (1.9)	---	---	305	5 (1.6)
p value		0.9				0.5
2001						
< 20 years	37	0 (0.0)	---	---	63	0 (0.0)
20 – 24	108	0 (0.0)	---	---	178	0 (0.0)
25 – 29	144	0 (0.0)	---	---	194	0 (0.0)
30 + years	259	8 (3.1)	---	---	361	8 (2.2)
p value		0.03				0.02
2002						
< 20 years	32	0 (0.0)	24	0 (0.0)	56	0 (0.0)
20 – 24	87	0 (0.0)	45	1 (2.2)	132	1 (0.8)
25 – 29	139	3 (0.0)	45	0 (0.0)	185	3 (1.6)
30 + years	219	7 (3.2)	85	1 (1.1)	309	9 (2.9)
p value		0.3		0.7		0.3

* Total includes people whose sex was not reported or reported as transgender.

QUEENSLAND
HIV ANTIBODY

Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.

Years of drug injection	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
<1 to 2 years	51	0 (0.0)	20	0 (0.0)	72	0 (0.0)
3 to 5 years	56	0 (0.0)	23	0 (0.0)	79	0 (0.0)
6 to 10 years	41	2 (4.9)	16	0 (0.0)	59	2 (3.4)
> 10 years	69	2 (2.9)	25	1 (4.0)	95	3 (3.2)
p value		0.2		0.5		0.2
1996						
<1 to 2 years	100	1 (1.0)	30	0 (0.0)	131	1 (0.8)
3 to 5 years	108	3 (2.8)	46	0 (0.0)	157	3 (1.9)
6 to 10 years	69	0 (0.0)	20	0 (0.0)	90	0 (0.0)
> 10 years	84	3 (3.6)	34	1 (2.9)	118	4 (3.4)
p value		0.3		0.4		0.2
1997						
<1 to 2 years	88	0 (0.0)	47	0 (0.0)	135	0 (0.0)
3 to 5 years	82	1 (1.2)	43	0 (0.0)	125	1 (0.8)
6 to 10 years	66	1 (1.5)	26	0 (0.0)	92	1 (1.1)
> 10 years	84	5 (6.0)	32	2 (6.3)	117	7 (6.0)
p value		0.05		0.06		0.003
1998						
<1 to 2 years	107	1 (0.9)	55	0 (0.0)	162	1 (0.6)
3 to 5 years	129	0 (0.0)	43	0 (0.0)	172	0 (0.0)
6 to 10 years	117	1 (0.9)	45	0 (0.0)	162	1 (0.6)
> 10 years	108	2 (1.9)	50	1 (2.0)	160	3 (1.9)
p value		0.5		0.4		0.3
1999						
<1 to 2 years	101	2 (2.0)	62	1 (1.6)	163	3 (1.8)
3 to 5 years	121	0 (0.0)	57	1 (1.8)	179	1 (0.6)
6 to 10 years	140	3 (2.1)	75	0 (0.0)	218	3 (1.4)
> 10 years	152	5 (3.3)	67	0 (0.0)	219	5 (2.3)
p value		0.3		0.5		0.6
2000						
<1 to 2 years	59	2 (3.4)	---	---	94	2 (2.1)
3 to 5 years	98	1 (1.0)	---	---	170	1 (0.6)
6 to 10 years	118	1 (0.9)	---	---	193	1 (0.5)
> 10 years	177	3 (1.7)	---	---	246	4 (1.6)
p value		0.6				0.5
2001						
<1 to 2 years	61	1 (1.6)	---	---	99	1 (1.0)
3 to 5 years	103	2 (1.9)	---	---	156	2 (1.3)
6 to 10 years	154	1 (0.7)	---	---	224	1 (0.5)
> 10 years	210	3 (1.4)	---	---	286	3 (1.1)
p value		0.8				0.8
2002						
<1 to 2 years	54	2 (3.7)	25	0 (0.0)	79	2 (2.5)
3 to 5 years	67	2 (3.0)	40	1 (2.5)	108	3 (2.8)
6 to 10 years	144	0 (0.0)	53	0 (0.0)	198	0 (0.0)
> 10 years	201	6 (3.0)	72	1 (1.4)	276	8 (2.9)
p value		0.2		0.6		0.1

* Total includes people whose sex was not reported or reported as transgender.

Table 11: HIV antibody prevalence according to year of survey, type of drug last injected and sex.

Last drug injected	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Amphetamine	75	1 (1.3)	30	0 (0.0)	108	1 (0.9)
Heroin	116	3 (2.6)	45	1 (2.2)	162	4 (2.5)
More than one	13	0 (0.0)	5	0 (0.0)	19	0 (0.0)
Other/not reported	21	0 (0.0)	3	0 (0.0)	15	0 (0.0)
p value		0.8		0.8		0.8
1996						
Amphetamine	133	3 (2.2)	36	1 (2.8)	173	4 (2.3)
Heroin	174	2 (1.2)	86	0 (0.0)	264	2 (0.8)
More than one	26	2 (7.7)	5	0 (0.0)	31	2 (6.5)
Other/not reported	39	0 (0.0)	5	0 (0.0)	40	0 (0.0)
p value		0.1		0.4		0.1
1997						
Amphetamine	136	1 (0.7)	53	0 (0.0)	191	1 (0.5)
Heroin	144	5 (3.5)	83	0 (0.0)	227	5 (2.2)
More than one	17	0 (0.0)	8	0 (0.0)	25	0 (0.0)
Other/not reported	30	1 (3.3)	6	2 (33.3)	22	0 (0.0)
p value		0.4		<0.001		<0.001
1998						
Amphetamine	227	2 (0.9)	77	1 (1.3)	304	3 (1.0)
Heroin	182	1 (0.6)	98	0 (0.0)	281	1 (0.4)
More than one	37	1 (2.7)	9	0 (0.0)	47	1 (2.1)
Other/not reported	26	0 (0.0)	12	0 (0.0)	30	0 (0.0)
p value		0.6		0.7		0.7
1999						
Amphetamine	237	7 (3.0)	106	2 (1.9)	344	9 (2.6)
Heroin	205	1 (0.5)	141	0 (0.0)	349	1 (0.3)
More than one	40	1 (2.5)	12	0 (0.0)	52	1 (1.9)
Other/not reported	49	2 (4.1)	9	0 (0.0)	34	1 (2.9)
p value		0.2		0.4		0.03
2000						
Amphetamine	183	3 (1.6)	---	---	270	3 (1.1)
Heroin	187	2 (1.1)	---	---	328	2 (0.6)
More than one	44	1 (2.3)	---	---	56	2 (3.6)
Other/not reported	50	1 (2.0)	---	---	45	0 (0.0)
p value		0.9				0.3
2001						
Amphetamine	285	5 (1.8)	---	---	413	5 (1.2)
Heroin	144	1 (0.7)	---	---	212	1 (0.5)
More than one	50	2 (4.0)	---	---	65	2 (3.1)
Other/not reported	71	0 (0.0)	---	---	69	0 (0.0)
p value		0.3				0.3
2002						
Amphetamine	217	6 (2.8)	85	0 (1.9)	304	6 (2.0)
Heroin	137	0 (0.0)	68	0 (0.0)	206	1 (0.5)
More than one	44	3 (6.8)	14	1 (7.1)	59	4 (6.8)
Other/not reported	81	1 (1.2)	33	1 (3.0)	116	2 (1.7)
p value		0.04		0.04		0.02

* Total includes people whose sex was not reported or reported as transgender.

QUEENSLAND
HIV ANTIBODY

Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.

Frequency of drug injection last month	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Not last month	21	0 (0.0)	3	0 (0.0)	25	0 (0.0)
Less than weekly	36	1 (2.8)	18	1 (5.6)	55	2 (3.6)
Weekly not daily	81	1 (1.2)	23	0 (0.0)	105	1 (1.0)
Daily or more	86	2 (2.3)	39	0 (0.0)	127	2 (1.6)
p value		0.8		0.3		0.5
1996						
Not last month	31	1 (3.2)	8	0 (0.0)	39	1 (2.6)
Less than weekly	87	3 (3.5)	35	1 (2.9)	124	4 (3.2)
Weekly not daily	122	2 (1.6)	41	0 (0.0)	164	2 (1.2)
Daily or more	131	1 (0.8)	48	0 (0.0)	183	1 (0.6)
p value		0.5		0.4		0.3
1997						
Not last month	39	3 (7.7)	7	0 (0.0)	46	3 (6.5)
Less than weekly	103	2 (1.9)	41	0 (0.0)	145	2 (1.4)
Weekly not daily	60	2 (3.3)	26	2 (7.7)	86	4 (4.7)
Daily or more	124	0 (0.0)	76	0 (0.0)	201	0 (0.0)
p value		0.03		0.02		0.005
1998						
Not last month	36	1 (2.8)	14	0 (0.0)	50	1 (2.0)
Less than weekly	107	2 (1.9)	33	0 (0.0)	140	2 (1.4)
Weekly not daily	142	1 (0.7)	55	0 (0.0)	198	1 (0.5)
Daily or more	186	0 (0.0)	94	1 (1.1)	281	1 (0.4)
p value		0.2		0.8		0.4
1999						
Not last month	44	0 (0.0)	23	0 (0.0)	67	0 (0.0)
Less than weekly	101	2 (2.0)	39	0 (0.0)	140	2 (1.4)
Weekly not daily	129	1 (0.8)	65	0 (0.0)	195	1 (0.5)
Daily or more	246	8 (3.3)	139	2 (1.4)	388	10 (2.6)
p value		0.3		0.6		0.2
2000						
Not last month	39	0 (0.0)	---	---	65	0 (0.0)
Less than weekly	95	1 (1.1)	---	---	128	1 (0.8)
Weekly not daily	120	4 (3.3)	---	---	190	5 (2.6)
Daily or more	207	2 (1.0)	---	---	331	2 (0.6)
p value		0.3				0.1
2001						
Not last month	55	0 (0.0)	---	---	80	0 (0.0)
Less than weekly	139	2 (1.4)	---	---	177	2 (1.1)
Weekly not daily	132	2 (1.5)	---	---	204	2 (1.0)
Daily or more	216	4 (1.9)	---	---	325	4 (1.2)
p value		0.8				0.8
2002						
Not last month	55	3 (5.5)	24	0 (0.0)	80	3 (3.8)
Less than weekly	84	3 (3.6)	27	0 (0.0)	114	4 (3.5)
Weekly not daily	108	2 (1.9)	50	1 (2.0)	160	3 (1.9)
Daily or more	227	2 (0.9)	98	1 (1.0)	325	3 (0.9)
p value		0.1		0.8		0.2

* Total includes people whose sex was not reported or reported as transgender.

Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.

Reused someone else's syringe last month	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	149	4 (2.7)	53	1 (1.9)	204	5 (2.5)
Yes	53	0 (0.0)	27	0 (0.0)	82	0 (0.0)
p value		0.2		0.5		0.2
1996						
No	243	5 (2.1)	92	1 (1.1)	340	6 (1.8)
Yes	96	1 (1.0)	32	0 (0.0)	130	1 (0.8)
p value		0.5		0.6		0.4
1997						
No	234	4 (1.7)	105	2 (1.9)	341	6 (1.8)
Yes	40	0 (0.0)	35	0 (0.0)	75	0 (0.0)
p value		0.4		0.4		0.2
1998						
No	356	1 (0.3)	149	1 (0.7)	507	2 (0.4)
Yes	65	1 (1.5)	30	0 (0.0)	95	1 (1.1)
p value		0.2		0.7		0.4
1999						
No	365	7 (1.9)	177	1 (0.6)	545	8 (1.5)
Yes	96	4 (4.2)	58	1 (1.7)	155	5 (3.2)
p value		0.2		0.4		0.2
2000						
No	362	7 (1.9)	---	---	536	8 (1.5)
Yes	46	0 (0.0)	---	---	91	0 (0.0)
p value		0.3				0.2
2001						
No	391	5 (1.3)	---	---	570	5 (0.9)
Yes	76	3 (4.0)	---	---	109	3 (2.8)
p value		0.1				0.1
2002						
No	338	6 (1.8)	140	1 (0.7)	483	8 (1.7)
Yes	76	1 (1.3)	31	1 (3.2)	107	2 (1.9)
p value		0.8		0.2		0.9

* Total includes people whose sex was not reported.

QUEENSLAND
HIV ANTIBODY

Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.

Imprisonment last year	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Yes	22	0 (0.0)	5	0 (0.0)	28	0 (0.0)
No	198	4 (2.0)	78	1 (1.3)	280	5 (1.8)
p value		0.5		0.8		0.5
1996						
Yes	33	1 (3.0)	4	0 (0.0)	37	1 (2.7)
No	333	6 (1.8)	123	1 (0.8)	462	7 (1.5)
p value		0.6		0.9		0.6
1997						
Yes	24	0 (0.0)	9	0 (0.0)	33	0 (0.0)
No	303	7 (2.3)	141	2 (1.4)	446	9 (2.0)
p value		0.5		0.7		0.4
1998						
Yes	50	0 (0.0)	10	0 (0.0)	61	0 (0.0)
No	417	4 (1.0)	185	1 (0.5)	603	5 (0.8)
p value		0.5		0.8		0.5
1999						
Yes	87	3 (3.5)	15	0 (0.0)	102	3 (2.9)
No	436	7 (1.6)	249	2 (0.8)	689	9 (1.3)
p value		0.3		0.7		0.2
2000						
Yes	73	0 (0.0)	---	---	95	1 (1.1)
No	382	7 (1.8)	---	---	613	7 (1.1)
p value		0.2				>0.9
2001						
Yes	89	3 (3.4)	---	---	113	3 (2.7)
No	437	5 (1.1)	---	---	656	5 (0.8)
p value		0.1				0.07
2002						
Yes	85	1 (1.2)	17	0 (0.0)	102	1 (1.0)
No	388	9 (2.3)	179	2 (1.1)	573	12 (2.1)
p value		0.5		0.7		0.5

* Total includes people whose sex was not reported or reported as transgender.

Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.

Condom use last sex	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Yes	69	2 (2.9)	29	1 (3.5)	100	3 (3.0)
No	115	1 (0.9)	46	0 (0.0)	164	1 (0.6)
p value		0.3		0.2		0.1
1996						
Yes	104	5 (4.8)	33	1 (3.0)	138	6 (4.4)
No	154	0 (0.0)	70	0 (0.0)	227	0 (0.0)
p value		0.006		0.1		0.002
1997						
Yes	128	4 (3.1)	55	0 (0.0)	185	4 (2.2)
No	196	3 (1.5)	95	2 (2.1)	291	5 (1.7)
p value		0.3		0.3		0.7
1998						
Yes	202	2 (1.0)	63	1 (1.6)	266	3 (1.1)
No	263	2 (0.8)	130	0 (0.0)	394	2 (0.5)
p value		0.8		0.2		0.4
1999						
Yes	197	8 (4.1)	79	1 (1.3)	278	9 (3.2)
No	321	3 (0.9)	175	1 (0.6)	498	4 (0.8)
p value		0.02		0.6		0.01
2000						
Yes	165	4 (2.4)	---	---	234	5 (2.1)
No	283	3 (1.1)	---	---	461	3 (0.7)
p value		0.3				0.08
2001						
Yes	197	6 (3.1)	---	---	267	6 (2.3)
No	326	2 (0.6)	---	---	491	2 (0.4)
p value		0.03				0.02
2002						
Yes	176	8 (4.6)	56	2 (3.6)	236	11 (4.7)
No	296	2 (0.7)	142	0 (0.0)	440	2 (0.5)
p value		0.02		0.07		0.001

* Total includes people whose sex was not reported or reported as transgender.

QUEENSLAND
HIV ANTIBODY

Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.

Sex work last month	Males		Females		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Yes	5	1 (20.0)	7	0 (0.0)	12	1 (8.3)
No	215	3 (1.4)	73	1 (1.4)	293	4 (1.4)
p value		0.002		0.8		0.06
1996						
Yes	9	1 (11.1)	6	0 (0.0)	15	1 (6.7)
No	356	6 (1.7)	124	1 (0.8)	485	7 (1.4)
p value		0.04		0.8		0.1
1997						
Yes	12	0 (0.0)	11	0 (0.0)	24	0 (0.0)
No	308	7 (2.3)	138	2 (1.5)	447	9 (2.0)
p value		0.6		0.7		0.5
1998						
Yes	7	0 (0.0)	16	0 (0.0)	23	0 (0.0)
No	456	4 (0.9)	178	1 (0.6)	636	5 (0.8)
p value		0.8		0.8		0.7
1999						
Yes	18	1 (5.6)	29	0 (0.0)	49	1 (2.0)
No	499	9 (1.8)	228	2 (0.9)	729	11 (1.5)
p value		0.3		0.6		0.8
2000						
Yes	10	0 (0.0)	---	---	38	0 (0.0)
No	436	7 (1.6)	---	---	653	8 (1.2)
p value		0.7				0.5
2001						
Yes	14	0 (0.0)	---	---	54	0 (0.0)
No	512	8 (1.6)	---	---	709	8 (1.1)
p value		0.6				0.4
2002						
Yes	19	0 (0.0)	21	0 (0.0)	42	0 (0.0)
No	452	10 (2.2)	175	2 (1.1)	631	13 (2.1)
p value		0.5		0.6		0.3

* Total includes people whose sex was not reported or reported as transgender.

HCV antibody prevalence

Table 17: HCV antibody prevalence according to year of survey and sex.

Year of survey	Males		Females		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	223	84 (38)	82	37 (45)	309	124 (40)
1996	358	107 (30)	125	54 (43)	489	162 (33)
1997	327	86 (26)	150	51 (34)	479	138 (29)
1998	472	114 (24)	196	76 (39)	670	192 (29)
1999	531	191 (36)	268	115 (43)	804	307 (38)
2000	467	172 (37)	250	110 (44)	723	285 (39)
2001	556	238 (43)	243	121 (50)	807	363 (45)
2002	479	231 (48)	198	93 (47)	683	329 (48)
χ^2 trend p value		<0.001		0.01		<0.001

* Total includes people whose sex was not reported or reported as transgender.

QUEENSLAND
HCV ANTIBODY

Table 18: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
< 20 years	22	4 (18)	8	3 (38)	30	7 (23)
20 – 24	76	12 (16)	35	7 (20)	114	21 (18)
25 – 29	43	15 (35)	13	6 (46)	56	21 (38)
30 + years	80	53 (66)	26	21 (81)	107	75 (70)
p value		<0.001		<0.001		<0.001
1996						
< 20 years	47	5 (11)	26	6 (23)	73	11 (15)
20 – 24	137	10 (7)	38	9 (24)	178	19 (11)
25 – 29	68	17 (25)	16	5 (31)	84	22 (26)
30 + years	106	75 (71)	45	34 (76)	152	109 (72)
p value		<0.001		<0.001		<0.001
1997						
< 20 years	40	0 (0)	29	2 (7)	69	2 (3)
20 – 24	119	9 (8)	60	14 (23)	180	23 (13)
25 – 29	63	9 (14)	24	8 (33)	88	18 (20)
30 + years	105	68 (65)	37	27 (73)	142	95 (67)
p value		<0.001		<0.001		<0.001
1998						
< 20 years	45	2 (4)	31	3 (10)	76	5 (7)
20 – 24	156	12 (8)	64	6 (9)	220	18 (8)
25 – 29	119	20 (17)	37	17 (46)	156	37 (24)
30 + years	151	80 (53)	64	50 (78)	217	132 (61)
p value		<0.001		<0.001		<0.001
1999						
< 20 years	65	6 (9)	45	14 (31)	110	20 (18)
20 – 24	129	23 (18)	78	18 (23)	209	41 (20)
25 – 29	152	36 (24)	56	18 (32)	209	54 (26)
30 + years	184	126 (68)	89	65 (73)	274	192 (70)
p value		<0.001		<0.001		<0.001
2000						
< 20 years	40	3 (8)	36	9 (25)	76	12 (16)
20 – 24	97	21 (21)	76	19 (25)	175	42 (24)
25 – 29	114	23 (20)	47	22 (47)	161	45 (28)
30 + years	214	125 (58)	91	60 (66)	308	185 (60)
p value		<0.001		<0.001		<0.001
2001						
< 20 years	37	8 (22)	25	7 (28)	63	15 (24)
20 – 24	108	25 (23)	69	23 (33)	178	48 (27)
25 – 29	146	44 (30)	49	18 (37)	197	64 (32)
30 + years	263	160 (61)	100	73 (73)	367	235 (64)
p value		<0.001		<0.001		<0.001
2002						
< 20 years	32	10 (31)	24	10 (42)	56	20 (36)
20 – 24	87	35 (40)	45	19 (42)	132	54 (41)
25 – 29	138	60 (43)	45	16 (36)	184	76 (41)
30 + years	220	125 (57)	83	48 (58)	308	178 (58)
p value		0.003		0.07		<0.001

* Total includes people whose sex was not reported or reported as transgender.

Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Males		Females		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
<1 to 2 years	50	4 (8)	20	3 (15)	70	7 (10)
3 to 5 years	56	15 (27)	22	7 (32)	78	22 (28)
6 to 10 years	41	14 (34)	16	7 (44)	59	23 (39)
> 10 years	68	48 (71)	24	20 (83)	93	69 (74)
p value		<0.001		<0.001		<0.001
1996						
<1 to 2 years	95	4 (4)	28	3 (11)	124	7 (6)
3 to 5 years	103	13 (13)	43	13 (30)	149	26 (17)
6 to 10 years	66	27 (41)	19	8 (42)	85	35 (41)
> 10 years	82	61 (74)	34	29 (85)	116	91 (78)
p value		<0.001		<0.001		<0.001
1997						
<1 to 2 years	88	4 (5)	47	3 (6)	135	7 (5)
3 to 5 years	82	6 (7)	43	9 (21)	125	15 (12)
6 to 10 years	66	12 (18)	26	13 (50)	92	25 (27)
> 10 years	84	62 (74)	32	26 (81)	117	89 (76)
p value		<0.001		<0.001		<0.001
1998						
<1 to 2 years	107	4 (4)	55	3 (5)	162	7 (4)
3 to 5 years	129	14 (11)	43	5 (12)	172	19 (11)
6 to 10 years	117	26 (22)	45	23 (51)	162	49 (30)
> 10 years	108	68 (63)	50	45 (90)	160	115 (72)
p value		<0.001		<0.001		<0.001
1999						
<1 to 2 years	101	8 (8)	62	15 (24)	163	23 (14)
3 to 5 years	121	22 (18)	57	13 (23)	179	35 (20)
6 to 10 years	140	40 (29)	75	29 (39)	218	70 (32)
> 10 years	152	116 (76)	67	55 (82)	219	171 (78)
p value		<0.001		<0.001		<0.001
2000						
<1 to 2 years	59	6 (10)	35	6 (17)	94	12 (13)
3 to 5 years	98	15 (15)	71	21 (30)	170	37 (22)
6 to 10 years	119	32 (27)	72	35 (49)	194	68 (35)
> 10 years	179	117 (65)	68	47 (69)	248	164 (66)
p value		<0.001		<0.001		<0.001
2001						
<1 to 2 years	62	5 (8)	39	7 (18)	101	12 (12)
3 to 5 years	103	24 (23)	51	20 (39)	156	45 (29)
6 to 10 years	157	54 (34)	69	31 (45)	227	85 (37)
> 10 years	212	149 (70)	75	60 (80)	290	211 (73)
p value		<0.001		<0.001		<0.001
2002						
<1 to 2 years	54	22 (41)	24	7 (29)	78	29 (37)
3 to 5 years	67	27 (40)	40	14 (35)	108	42 (39)
6 to 10 years	144	60 (42)	53	27 (51)	198	87 (44)
> 10 years	201	116 (58)	71	41 (58)	275	160 (58)
p value		0.006		0.03		<0.001

* Total includes people whose sex was not reported or reported as transgender.

QUEENSLAND
HCV ANTIBODY

Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Amphetamine	39	2 (5)	65	25 (38)	106	28 (26)
Heroin	19	3 (16)	135	69 (51)	159	74 (47)
More than one	4	1 (25)	14	7 (50)	19	8 (42)
Other/not reported	8	1 (13)	16	13 (81)	25	14 (56)
p value		0.4		0.02		0.003
1996						
Amphetamine	74	4 (5)	91	19 (21)	168	23 (14)
Heroin	36	2 (6)	209	109 (52)	253	114 (45)
More than one	5	1 (20)	24	9 (38)	31	11 (35)
Other/not reported	9	0 (0)	26	15 (58)	37	15 (41)
p value		0.8		<0.001		<0.001
1997						
Amphetamine	88	4 (5)	97	19 (20)	191	23 (12)
Heroin	31	3 (10)	194	90 (46)	227	94 (41)
More than one	5	0 (0)	20	11 (55)	25	11 (44)
Other/not reported	11	0 (0)	23	9 (39)	36	10 (28)
p value		0.5		<0.001		<0.001
1998						
Amphetamine	104	4 (4)	193	37 (19)	304	41 (13)
Heroin	34	2 (6)	244	119 (49)	281	123 (44)
More than one	11	1 (9)	34	16 (47)	47	17 (36)
Other/not reported	13	0 (0)	23	11 (48)	38	11 (29)
p value		0.7		<0.001		<0.001
1999						
Amphetamine	113	7 (6)	227	66 (29)	344	74 (22)
Heroin	31	13 (42)	312	177 (57)	349	194 (56)
More than one	9	2 (22)	40	16 (40)	52	21 (40)
Other/not reported	10	1 (10)	37	17 (46)	59	18 (31)
p value		<0.001		<0.001		<0.001
2000						
Amphetamine	52	4 (8)	212	56 (26)	270	61 (23)
Heroin	22	6 (27)	305	169 (55)	328	176 (54)
More than one	6	2 (33)	51	23 (45)	58	25 (43)
Other/not reported	14	0 (0)	44	21 (48)	67	23 (34)
p value		0.02		<0.001		<0.001
2001						
Amphetamine	71	8 (11)	327	123 (38)	417	134 (32)
Heroin	15	4 (27)	195	119 (61)	215	126 (59)
More than one	4	0 (0)	60	37 (62)	65	38 (58)
Other/not reported	11	0 (0)	91	62 (68)	110	65 (59)
p value		0.2		<0.001		<0.001
2002						
Amphetamine	52	21 (40)	238	95 (40)	302	120 (40)
Heroin	7	2 (29)	197	111 (56)	206	113 (55)
More than one	3	2 (67)	56	34 (61)	60	37 (62)
Other/not reported	16	4 (25)	90	49 (54)	115	59 (51)
p value		0.5		0.001		0.001

* Total includes people who did not report duration of drug injection.

Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Less than daily	47	6 (13)	109	52 (48)	160	60 (38)
Daily or more	15	1 (7)	105	54 (51)	124	56 (45)
p value		0.5		0.6		0.2
1996						
Less than daily	90	5 (6)	183	78 (43)	276	83 (30)
Daily or more	26	2 (8)	140	67 (48)	177	72 (41)
p value		0.7		0.4		0.03
1997						
Less than daily	81	3 (4)	145	45 (31)	231	49 (21)
Daily or more	41	2 (5)	157	70 (45)	201	73 (36)
p value		0.4		0.02		0.001
1998						
Less than daily	93	3 (3)	240	80 (33)	338	84 (25)
Daily or more	55	4 (7)	222	96 (43)	281	101 (36)
p value		0.3		0.03		0.003
1999						
Less than daily	90	7 (8)	239	87 (36)	335	97 (29)
Daily or more	59	15 (25)	323	166 (51)	388	184 (47)
p value		0.003		<0.001		<0.001
2000						
Less than daily	51	5 (10)	262	97 (37)	319	104 (33)
Daily or more	27	6 (22)	301	156 (52)	333	163 (49)
p value		0.2		<0.001		<0.001
2001						
Less than daily	57	9 (16)	318	143 (45)	385	153 (40)
Daily or more	29	2 (7)	289	169 (58)	330	177 (54)
p value		0.2		0.001		<0.001
2002						
Less than daily	35	13 (37)	231	105 (45)	272	121 (44)
Daily or more	31	11 (35)	286	159 (56)	325	170 (52)
p value		0.9		0.02		0.06

* Total includes people who did not report duration of drug injection.

QUEENSLAND
HCV ANTIBODY

Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe and last month and duration of drug injection.

Reused someone else's syringe last month	<3 years IDU		3+ years IDU		Total	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Yes	10	2 (20)	69	44 (64)	82	47 (57)
No	52	5 (10)	145	62 (43)	201	69 (34)
p value		0.3		0.004		<0.001
1996						
Yes	29	2 (7)	97	50 (52)	129	53 (41)
No	87	5 (6)	225	94 (42)	323	101 (31)
p value		0.2		0.1		0.05
1997						
Yes	18	0 (0)	56	31 (55)	75	31 (41)
No	99	5 (5)	235	79 (34)	341	86 (25)
p value		0.3		0.003		0.005
1998						
Yes	19	0 (0)	73	33 (45)	95	35 (37)
No	125	7 (6)	377	136 (36)	507	143 (28)
p value		0.3		0.1		0.09
1999						
Yes	31	8 (26)	121	52 (43)	155	61 (39)
No	115	14 (12)	421	192 (46)	545	211 (39)
p value		0.06		0.6		0.9
2000						
Yes	8	2 (25)	84	48 (57)	92	50 (54)
No	68	9 (13)	459	200 (44)	538	212 (39)
p value		0.4		0.02		0.007
2001						
Yes	11	4 (36)	99	64 (65)	112	69 (62)
No	84	7 (8)	547	259 (47)	654	273 (42)
p value		0.006		0.002		<0.001
2002						
Yes	11	3 (27)	92	50 (54)	481	232 (48)
No	55	21 (38)	417	209 (50)	107	54 (50)
p value		0.5		0.5		0.7

* Total includes people who did not report duration of drug injection.

Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection.

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Yes	4	0 (0)	22	13 (59)	28	13 (46)
No	66	7 (11)	203	98 (48)	275	107 (39)
p value		0.5		0.3		0.4
1996						
Yes	0	0 (0)	34	24 (71)	36	24 (67)
No	119	7 (6)	308	124 (40)	439	134 (31)
p value		-		0.001		<0.001
1997						
Yes	3	0 (0)	30	19 (63)	33	19 (58)
No	132	7 (5)	304	110 (36)	446	119 (27)
p value		0.7		0.004		<0.001
1998						
Yes	5	0 (0)	55	34 (62)	61	34 (56)
No	155	7 (4)	435	148 (34)	603	157 (26)
p value		0.6		<0.001		<0.001
1999						
Yes	4	1 (25)	97	63 (65)	102	64 (63)
No	157	21 (13)	511	208 (41)	689	237 (34)
p value		0.5		<0.001		<0.001
2000						
Yes	3	1 (33)	90	61 (68)	96	63 (66)
No	90	11 (12)	512	206 (40)	615	219 (36)
p value		0.3		<0.001		<0.001
2001						
Yes	4	0 (0)	107	65 (61)	115	68 (59)
No	94	12 (13)	545	265 (49)	663	283 (43)
p value		0.4		0.02		0.001
2002						
Yes	9	4 (44)	91	59 (65)	102	64 (63)
No	68	25 (37)	481	225 (47)	571	260 (46)
p value		0.7		0.002		0.001

* Total includes people who did not report duration of drug injection.

QUEENSLAND
HCV ANTIBODY

Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection.

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Yes	1	0 (0)	10	7 (70)	11	7 (64)
No	65	7 (11) 0.7	216	105 (49) 0.2	290	115 (40) 0.1
p value						
1996						
Yes	1	0 (0)	13	6 (46)	15	7 (47)
No	118	7 (6) 0.8	331	143 (43) 0.8	462	152 (33) 0.3
p value						
1997						
Yes	2	0 (0)	21	9 (43)	24	9 (38)
No	131	7 (5) 0.7	307	119 (39) 0.7	447	128 (29) 0.4
p value						
1998						
Yes	1	0 (0)	21	13 (62)	23	13 (57)
No	160	7 (4) 0.8	463	163 (35) 0.01	636	172 (27) 0.002
p value						
1999						
Yes	5	3 (60)	42	22 (52)	49	26 (53)
No	154	20 (13) 0.003	555	244 (44) 0.3	729	271 (37) 0.03
p value						
2000						
Yes	3	3 (33)	34	22 (65)	38	23 (61)
No	90	11 (12) 0.3	551	233 (42) 0.01	656	247 (38) 0.005
p value						
2001						
Yes	7	0 (0)	44	32 (73)	54	32 (59)
No	88	10 (11) 0.3	607	299 (49) 0.003	717	317 (44) 0.03
p value						
2002						
Yes	4	3 (75)	36	21 (58)	42	25 (60)
No	73	26 (36) 0.1	535	263 (49) 0.3	629	299 (48) 0.1
p value						

* Total includes people who did not report duration of drug injection.

SOUTH AUSTRALIA
1995-2002

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	3	3	3	5	6	7	6	6
Response								
Nº surveyed	N = 37	N = 45	N = 59	N = 230	N = 250	N = 312	N = 276	N = 318
% response	46%	36%	26%	46%	70%	64%	60%	49%
Sex (%)								
Male	21 (57)	30 (67)	39 (66)	134 (58)	152 (61)	212 (68)	174 (63)	199 (63)
Female	13 (35)	14 (31)	20 (34)	95 (41)	98 (39)	97 (31)	100 (36)	117 (37)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (1)	2 (1)	1 (<1)
Not reported	3 (8)	1 (2)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (<1)
Sexual identity (%)								
Heterosexual	27 (73)	36 (80)	47 (80)	178 (78)	187 (75)	231 (75)	208 (76)	240 (76)
Bisexual	6 (16)	1 (2)	4 (7)	17 (7)	33 (13)	40 (13)	28 (10)	41 (13)
Gay/lesbian	1 (3)	5 (11)	3 (5)	28 (12)	17 (7)	17 (7)	26 (9)	11 (3)
Not reported	3 (8)	3 (7)	5 (8)	7 (3)	13 (5)	13 (5)	14 (5)	26 (8)
Age and duration of injection (years)								
Median age	31	30	30	29	30	29	30	30
Age range	16—45	18—48	16—50	16—53	17—50	14—52	14—53	15—54
Not reported	1	0	1	0	1	1	0	0
Median age 1 st IDU	18	18	18	18	18	18	18	18
Age range	14—33	14—40	12—43	10—43	10—47	11—40	11—53	7—50
Not reported	1	1	2	2	4	2	2	7
Median years IDU	10	11	7	7	9.5	8	9	11
Range	<1—23	1—25	<1—24	<1—33	<1—36	<1—35	<1—31	<1—37
Not reported	1	1	3	2	4	3	2	7
Aboriginal and Torres Strait Islander Origin (%)								
Yes	1 (3)	0 (0)	2 (3)	17 (7)	10 (4)	40 (13)	24 (9)	18 (6)
No	34 (92)	42 (93)	56 (95)	209 (91)	237 (95)	267 (85)	246 (89)	295 (92)
Not reported	2 (5)	3 (7)	1 (2)	4 (2)	3 (1)	5 (2)	6 (2)	5 (2)
Imprisonment last year (%)								
Yes	6 (16)	4 (9)	13 (22)	30 (13)	38 (15)	60 (19)	34 (12)	44 (14)
No	30 (81)	38 (84)	46 (78)	200 (87)	209 (84)	247 (79)	239 (87)	265 (83)
Not reported	1 (3)	3 (7)	0 (0)	0 (0)	3 (1)	5 (2)	3 (1)	9 (3)
Injected in prison (%)								
Yes	5 (83)	1 (25)	3 (23)	10 (33)	16 (42)	20 (33)	16 (47)	12 (27)
Frequency of injection last month (%)								
Not last month	0 (0)	4 (9)	4 (7)	12 (5)	13 (5)	18 (6)	11 (4)	11 (3)
Less than weekly	6 (16)	6 (13)	13 (22)	39 (16)	38 (15)	39 (12)	56 (20)	58 (18)
Weekly not daily	12 (32)	20 (45)	12 (20)	61 (27)	82 (33)	70 (22)	88 (32)	89 (28)
Daily or more	18 (49)	15 (33)	29 (49)	119 (52)	116 (46)	183 (59)	120 (43)	156 (49)
Not reported	1 (3)	0 (0)	1 (2)	0 (0)	1 (1)	2 (1)	1 (1)	4 (1)
Last drug injected (%)								
Amphetamine	8 (21)	14 (31)	26 (43)	87 (38)	104 (42)	93 (30)	143 (52)	144 (45)
Anabolic steroids	0 (0)	0 (0)	1 (2)	0 (0)	1 (<1)	2 (1)	0 (0)	4 (1)
Benzos	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)	0 (0)	0 (0)
Buprenorphine	---	---	---	---	---	---	---	3 (1)
Cocaine	0 (0)	2 (4)	1 (2)	7 (3)	4 (2)	3 (1)	9 (3)	1 (<1)
Heroin	26 (70)	24 (54)	23 (38)	104 (45)	113 (45)	175 (56)	68 (25)	78 (25)
Heroin + Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	3 (1)	3 (1)	6 (2)
Methadone	0 (0)	2 (4)	4 (7)	7 (3)	3 (1)	7 (2)	10 (4)	13 (4)
Morphine	1 (3)	2 (4)	1 (2)	5 (2)	10 (4)	10 (3)	20 (7)	27 (8)
More than one	1 (3)	0 (0)	1 (2)	15 (7)	11 (4)	15 (5)	18 (6)	28 (9)
Other	0 (0)	0 (0)	1 (2)	2 (1)	1 (<1)	0 (0)	0 (0)	1 (<1)
Not reported	1 (3)	1 (2)	1 (2)	2 (1)	2 (1)	3 (1)	5 (2)	13 (4)

SOUTH AUSTRALIA

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 36	N = 41	N = 54	N = 218	N = 236	N = 292	N = 264	N = 303
Places injected last month (%)*								
Own home	45 (83)	194 (89)	199 (84)	245 (84)	242 (92)	261 (86)		
Friend's home	20 (37)	126 (58)	130 (55)	157 (54)	145 (55)	143 (47)		
Dealer's home	9 (17)	51 (23)	38 (16)	80 (27)	60 (23)	59 (19)		
Street, park, beach	5 (9)	46 (21)	33 (14)	67 (23)	34 (13)	47 (16)		
Car	7 (13)	28 (13)	111 (47)	143 (49)	101 (38)	120 (40)		
Public toilet	7 (13)	35 (16)	49 (21)	75 (26)	41 (16)	45 (15)		
"Shooting" room	1 (2)	6 (3)	1 (1)	4 (1)	1 (1)	2 (1)		
Squat	---	---	6 (3)	11 (4)	4 (2)	8 (3)		
Use of new sterile needles & syringes last month (%)								
All injections	41 (76)	151 (69)	169 (72)	206 (71)	214 (81)	223 (74)		
Most of the time	8 (15)	51 (23)	53 (22)	65 (22)	41 (16)	61 (20)		
Half of the time	1 (2)	7 (3)	4 (2)	7 (2)	3 (1)	9 (3)		
Some of the time	0 (0)	8 (4)	3 (1)	6 (2)	3 (1)	3 (1)		
Not last month	1 (2)	1 (<1)	1 (<1)	0 (0)	2 (1)	1 (<1)		
Not reported	3 (5)	0 (0)	6 (3)	8 (3)	1 (<1)	6 (2)		
Re-used another's syringe last month (%)								
None	24 (67)	32 (78)	47 (87)	182 (83)	186 (79)	240 (82)	229 (87)	250 (82)
Once	3 (8)	4 (10)	2 (4)	15 (7)	16 (7)	11 (4)	14 (5)	11 (4)
Twice	5 (14)	2 (5)	3 (5)	10 (5)	7 (3)	12 (3)	5 (2)	13 (4)
3-5 times	4 (11)	2 (5)	0 (0)	5 (2)	4 (2)	8 (3)	3 (1)	9 (3)
>5 times	0 (0)	1 (2)	1 (2)	6 (3)	10 (4)	5 (2)	9 (3)	8 (3)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	7 (3)	5 (2)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	6 (2)	11 (4)	4 (2)	12 (4)
Number of people syringe was re-used after last month (%)								
None	24 (67)	32 (78)	47 (87)	182 (83)	186 (79)	240 (82)	229 (87)	250 (82)
One	7 (19)	6 (15)	5 (9)	34 (16)	33 (14)	31 (11)	18 (7)	25 (8)
Two	4 (11)	2 (5)	1 (2)	2 (1)	4 (2)	2 (1)	0 (0)	3 (1)
Three to five	1 (3)	1 (2)	0 (0)	0 (0)	4 (2)	4 (1)	2 (1)	1 (<1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	3 (1)	3 (1)	1 (<1)	1 (<1)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	5 (2)	3 (1)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	6 (2)	11 (4)	9 (3)	20 (7)
Relationship to people syringe was re-used after last month (%)*								
Regular sex partner	2 (4)	25 (11)	27 (11)	23 (8)	19 (7)	19 (6)		
Casual sex partner	1 (2)	1 (<1)	0 (0)	1 (<1)	2 (1)	2 (1)		
Close friend	1 (2)	8 (4)	14 (6)	15 (5)	3 (1)	13 (94)		
Acquaintance	0 (0)	4 (2)	5 (2)	5 (2)	6 (2)	0 (0)		
Other	0 (0)	1 (<1)	2 (1)	1 (<1)	3 (1)	0 (0)		
Equipment used after someone else last month (%)*								
Spoon				101 (43)	121 (41)	52 (20)	66 (22)	
Water				71 (30)	98 (34)	56 (21)	64 (21)	
Filter				70 (30)	80 (27)	45 (17)	49 (16)	
Tourniquet				51 (22)	49 (17)	33 (13)	43 (14)	
Drug mix				56 (24)	60 (21)	19 (19)	53 (17)	
Injected by someone else who'd already injected themselves or others last month (%)								
Yes				43 (18)	48 (17)	51 (20)	53 (17)	
No				187 (79)	232 (79)	207 (78)	239 (79)	
Not reported				6 (3)	12 (4)	6 (2)	11 (4)	

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 37	N = 45	N = 59	N = 230	N = 250	N = 312	N = 276	N = 318
Any treatment/therapy for drug use (%)								
No	15 (40)	16 (36)	33 (56)	122 (53)	119 (48)	121 (39)	119 (43)	129 (41)
Yes	21 (57)	29 (64)	26 (44)	108 (47)	131 (52)	190 (61)	157 (57)	189 (59)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)
History of methadone treatment (%)								
Currently	5 (14)	17 (38)	14 (24)	42 (18)	57 (23)	66 (21)	59 (21)	71 (22)
Previously	7 (19)	5 (11)	5 (8)	37 (16)	40 (16)	54 (17)	53 (19)	79 (25)
Never	24 (64)	23 (51)	40 (68)	151 (66)	153 (61)	191 (61)	164 (60)	168 (53)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)
History of other pharmacological therapy (%)								
Currently				2 (1)	4 (2)	15 (5)	14 (5)	20 (6)
Previously				9 (4)	14 (6)	26 (8)	25 (9)	33 (10)
Never				218 (95)	121 (48)	269 (86)	233 (84)	261 (83)
Not reported				1 (<1)	111 (44)	2 (1)	4 (2)	4 (1)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 250	N = 312	N = 276	N = 318
From an NSP last month (%)								
Daily or almost daily				13 (5)	16 (5)	6 (2)	17 (5)	
A couple of times each week				57 (23)	87 (28)	63 (23)	65 (20)	
Less than weekly				67 (27)	94 (30)	116 (42)	97 (31)	
Once last month				79 (31)	79 (25)	67 (24)	92 (29)	
Not in the last month				30 (12)	34 (11)	22 (8)	40 (13)	
Not reported				4 (2)	2 (1)	2 (1)	7 (2)	
From a chemist last month (%)								
Daily or almost daily				10 (4)	8 (3)	6 (2)	9 (3)	
A couple of times each week				25 (10)	36 (12)	16 (6)	25 (8)	
Less than weekly				47 (19)	40 (13)	52 (19)	33 (10)	
Once last month				48 (23)	58 (19)	39 (14)	59 (19)	
Not in the last month				101 (40)	160 (50)	154 (56)	182 (57)	
Not reported				9 (4)	10 (3)	9 (3)	10 (3)	

SOUTH AUSTRALIA

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 37	N = 45	N = 59	N = 230	N = 250	N = 312	N = 276	N = 318
Sex last month (%)								
No	13 (35)	10 (22)	13 (22)	57 (25)	62 (25)	106 (34)	77 (28)	77 (24)
Yes	22 (60)	34 (76)	46 (78)	171 (74)	185 (74)	205 (66)	192 (70)	234 (74)
Not reported	2 (5)	1 (2)	0 (0)	2 (1)	3 (1)	1 (<1)	7 (2)	7 (2)
Condom use last sex (%)								
No	19 (52)	21 (47)	40 (68)	153 (67)	163 (65)	216 (69)	195 (71)	223 (70)
Yes	9 (24)	11 (24)	18 (30)	70 (30)	83 (33)	95 (30)	72 (26)	82 (26)
Not reported	9 (24)	13 (29)	1 (2)	7 (3)	4 (2)	1 (<1)	9 (3)	13 (4)
Condom use with regular sex partner(s) last month (%)*								
No	18 (62)	31 (79)	94 (68)	108 (68)	113 (69)	98 (74)	97 (69)	
Sometimes	3 (10)	3 (8)	17 (12)	14 (9)	18 (11)	19 (14)	14 (10)	
Always	8 (28)	5 (13)	28 (20)	37 (23)	32 (20)	15 (12)	29 (21)	
Condom use with new sex partner(s) last month (%)*								
No	4 (36)	14 (58)	16 (36)	39 (48)	15 (23)	31 (43)	44 (43)	
Sometimes	1 (9)	0 (0)	9 (21)	6 (7)	10 (15)	10 (14)	19 (18)	
Always	6 (55)	10 (42)	19 (43)	37 (45)	40 (62)	31 (43)	40 (39)	
Condom use with casual sex partner(s) last month (%)*								
No			16 (27)	41 (44)	27 (29)	32 (44)	31 (33)	
Sometimes			13 (22)	8 (9)	20 (21)	10 (14)	24 (26)	
Always			31 (51)	44 (47)	47 (50)	31 (42)	39 (41)	
Duration of regular sexual relationship (%)**								
One month						8 (6)	10 (6)	
2 - 6 months						19 (14)	21 (13)	
6 - 12 months						26 (18)	15 (9)	
>12 months						87 (62)	121 (72)	
Sex work last month (%)								
No	31 (84)	42 (93)	57 (96)	209 (91)	223 (89)	282 (90)	242 (88)	286 (0)
Yes	3 (8)	2 (5)	1 (2)	12 (5)	22 (9)	30 (10)	25 (9)	16 (5)
Not reported	3 (8)	1 (2)	1 (2)	9 (4)	5 (2)	0 (0)	9 (3)	16 (5)
Condom use last sex work last month (%)**								
Yes	3 (100)	2 (100)	1 (100)	8 (80)	17 (89)	24 (96)	15 (75)	13 981

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1996-2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 37	N = 45	N = 59	N = 230	N = 250	N = 312	N = 276	N = 318
Previous HIV test (%)								
Yes, last year	24 (65)	28 (62)	44 (75)	128 (56)	144 (58)	183 (59)	161 (58)	199 (63)
> 1 year ago	10 (27)	11 (25)	9 (15)	67 (29)	61 (24)	82 (26)	80 (29)	81 (25)
Never tested	2 (5)	6 (13)	6 (10)	35 (15)	45 (18)	47 (15)	35 (13)	35 (11)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Self report HBV infection (%)								
Yes	12 (32)	17 (38)	6 (10)	37 (16)	44 (17)	50 (16)	35 (13)	32 (10)
No	24 (65)	27 (60)	49 (83)	160 (70)	160 (64)	210 (67)	212 (77)	238 (75)
Don't know	0 (0)	0 (0)	4 (7)	33 (14)	42 (17)	51 (16)	26 (9)	37 (12)
Not reported	1 (3)	1 (2)	0 (0)	0 (0)	4 (2)	1 (<1)	3 (1)	11 (3)
Self report HBV vaccination (%)*								
Yes	9 (36)	14 (50)	18 (34)	75 (39)	90 (44)	150 (57)	124 (51)	157 (54)
No	13 (52)	11 (39)	26 (49)	82 (42)	74 (36)	71 (27)	87 (36)	94 (33)
Don't know	0 (0)	0 (0)	91 (17)	36 (19)	34 (16)	37 (14)	25 (9)	25 (9)
Not reported	3 (12)	3 (11)	0 (0)	0 (0)	8 (4)	4 (2)	10 (4)	10 (4)
Previous HCV test (%)								
Yes ever	25 (68)	36 (80)	---	---	---	---	---	---
Yes, last year	---	---	46 (78)	134 (58)	150 (60)	197 (63)	153 (55)	198 (62)
> 1 year ago	---	---	6 (10)	50 (22)	54 (21)	72 (23)	87 (32)	78 (25)
Never tested	10 (27)	8 (18)	7 (12)	46 (20)	44 (18)	43 (14)	36 (13)	38 (12)
Not reported	2 (5)	1 (20)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	4 (1)
Any treatment for HCV (%)								
Interferon					N = 77	N = 115	N = 91	N = 115
Interferon+Ribarvarin					68 (88)	107 (93)	85 (94)	95 (82)
Other					2 (3)	4 (3)	0 (0)	5 (4)
No treatment					0 (0)	1 (1)	0 (0)	2 (2)
Not reported					4 (5)	2 (2)	4 (4)	3 (3)
Current treatment for HCV								
Interferon				N = 2	N = 6	N = 0	N = 0	
Interferon+Ribarvarin				2	6	---	---	
Other				0	0	---	---	
				0	0	---	---	

* Number (percentage) among participants not reporting HBV infection.

SOUTH AUSTRALIA

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995	19	0 (0.0)	11	0 (0.0)	32	0 (0.0)
1996	30	0 (0.0)	14	0 (0.0)	45	0 (0.0)
1997	25	1 (4.0)	14	0 (0.0)	39	1 (2.6)
1998	96	1 (1.0)	71	1 (1.4)	168	2 (1.2)
1999	142	2 (1.4)	96	4 (4.2)	238	6 (2.5)
2000	200	0 (0.0)	92	0 (0.0)	294	0 (0.0)
2001	173	3 (1.7)	99	1 (1.0)	274	4 (1.5)
2002	194	1 (0.5)	115	1 (0.9)	311	2 (0.6)
χ^2 trend p value		0.8		0.7		0.6

Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.

Sexual identity	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
Heterosexual	58	1 (1.7)	---	---	91	1 (1.1)
Bisexual	3	0 (0.0)	---	---	8	0 (0.0)
Homosexual	7	0 (0.0)	---	---	8	0 (0.0)
p value		0.9				0.9
1998						
Heterosexual	80	0 (0.0)	46	1 (2.2)	127	1 (0.8)
Bisexual	6	0 (0.0)	8	0 (0.0)	14	0 (0.0)
Homosexual	11	1 (9.1)	15	0 (0.0)	24	1 (4.2)
p value		0.007		0.8		0.3
1999						
Heterosexual	118	2 (1.7)	60	3 (5.0)	178	5 (2.8)
Bisexual	7	0 (0.0)	26	1 (3.9)	33	1 (3.0)
Homosexual	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)
p value		0.9		0.8		0.8
2000						
Heterosexual	---	---	---	---	---	---
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p value						
2001						
Heterosexual	146	0 (0.0)	58	1 (1.7)	206	1 (0.5)
Bisexual	8	1 (12.5)	20	0 (0.0)	28	1 (3.6)
Homosexual	14	2 (14.3)	12	0 (0.0)	26	2 (7.7)
p value		<0.001		0.8		0.01
2002						
Heterosexual	158	1 (0.60)	76	1 (1.3)	234	2 (0.9)
Bisexual	12	0 (0.0)	28	0 (0.0)	40	0 (0.0)
Homosexual	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
p value		0.9		0.8		0.8

* Total includes people whose sex was not reported or reported as transgender.

Table 9: HIV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
< 20 years	8	0 (0.0)	---	---	9	0 (0.0)
20 – 24	10	0 (0.0)	---	---	15	0 (0.0)
25 – 29	14	0 (0.0)	---	---	24	0 (0.0)
30 + years	41	1 (2.4)	---	---	67	1 (1.5)
p value		0.9				0.9
1998						
< 20 years	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)
20 – 24	23	0 (0.0)	18	0 (0.0)	41	0 (0.0)
25 – 29	21	0 (0.0)	18	0 (0.0)	39	0 (0.0)
30 + years	45	1 (2.2)	32	1 (3.1)	78	2 (2.6)
p value		0.8		0.7		0.5
1999						
< 20 years	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
20 – 24	22	0 (0.0)	19	1 (5.3)	41	1 (2.4)
25 – 29	23	0 (0.0)	24	1 (4.2)	47	1 (2.1)
30 + years	82	2 (2.4)	43	2 (4.7)	125	4 (3.2)
p value		0.7		0.9		0.8
2000						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	---	---	---	---
25 – 29	---	---	---	---	---	---
30 + years	---	---	---	---	---	---
p value						
2001						
< 20 years	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)
20 – 24	39	0 (0.0)	15	0 (0.0)	54	0 (0.0)
25 – 29	33	0 (0.0)	20	0 (0.0)	53	0 (0.0)
30 + years	88	3 (3.4)	56	1 (1.8)	146	4 (2.7)
p value		0.4		0.9		0.3
2002						
< 20 years	6	0 (0.0)	8	0 (0.0)	14	0 (0.0)
20 – 24	35	0 (0.0)	21	0 (0.0)	56	0 (0.0)
25 – 29	35	0 (0.0)	27	0 (0.0)	62	0 (0.0)
30 + years	118	1 (0.9)	59	1 (1.7)	179	2 (1.1)
p value		0.9		0.8		0.7

* Total includes people whose sex was not reported or reported as transgender.

SOUTH AUSTRALIA
HIV ANTIBODY

Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
<1 to 2 years	10	0 (0.0)	---	---	16	0 (0.0)
3 to 5 years	7	0 (0.0)	---	---	16	0 (0.0)
6 to 10 years	17	0 (0.0)	---	---	28	0 (0.0)
10 + years	37	1 (2.7)	---	---	53	1 (1.9)
p value		0.8				0.8
1998						
<1 to 2 years	18	0 (0.0)	17	0 (0.0)	35	0 (0.0)
3 to 5 years	16	0 (0.0)	19	0 (0.0)	35	0 (0.0)
6 to 10 years	23	0 (0.0)	13	0 (0.0)	37	0 (0.0)
10 + years	37	1 (2.7)	22	1 (4.6)	59	2 (3.4)
p value		0.7		0.5		0.3
1999						
<1 to 2 years	22	0 (0.0)	10	0 (0.0)	32	0 (0.0)
3 to 5 years	30	0 (0.0)	25	2 (8.0)	55	2 (3.6)
6 to 10 years	19	0 (0.0)	27	0 (0.0)	46	0 (0.0)
10 + years	71	2 (2.8)	32	2 (6.3)	103	4 (3.9)
p value		0.6		0.4		0.4
2000						
<1 to 2 years	---	---	---	---	---	---
3 to 5 years	---	---	---	---	---	---
6 to 10 years	---	---	---	---	---	---
10 + years	---	---	---	---	---	---
p value						
2001						
<1 to 2 years	21	0 (0.0)	17	0 (0.0)	38	0 (0.0)
3 to 5 years	29	0 (0.0)	18	0 (0.0)	47	0 (0.0)
6 to 10 years	42	1 (2.4)	23	0 (0.0)	65	1 (1.5)
10 + years	79	2 (2.5)	41	1 (2.4)	122	3 (2.5)
p value		0.7		0.7		0.6
2002						
<1 to 2 years	17	0 (0.0)	12	0 (0.0)	30	0 (0.0)
3 to 5 years	32	0 (0.0)	10	0 (0.0)	50	0 (0.0)
6 to 10 years	37	0 (0.0)	35	0 (0.0)	72	0 (0.0)
10 + years	105	1 (1.0)	47	1 (2.1)	152	2 (1.3)
p value		0.8		0.7		0.6

* Total includes people whose sex was not reported or reported as transgender.

Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex.

Last drug injected	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
Amphetamine	17	0 (0.0)	---	---	33	0 (0.0)
Heroin	44	0 (0.0)	---	---	66	0 (0.0)
More than one	2	0 (0.0)	---	---	2	0 (0.0)
Other/not reported	11	1 (9.1)	---	---	15	1 (6.7)
p value		0.1				0.08
1998						
Amphetamine	39	0 (0.0)	28	0 (0.0)	67	0 (0.0)
Heroin	37	1 (2.7)	34	1 (2.9)	71	2 (2.8)
More than one	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
Other/not reported	14	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		0.7		0.8		0.4
1999						
Amphetamine	59	0 (0.0)	41	0 (0.0)	100	0 (0.0)
Heroin	64	1 (1.6)	43	3 (7.0)	107	4 (3.7)
More than one	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
Other/not reported	14	1 (7.1)	7	1 (14.3)	21	2 (9.5)
p value		0.2		0.2		0.05
2000						
Amphetamine	---	---	---	---	---	---
Heroin	---	---	---	---	---	---
More than one	---	---	---	---	---	---
Other/not reported	---	---	---	---	---	---
p value						
2001						
Amphetamine	98	2 (2.0)	43	0 (0.0)	141	2 (1.4)
Heroin	28	1 (3.6)	38	1 (2.6)	68	2 (2.9)
More than one	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
Other/not reported	31	0 (0.0)	13	0 (0.0)	44	0 (0.0)
p value		0.7		0.7		0.6
2002						
Amphetamine	81	0 (0.0)	62	0 (0.0)	143	0 (0.0)
Heroin	55	1 (1.8)	21	1 (4.8)	76	2 (2.6)
More than one	22	0 (0.0)	9	0 (0.0)	31	0 (0.0)
Other/not reported	36	0 (0.0)	23	0 (0.0)	61	0 (0.0)
p value		0.5		0.2		0.1

* Total includes people whose sex was not reported or reported as transgender.

SOUTH AUSTRALIA
HIV ANTIBODY

Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.

Frequency of drug injection last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
Less than daily	34	0 (0.0)	---	---	59	0 (0.0)
Daily or more	35	1 (2.9)	---	---	51	1 (2.0)
p value		0.3				0.3
1998						
Less than daily	49	0 (0.0)	31	0 (0.0)	80	0 (0.0)
Daily or more	44	1 (2.3)	37	1 (2.7)	81	2 (2.5)
p value		0.3		0.4		0.2
1999						
Less than daily	66	0 (0.0)	50	2 (4.0)	116	2 (1.7)
Daily or more	69	0 (0.0)	41	2 (4.9)	110	2 (1.8)
p value		---		0.8		>0.9
2000						
Less than daily	---	---	---	---	---	---
Daily or more	---	---	---	---	---	---
p value						
2001						
Less than daily	91	1 (1.1)	53	1 (1.9)	144	2 (1.4)
Daily or more	75	1 (1.3)	41	0 (0.0)	118	1 (0.9)
p value		0.9		0.4		0.7
2002						
Less than daily	---	---	49	1 (2.0)	146	1 (0.7)
Daily or more	---	---	60	0 (0.0)	150	0 (0.0)
p value		---		0.3		0.3

Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.

Reused someone else's syringe last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
Yes	17	0 (0.0)	---	---	26	0 (0.0)
No	52	1 (1.9)	---	---	83	1 (1.2)
p value		0.6				0.6
1998						
Yes	8	0 (0.0)	16	0 (0.0)	24	0 (0.0)
No	85	1 (1.2)	52	1 (1.9)	137	2 (1.5)
p value		0.8				0.6
1999						
Yes	28	0 (0.0)	16	0 (0.0)	44	0 (0.0)
No	103	0 (0.0)	73	4 (5.5)	176	4 (2.3)
p value		---		0.3		0.3
2000						
Yes	---	---	---	---	---	---
No	---	---	---	---	---	---
p value						
2001						
Yes	19	1 (5.3)	12	0 (0.0)	31	1 (3.2)
No	150	2 (1.3)	86	1 (1.2)	238	3 (1.3)
p value		0.2		0.7		0.4
2002						
Yes	24	0 (0.0)	16	0 (0.0)	40	1 (0.0)
No	155	0 (0.0)	88	1 (1.1)	244	1 (0.4)
p value		---		0.7		0.7

* Total includes people whose sex was not reported or reported as transgender.

Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.

Imprisonment last year	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
Yes	12	0 (0.0)	---	---	16	0 (0.0)
No	60	1 (1.7) 0.7	---	---	96	1 (1.0) 0.7
p value						
1998						
Yes	14	0 (0.0)	3	0 (0.0)	18	0 (0.0)
No	82	1 (1.2) 0.7	68	1 (1.5) 0.8	150	2 (1.3) 0.6
p value						
1999						
Yes	27	0 (0.0)	9	0 (0.0)	36	0 (0.0)
No	113	2 (1.8) 0.5	86	4 (4.7) 0.5	199	6 (3.0) 0.3
p value						
2000						
Yes	---	---	---	---	---	---
No	---	---	---	---	---	---
p value						
2001						
Yes	29	0 (0.0)	5	0 (0.0)	34	0 (0.0)
No	143	3 (2.1) 0.4	92	1 (1.1) 0.8	237	4 (1.7) 0.4
p value						
2002						
Yes	33	0 (0.0)	9	0 (0.0)	42	0 (0.0)
No	155	1 (0.71) 0.6	105	1 (1.0) 0.8	261	2 (0.8) 0.6
p value						

Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.

Condom use last sex	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
Yes	23	1 (4.4)	---	---	30	1 (3.3)
No	38	0 (0.0) 0.2	---	---	65	0 (0.0) 0.1
p value						
1998						
Yes	38	1 (2.6)	16	1 (6.3)	54	2 (3.7)
No	54	0 (0.0) 0.2	53	0 (0.0) 0.07	108	0 (0.0) 0.04
p value						
1999						
Yes	43	2 (4.7)	35	4 (11.4)	78	6 (7.7)
No	97	0 (0.0) 0.03	59	0 (0.0) 0.008	156	0 (0.0) <0.001
p value						
2000						
Yes	---	---	---	---	---	---
No	---	---	---	---	---	---
p value						
2001						
Yes	55	2 (3.6)	13	0 (0.0)	70	2 (2.9)
No	113	1 (0.9) 0.2	82	1 (1.2) 0.7	195	2 (1.0) 0.3
p value						
2002						
Yes	57	1 (1.2)	22	1 (4.6)	79	2 (2.5)
No	130	0 (0.0) 0.3	88	0 (0.0) 0.1	219	0 (0.0) 0.05
p value						

* Total includes people whose sex was not reported or reported as transgender.

SOUTH AUSTRALIA
HIV ANTIBODY

Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.

Sex work last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995-1997						
Yes	0	---	---	---	6	0 (0.0)
No	72	1 (1.4) ---	---	---	106	1 (0.9) 0.8
p value						
1998						
Yes	5	0 (0.0)	3	1 (33.3)	8	1 (12.5)
No	88	1 (1.1) 0.8	65	0 (0.0) <0.001	154	1 (0.7) 0.003
p value						
1999						
Yes	4	0 (0.0)	17	2 (11.8)	21	2 (9.5)
No	136	1 (0.7) 0.9	76	2 (2.6) 0.09	212	3 (1.4) 0.01
p value						
2000						
Yes	---	---	---	---	---	---
No	---	---	---	---	---	---
p value						
2001						
Yes	13	0 (0.0)	9	0 (0.0)	24	0 (0.0)
No	155	3 (1.9) 0.6	86	1 (1.2) 0.7	241	4 (1.7) 0.5
p value						
2002						
Yes	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
No	174	1 (0.6) 0.8	104	1 (1.0) 0.8	279	2 (0.7) 0.7
p value						

* Total includes people whose sex was not reported or reported as transgender.

HCV antibody prevalence

Table 17: HCV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	19	14 (74)	11	4 (36)	32	19 (59)
1996	30	17 (57)	13	6 (46)	44	24 (55)
1997	25	9 (36)	14	8 (57)	39	17 (44)
1998	96	28 (29)	71	17 (24)	168	45 (27)
1999	142	61 (43)	96	37 (39)	238	98 (41)
2000	200	96 (48)	92	42 (46)	294	138 (47)
2001	174	89 (51)	99	51 (52)	275	142 (52)
2002	192	90 (47)	115	43 (37)	309	133 (43)
		χ^2 trend p value				0.06

Table 18: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1997						
< 20 years	8	2 (25)	1	0 (0)	9	2 (22)
20 - 24	10	4 (40)	5	0 (0)	15	4 (27)
25 - 29	14	7 (50)	8	3 (38)	24	11 (45)
30 + years	41	27 (66)	24	15 (63)	66	42 (64)
p value		0.1		0.05		0.01
1998						
< 20 years	7	0 (0)	3	0 (0)	10	0 (0)
20 - 24	23	0 (0)	18	0 (0)	41	0 (0)
25 - 29	21	4 (19)	18	3 (17)	39	7 (18)
30 + years	45	24 (53)	32	14 (44)	78	38 (49)
p value		<0.001		0.003		<0.001
1999						
< 20 years	15	2 (13)	9	2 (22)	24	4 (17)
20 - 24	22	4 (18)	19	1 (5)	41	5 (12)
25 - 29	23	7 (30)	24	11 (46)	47	18 (38)
30 + years	82	48 (59)	43	22 (51)	125	70 (56)
p value		<0.001		0.004		<0.001
2000						
< 20 years	13	3 (23)	9	4 (44)	22	7 (32)
20 - 24	47	10 (21)	22	9 (41)	70	19 (27)
25 - 29	38	15 (39)	21	7 (33)	60	22 (37)
30 + years	102	68 (67)	40	22 (55)	142	90 (63)
p value		<0.001		0.4		<0.001
2001						
< 20 years	13	6 (46)	8	1 (13)	21	7 (33)
20 - 24	39	14 (36)	15	9 (60)	54	23 (43)
25 - 29	33	11 (33)	20	9 (45)	53	20 (38)
30 + years	89	58 (65)	56	32 (57)	147	92 (63)
p value		0.002		0.1		0.001
2002						
< 20 years	6	0 (0)	8	2 (25)	14	2 (14)
20 - 24	35	8 (23)	21	1 (5)	56	9 (16)
25 - 29	35	9 (26)	27	10 (37)	62	19 (31)
30 + years	116	73 (63)	59	30 (51)	177	103 (58)
p value		<0.001		0.002		<0.001

* Total includes people whose sex was not reported or reported as transgender.

SOUTH AUSTRALIA
HCV ANTIBODY

Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1997						
<1 to 2 years	10	4 (40)	6	2 (33)	16	6 (38)
3 to 5 years	7	2 (29)	8	3 (38)	16	6 (38)
6 to 10 years	17	7 (41)	10	3 (10)	28	11 (39)
10 + years	37	26 (70)	14	10 (71)	52	36 (69)
p value		0.05		0.2		0.01
1998						
<1 to 2 years	18	1 (6)	17	2 (12)	35	3 (9)
3 to 5 years	16	1 (6)	19	0 (0)	35	1 (3)
6 to 10 years	23	3 (13)	13	3 (23)	37	6 (16)
10 + years	37	22 (59)	22	12 (55)	59	34 (58)
p value		<0.001		<0.001		<0.001
1999						
<1 to 2 years	22	1 (5)	10	2 (20)	32	3 (9)
3 to 5 years	30	8 (27)	25	4 (16)	55	12 (22)
6 to 10 years	19	8 (42)	27	9 (33)	46	17 (37)
10 + years	71	44 (62)	32	21 (66)	103	65 (63)
p value		<0.001		0.001		<0.001
2000						
<1 to 2 years	25	5 (20)	18	3 (17)	43	8 (19)
3 to 5 years	35	8 (23)	20	9 (45)	56	17 (30)
6 to 10 years	57	24 (42)	18	8 (44)	76	32 (42)
10 + years	82	59 (72)	35	21 (60)	117	80 (68)
p value		<0.001		0.03		<0.001
2001						
<1 to 2 years	21	7 (33)	17	6 (35)	38	13 (34)
3 to 5 years	29	12 (41)	18	8 (44)	47	20 (43)
6 to 10 years	43	16 (37)	23	12 (52)	66	28 (42)
10 + years	79	52 (66)	41	25 (61)	122	79 (65)
p value		0.003		0.3		0.001
2002						
<1 to 2 years	17	3 (18)	12	3 (25)	30	6 (20)
3 to 5 years	31	10 (32)	18	1 (6)	49	11 (22)
6 to 10 years	37	6 (16)	35	9 (26)	72	15 (21)
10 + years	104	70 (67)	47	27 (57)	151	97 (64)
p value		<0.001		<0.001		<0.001

* Total includes people whose sex was not reported or reported as transgender.

Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1997						
Amphetamine	8	1 (12)	25	7 (28)	33	8 (24)
Heroin	7	5 (71)	56	37 (66)	65	43 (66)
More than one	1	0 (0)	1	0 (0)	2	0 (0)
Other/not reported	0	---	14	8 (57)	15	9 (60)
p value		0.05		0.01		<0.001
1998						
Amphetamine	21	0 (0)	45	5 (11)	67	6 (9)
Heroin	10	3 (30)	60	28 (47)	71	31 (44)
More than one	3	0 (0)	6	1 (17)	9	1 (11)
Other/not reported	1	0 (0)	20	7 (14)	21	7 (33)
p value		0.04		0.001		<0.001
1999						
Amphetamine	23	1 (4)	77	15 (19)	100	16 (16)
Heroin	7	2 (29)	99	62 (63)	107	65 (61)
More than one	0	---	9	6 (67)	10	6 (60)
Other/not reported	2	0 (0)	19	11 (58)	21	11 (52)
p value		0.1		<0.001		<0.001
2000						
Amphetamine	26	3 (12)	62	20 (32)	89	23 (26)
Heroin	15	4 (27)	149	88 (59)	165	93 (56)
More than one	2	1 (50)	14	7 (50)	16	8 (50)
Other/not reported	0	---	24	14 (58)	24	14 (58)
p value		0.2		0.005		<0.001
2001						
Amphetamine	28	7 (25)	114	44 (39)	142	51 (36)
Heroin	6	3 (50)	62	48 (77)	68	51 (75)
More than one	3	2 (67)	17	9 (53)	21	12 (57)
Other/not reported	1	1 (100)	42	26 (62)	44	28 (64)
p value		0.2		<0.001		<0.001
2002						
Amphetamine	21	3 (14)	120	41 (34)	142	45 (32)
Heroin	1	1(100)	73	42 (58)	75	44 (59)
More than one	1	0 (0)	30	17 (57)	31	17 (55)
Other/not reported	7	2 (29)	49	23 (47)	614	27 (44)
p value		0.2		0.007		0.001

* Total includes people who did not report duration of drug injection.

SOUTH AUSTRALIA
HCV ANTIBODY

Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.

Frequency of drug injection last month	Nº tested	Nº with HCV (%)
1995-1997		
Less than daily	58	33 (57)
Daily or more	51	22 (43)
p value		0.2
1998		
Less than daily	80	15 (19)
Daily or more	81	29 (36)
p value		0.04
1999		
Less than daily	116	43 (37)
Daily or more	110	48 (44)
p value		0.3
2000		
Less than daily	104	39 (38)
Daily or more	174	89 (51)
p value		0.03
2001		
Less than daily	144	63 (44)
Daily or more	119	71 (60)
p value		0.01
2002		
Less than daily	146	53 (36)
Daily or more	148	78 (53)
p value		0.005

Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month and duration of drug injection.

Reused someone else's syringe last month	Nº tested	Nº with HCV (%)
1995-1997		
Yes	25	18 (72)
No	83	37 (45)
p value		0.02
1998		
Yes	24	8 (33)
No	137	36 (26)
p value		0.5
1999		
Yes	44	23 (52)
No	176	66 (38)
p value		0.07
2000		
Yes	40	25 (63)
No	227	96 (42)
p value		0.02
2001		
Yes	31	20 (65)
No	228	113 (50)
p value		0.1
2002		
Yes	40	21 (53)
No	242	103 (43)
p value		0.2

* Total includes people who did not report duration of drug injection.

Table 23: HCV antibody prevalence according to year of survey, imprisonment last year.

Imprisonment last year	Nº tested	Nº with HCV (%)
1995-1997		
Yes	16	8 (50)
No	95	48 (51)
p value		>0.9
1998		
Yes	18	5 (28)
No	150	40 (27)
p value		0.9
1999		
Yes	36	21 (58)
No	199	75 (38)
p value		0.02
2000		
Yes	60	32 (53)
No	230	104 (45)
p value		0.3
2001		
Yes	34	23 (68)
No	238	117 (49)
p value		0.04
2002		
Yes	41	20 (49)
No	260	110 (42)
p value		0.4

Table 24: HCV antibody prevalence according to year of survey, sex work last month.

Sex work last month	Nº tested	Nº with HCV (%)
1995-1997		
Yes	6	4 (67)
No	105	53 (50)
p value		0.4
1998		
Yes	8	4 (50)
No	154	40 (26)
p value		0.1
1999		
Yes	21	7 (33)
No	212	88 (42)
p value		0.5
2000		
Yes	28	14 (50)
No	266	124 (47)
p value		0.7
2001		
Yes	24	17 (71)
No	242	121 (50)
p value		0.05
2002		
Yes	16	7 (44)
No	277	121 (44)
p value		>0.9

* Total includes people who did not report duration of drug injection.

TASMANIA
1995-2002

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	1	1	1	2	1	1	1	4
Response								
Nº surveyed	N = 6	N = 18	N = 23	N = 51	N = 25	N = 27	N = 28	N = 151
% response	7%	11%	34%	29%	29%	30%	27%	58%
Sex (%)								
Males	4 (67)	11 (61)	17 (74)	40 (78)	19 (76)	18 (67)	22 (79)	97 (64)
Females	2 (33)	7 (39)	6 (26)	11 (22)	6 (24)	9 (33)	6 (21)	52 (34)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Sexual identity (%)								
Heterosexual	4 (67)	14 (78)	18 (79)	44 (86)	20 (80)	19 (71)	20 (71)	120 (79)
Bisexual	2 (33)	0 (0)	3 (13)	4 (8)	3 (12)	3 (11)	2 (7)	10 (7)
Gay/lesbian	0 (0)	4 (22)	1 (4)	2 (4)	1 (4)	2 (7)	1 (4)	4 (3)
Not reported	0 (0)	0 (0)	1 (4)	1 (2)	1 (4)	3 (11)	5 (18)	17 (11)
Age and duration of injection (years)								
Median age	28.5	20.5	28	25	29	33	28	29
Age range	20—31	16—43	21—40	16—51	19—49	20—45	19—36	15—55
Not reported	0	0	0	0	0	0	0	0
Median age 1 st IDU	16.5	16	17	17	18	19	17.5	17
Age range	14—18	13—22	13—30	12—31	14—31	13—40	10—25	12—42
Not reported	0	0	0	1	0	0	0	2
Median years IDU	11.5	5	10	6	8	8	9	9
Range	2—17	<1—24	1—27	<1—23	1—27	<1—26	2—19	<1—31
Not reported	0	0	0	1	0	0	0	2
Aboriginal and Torres Strait Islander Origin (%)								
Yes	1 (17)	0 (0)	2 (9)	3 (6)	4 (16)	1 (4)	4 (14)	17 (11)
No	5 (83)	17 (94)	21 (91)	47 (92)	20 (80)	25 (92)	23 (83)	129 (84)
Not reported	0 (0)	1 (6)	0 (0)	1 (2)	1 (4)	1 (4)	1 (3)	5 (3)
Imprisonment last year (%)								
Yes	1 (17)	0 (0)	2 (9)	5 (10)	3 (12)	4 (15)	2 (7)	13 (9)
No	5 (83)	17 (100)	20 (87)	45 (88)	22 (88)	21 (78)	25 (89)	136 (90)
Not reported	0 (0)	0 (0)	1 (4)	1 (2)	0 (0)	2 (7)	1 (4)	2 (1)
Injected in prison (%)								
Yes	---	---	---	---	---	---	---	5 (38)
Frequency of injection last month (%)								
Not last month	0 (0)	2 (11)	1 (4)	1 (2)	0 (0)	4 (15)	2 (7)	4 (3)
Less than weekly	1 (17)	5 (28)	5 (22)	4 (8)	5 (20)	2 (7)	4 (15)	20 (13)
Weekly not daily	1 (17)	7 (39)	8 (35)	24 (47)	7 (28)	6 (22)	11 (39)	55 (36)
Daily or more	4 (66)	4 (22)	9 (39)	22 (43)	13 (52)	15 (56)	11 (39)	72 (48)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Last drug injected (%)								
Amphetamine	1 (17)	4 (22)	8 (35)	16 (31)	5 (20)	6 (22)	6 (22)	45 (30)
Anabolic steroids	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	1 (1)
Benzos	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	3 (2)
Buprenorphine	---	---	---	---	---	---	---	1 (1)
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	2 (33)	1 (6)	0 (0)	5 (10)	0 (0)	3 (11)	0 (0)	4 (3)
Heroin + Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (1)
Methadone	0 (0)	5 (28)	10 (44)	17 (33)	9 (36)	4 (15)	8 (28)	49 (32)
Morphine	2 (33)	6 (33)	4 (17)	10 (20)	4 (20)	6 (22)	8 (28)	25 (16)
More than one	1 (17)	0 (0)	1 (4)	2 (4)	4 (16)	7 (26)	4 (14)	19 (12)
Other	0 (0)	2 (11)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	3 (2)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)

TASMANIA

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 6	N = 16	N = 22	N = 50	N = 25	N = 23	N = 26	N = 147
Places injected last month (%)*								
Own home	20 (91)	44 (88)	24 (96)	19 (83)	22 (85)	128 (87)		
Friend's home	13 (59)	23 (46)	8 (32)	8 (35)	7 (27)	53 (36)		
Dealer's home	6 (27)	14 (28)	3 (12)	5 (22)	3 (12)	18 (12)		
Street, park, beach	4 (18)	5 (10)	0 (0)	1 (4)	2 (8)	19 (13)		
Car	1 (5)	18 (36)	3 (12)	5 (22)	4 (15)	49 (33)		
Public toilet	6 (27)	9 (18)	3 (12)	1 (4)	2 (8)	29 (20)		
"Shooting" room	1 (5)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)		
Squat			0 (0)	1 (4)	0 (0)	4 (3)		
Use of new sterile needles & syringes last month (%)								
All injections	14 (64)	37 (74)	21 (84)	20 (87)	18 (69)	118 (80)		
Most of the time	7 (32)	11 (22)	2 (8)	2 (9)	7 (27)	25 (17)		
Half of the time	0 (0)	1 (2)	2 (8)	0 (0)	0 (0)	3 (2)		
Some of the time	1 (4)	1 (2)	0 (0)	0 (0)	0 (0)	1 (1)		
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)		
Not reported	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)		
Re-used another's syringe last month (%)								
None	5 (83)	11 (69)	19 (86)	42 (84)	23 (92)	19 (83)	23 (88)	130 (88)
One	0 (0)	2 (12)	0 (0)	2 (4)	0 (0)	1 (4)	2 (8)	2 (1)
Twice	0 (0)	3 (19)	1 (5)	3 (6)	1 (4)	0 (0)	0 (0)	5 (4)
3-5 times	1 (17)	0 (0)	2 (9)	1 (2)	1 (4)	0 (0)	0 (0)	6 (5)
>5 times	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (13)	1 (4)	2 (1)
Number of people syringe was re-used after last month (%)								
None	5 (83)	11 (69)	19 (86)	42 (84)	23 (92)	19 (83)	23 (88)	130 (88)
One	0 (0)	2 (12)	3 (14)	5 (10)	2 (8)	0 (0)	1 (4)	10 (7)
Two	1 (17)	3 (19)	0 (0)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (13)	2 (8)	2 (8)
Relationship to people syringe was re-used after last month (%)*								
Regular sex partner	2 (9)	4 (8)	1 (4)	0 (0)	1 (4)	9 (6)		
Casual sex partner	0 (0)	1 (2)	0 (0)	0 (0)	1 (4)	1 (1)		
Close friend	0 (0)	3 (6)	0 (0)	0 (0)	1 (4)	1 (1)		
Acquaintance	0 (0)	2 (4)	0 (0)	1 (4)	0 (0)	2 (1)		
Other	1 (5)	0 (0)	1 (4)	3 (13)	0 (0)	0 (0)		
Equipment used after someone else last month (%)*								
Spoon			4 (16)	2 (9)	6 (23)	17 (12)		
Water			2 (8)	2 (9)	4 (15)	12 (8)		
Filter			2 (8)	1 (4)	4 (15)	6 (4)		
Tourniquet			3 (12)	2 (9)	5 (19)	19 (13)		
Drug mix			0 (0)	1 (4)	4 (15)	13 (9)		
Injected by someone else who'd already injected themselves or others last month (%)								
Yes			5 (20)	4 (17)	6 (23)	21 (16)		
No			20 (80)	16 (70)	19 (73)	117 (80)		
Not reported			0 (0)	3 (13)	1 (4)	6 (4)		

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 6	N = 18	N = 23	N = 51	N = 25	N = 27	N = 28	N = 151
Any treatment/therapy for drug use (%)								
No	3 (50)	10 (56)	4 (17)	16 (31)	9 (36)	9 (33)	5 (18)	26 (17)
Yes	3 (50)	8 (44)	19 (83)	35 (69)	16 (64)	17 (73)	23 (82)	125 (83)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
History of methadone treatment (%)								
Currently	2 (33)	4 (22)	14 (61)	23 (45)	12 (48)	12 (44)	20 (72)	79 (52)
Previously	1 (17)	2 (11)	3 (13)	7 (14)	3 (12)	3 (11)	2 (7)	26 (17)
Never	3 (50)	12 (67)	6 (26)	21 (41)	1 (4)	11 (41)	6 (21)	45 (30)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	9 (36)	1 (4)	0 (0)	1 (1)
History of other pharmacological therapy (%)								
Currently				0 (0)	0 (0)	1 (4)	1 (4)	6 (4)
Previously				0 (0)	0 (0)	0 (0)	3 (10)	12 (8)
Never				50 (98)	16 (64)	25 (92)	23 (82)	130 (86)
Not reported				1 (2)	9 (36)	1 (4)	1 (4)	31 (2)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Site of syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 25	N = 27	N = 28	N = 151
From an NSP last month (%)								
Daily or almost daily				0 (0)	1 (4)	2 (7)	16 (11)	
A couple of times each week				6 (24)	7 (26)	13 (46)	58 (38)	
Less than weekly				6 (24)	6 (22)	7 (25)	45 (30)	
Once last month				11 (44)	5 (18)	3 (11)	23 (15)	
Not in the last month				1 (4)	7 (26)	3 (11)	8 (51)	
Not reported				1 (4)	1 (4)	0 (0)	1 (1)	
From a chemist last month (%)								
Daily or almost daily				0 (0)	2 (7)	0 (0)	4 (30)	
A couple of times each week				0 (0)	0 (0)	4 (14)	17 (11)	
Less than weekly				4 (16)	2 (7)	3 (11)	16 (11)	
Once last month				19 (76)	3 (11)	2 (7)	19 (13)	
Not in the last month				0 (0)	18 (68)	19 (68)	92 (60)	
Not reported				2 (8)	2 (7)	0 (0)	3 (2)	

TASMANIA

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 6	N = 18	N = 23	N = 51	N = 25	N = 27	N = 28	N = 151
Sex last month (%)								
Yes	5 (83)	14 (78)	16 (70)	39 (76)	18 (72)	20 (74)	19 (68)	113 (75)
No	1 (17)	4 (22)	7 (30)	12 (24)	7 (28)	6 (22)	9 (32)	36 (24)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	2 (1)
Condoms last sex (%)								
Yes	2 (33)	2 (11)	4 (17)	10 (20)	4 (16)	7 (26)	7 (25)	38 (25)
No	3 (50)	12 (67)	19 (83)	41 (80)	20 (80)	19 (70)	21 (75)	110 (73)
Not reported	1 (17)	4 (22)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)	3 (2)
Condom use with regular sex partner(s) last month (%)*								
No	---	---	---	---	---	---	---	51 (75)
Sometimes	---	---	---	---	---	---	---	7 (10)
Always	---	---	---	---	---	---	---	10 (15)
Condom use with new sex partner(s) last month (%)*								
No	---	---	---	---	---	---	---	24 (59)
Sometimes	---	---	---	---	---	---	---	5 (13)
Always	---	---	---	---	---	---	---	11 (28)
Condom use with casual sex partner(s) last month (%)*								
No	---	---	---	---	---	---	---	20 (47)
Sometimes	---	---	---	---	---	---	---	7 (17)
Always	---	---	---	---	---	---	---	15 (36)
Duration of regular sexual relationship (%)**								
One month	---	---	---	---	---	---	0 (0)	20 (2)
2 - 6 months	---	---	---	---	---	---	1 (7)	16 (18)
6 - 12 months	---	---	---	---	---	---	1 (7)	9 (10)
>12 months	---	---	---	---	---	---	13 (87)	60 (70)
Sex work last month (%)								
Yes	0 (0)	0 (0)	1 (4)	0 (0)	1 (4)	0 (0)	0 (0)	5 (3)
No	6 (100)	18 (100)	22 (96)	51 (100)	23 (92)	26 (96)	27 (96)	140 (93)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	1 (4)	6 (4)

* Percentages exclude missing data (2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 6	N = 18	N = 23	N = 51	N = 25	N = 27	N = 28	N = 151
Previous HIV test (%)								
Yes, last year	4 (66)	14 (78)	13 (57)	36 (71)	12 (48)	18 (67)	17 (61)	103 (68)
> 1 year ago	1 (17)	1 (6)	7 (30)	11 (21)	10 (40)	6 (22)	9 (32)	36 (24)
Never tested	0 (0)	0 (0)	1 (4)	3 (6)	3 (12)	2 (7)	2 (7)	12 (8)
Not reported	1 (17)	3 (17)	2 (9)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)
Self report HBV infection (%)								
Yes	0 (0)	2 (11)	6 (26)	6 (12)	3 (12)	3 (11)	3 (11)	28 (19)
No	6 (100)	16 (89)	15 (65)	43 (84)	20 (80)	20 (74)	22 (78)	119 (78)
Don't know	0 (0)	0 (0)	2 (9)	2 (4)	1 (4)	3 (11)	3 (11)	4 (3)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)	0 (0)
Self report HBV vaccination (%)*								
Yes	1 (17)	5 (31)	5 (29)	16 (36)	7 (32)	11 (46)	17 (68)	68 (55)
No	4 (66)	11 (69)	10 (59)	23 (51)	13 (60)	12 (50)	6 (24)	46 (37)
Don't know	0 (0)	0 (0)	2 (12)	6 (13)	1 (4)	0 (0)	1 (4)	8 (7)
Not reported	1 (17)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	1 (4)	1 (1)
Previous HCV test (%)								
Yes ever	5 (83)	14 (78)	---	---	---	---	---	---
Yes, last year	---	---	15 (65)	34 (66)	15 (60)	17 (63)	14 (50)	98 (65)
> 1 year ago	---	---	6 (26)	8 (16)	6 (24)	7 (26)	8 (29)	37 (24)
Never tested	1 (17)	4 (22)	2 (9)	8 (16)	4 (16)	2 (7)	6 (21)	15 (10)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	1 (4)	0 (0)	1 (1)
Any treatment for HCV								
Interferon					0	---	---	1
Interferon+Ribavarin					0	---	---	1
Other					1	---	---	0
					N = 1	N = 0	N = 0	N = 2

* Number (percentage) among participants not reporting HBV infection.

TASMANIA

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey.

Year	Nº tested	Nº with HIV (%)
1995	5	0 (0.0)
1996	18	0 (0.0)
1997	20	1 (5.0)
1998	43	1 (2.3)
1999	24	0 (0.0)
2000	25	1 (4.0)
2001	27	1 (3.7)
2002	148	0 (0.0)

Table 8: HIV antibody prevalence according to sex and sexual identity, 1995-2002.

	Nº tested	Nº with HIV (%)
Sex		
Male	217	4 (1.8)
Female	91	0 (0.0)
p value		0.6
Sexual identity		
Heterosexual	244	1 (0.4)
Bisexual	25	0 (0.0)
Homosexual	14	3 (21.4)
p value		<0.001

HCV antibody prevalence

Table 9: HCV antibody prevalence according to year of survey and sex.

Year of survey	Males		Females		Total*	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	2	2 (100)	2	1 (50)	4	3 (75)
1996	10	2 (20)	7	0 (0)	17	2 (12)
1997	16	7 (44)	5	4 (80)	21	11 (52)
1998	35	14 (40)	8	4 (50)	43	18 (42)
1999	18	7 (39)	6	4 (67)	24	11 (46)
2000	17	9 (53)	8	1 (13)	25	10 (40)
2001	22	8 (36)	6	2 (33)	28	10 (36)
2002	96	47 (49)	50	18 (36)	148	66 (45)
χ² trend p value		0.2		0.8		0.5

* Total includes people whose sex was not reported or reported as transgender.

Table 10: HCV antibody prevalence according to age group and duration of drug injection, 1995-2002.

	Nº tested	Nº with HCV (%)
Age group		
< 25 years	106	24 (23)
25 + years	202	106 (52)
p value		<0.001
Duration of drug injection		
< 3 years	32	7 (21)
3 to 5 years	58	13 (22)
6 to 10 years	87	32 (37)
10 + years	128	75 (58)
p value		<0.001

Table 11: HCV antibody prevalence according to frequency of drug injection last month, re-use of someone else's syringe last month, sex work last month and imprisonment last year, 1995-2002.

	Number tested	Nº with HCV (%)
Frequency of injection last month		
Less than daily	155	61 (39)
Daily or more	140	65 (46)
p value		0.2
Reused someone else's syringe last month		
Yes	22	9 (24)
No	252	114 (45)
p value		0.02
Sex work last month		
Yes	6	2 (33)
No	293	127 (43)
p value		0.8
Imprisonment last year		
Yes	27	14 (52)
No	273	113 (41)
p value		0.2

VICTORIA
1995-2002

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	5	3	4	4	3	3	4	4
Response								
Nº surveyed	N = 120	N = 195	N = 457	N = 288	N = 214	N = 293	N = 340	N = 265
% response	25%	45%	44%	35%	26%	43%	39%	23%
Sex (%)								
Males	79 (66)	131 (67)	308 (67)	197 (68)	141 (66)	177 (60)	219 (64)	167 (63)
Females	41 (34)	63 (32)	147 (32)	91 (32)	72 (34)	115 (39)	119 (35)	96 (36)
Transgender	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)
Not reported	0 (0)	1 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)	0 (0)	2 (1)
Sexual identity (%)								
Heterosexual	96 (80)	159 (82)	364 (80)	246 (85)	174 (81)	239 (82)	264 (78)	206 (78)
Bisexual	15 (13)	21 (11)	56 (12)	22 (8)	29 (14)	39 (13)	35 (10)	37 (14)
Gay/lesbian	9 (8)	11 (6)	27 (6)	12 (4)	7 (3)	10 (3)	17 (5)	2 (<1)
Not reported	0 (0)	4 (2)	10 (2)	8 (3)	4 (2)	5 (2)	24 (7)	20 (8)
Age and duration of injection (years)								
Median age	28.5	27	26	26	26	27	28	29
Age range	17 - 50	16 - 53	15 - 50	14 - 51	16 - 47	15 - 50	16 - 55	15 - 54
Not reported	0	3	0	0	2	0	0	0
Median age 1 st IDU	18	18	18	18	18	18	18	18
Age range	10 - 40	9 - 37	9 - 45	11 - 42	11 - 44	9 - 40	9 - 45	7 - 51
Not reported	0	4	5	3	1	2	8	6
Median years IDU	8	8	7	6	7	8	9	10
Range	<1 - 31	<1 - 37	<1 - 33	<1 - 33	<1 - 27	<1 - 31	<1 - 37	<1 - 37
Not reported	0	4	5	3	2	2	8	10
Aboriginal and Torres Strait Islander Origin (%)								
Yes	6 (5)	6 (3)	12 (3)	5 (2)	15 (7)	15 (5)	20 (6)	11 (4)
No	114 (95)	184 (94)	438 (96)	281 (97)	196 (92)	276 (94)	312 (92)	251 (95)
Not reported	0 (0)	5 (3)	7 (2)	2 (1)	3 (1)	2 (1)	8 (2)	3 (1)
Imprisonment last year (%)								
Yes	17 (14)	20 (11)	65 (14)	40 (14)	42 (20)	54 (18)	68 (20)	58 (22)
No	103 (86)	169 (89)	391 (86)	245 (85)	170 (79)	228 (78)	259 (76)	204 (77)
Not reported	0 (0)	0 (0)	1 (<1)	3 (1)	2 (1)	11 (4)	13 (4)	3 (1)
Injected in prison	N = 17	N = 20	N = 65	N = 40	N = 42	N = 54	N = 68	N = 58
Yes	4 (24)	8 (40)	20 (31)	16 (40)	18 (43)	21 (39)	21 (31)	20 (34)
Frequency of injection last month (%)								
Not last month	11 (9)	6 (3)	23 (5)	8 (3)	12 (6)	13 (4)	27 (8)	17 (6)
Less than weekly	24 (20)	27 (14)	96 (21)	23 (8)	25 (12)	32 (11)	59 (17)	47 (18)
Weekly not daily	41 (34)	68 (34)	75 (16)	64 (22)	42 (20)	60 (20)	79 (23)	57 (22)
Daily or more	44 (37)	93 (48)	262 (57)	193 (67)	134 (63)	186 (64)	168 (50)	141 (53)
Not reported	0 (0)	3 (2)	1 (<1)	0 (0)	1 (<1)	2 (1)	7 (2)	3 (1)
Last drug injected (%)								
Amphetamine	37 (31)	18 (9)	37 (8)	13 (5)	15 (7)	19 (6)	84 (24)	60 (23)
Anabolic steroids	1 (1)	1 (1)	2 (<1)	1 (<1)	0 (0)	1 (<1)	2 (1)	6 (2)
Benzos	0 (0)	0 (0)	5 (1)	1 (<1)	1 (<1)	0 (0)	2 (1)	0 (0)
Buprenorphine	---	---	---	---	---	---	---	12 (5)
Cocaine	1 (1)	0 (0)	3 (1)	0 (0)	0 (0)	0 (0)	5 (1)	0 (0)
Heroin	75 (63)	159 (82)	391 (86)	259 (90)	186 (87)	255 (87)	197 (58)	150 (57)
Heroin + Cocaine	0 (0)	0 (0)	2 (<1)	0 (0)	0 (0)	2 (1)	10 (3)	2 (1)
Methadone	1 (1)	2 (1)	2 (<1)	2 (1)	1 (<1)	0 (0)	0 (0)	1 (<1)
Morphine	2 (2)	0 (0)	4 (1)	1 (<1)	2 (1)	5 (2)	9 (3)	6 (2)
More than one	1 (1)	1 (1)	10 (2)	10 (3)	0 (0)	9 (3)	24 (7)	24 (9)
Other	1 (1)	1 (1)	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)	2 (1)
Not reported	1 (1)	1 (1)	1 (<1)	1 (<1)	8 (4)	2 (1)	6 (2)	1 (<1)

VICTORIA

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº Injected last month	N = 109	N = 188	N = 433	N = 280	N = 201	N = 278	N = 306	N = 245
Places injected last month (%)*								
Own home	366 (85)	241 (86)	158 (79)	219 (79)	226 (74)	176 (72)		
Friend's home	239 (55)	136 (49)	91 (46)	119 (43)	144 (47)	96 (39)		
Dealer's home	76 (18)	36 (13)	22 (11)	49 (18)	61 (20)	43 (18)		
Street, park, beach	182 (42)	148 (53)	118 (59)	147 (53)	121 (40)	96 (39)		
Car	-	163 (58)	113 (56)	154 (55)	148 (48)	115 (47)		
Public toilet	183 (42)	125 (45)	94 (47)	109 (39)	92 (30)	89 (36)		
"Shooting" room	8 (2)	6 (2)	1 (1)	4 (1)	1 (<1)	1 (1)		
Squat	---	---	41 (20)	55 (20)	37 (12)	41 (17)		
Use of new sterile needles & syringes last month (%)								
All injections	276 (64)	151 (54)	107 (53)	189 (68)	231 (75)	179 (73)		
Most of the time	135 (31)	104 (37)	79 (39)	66 (24)	57 (19)	50 (20)		
Half of the time	7 (2)	14 (5)	6 (3)	9 (3)	2 (1)	7 (3)		
Some of the time	4 (1)	6 (2)	3 (1)	3 (1)	6 (2)	0 (0)		
Not last month	5 (1)	0 (0)	2 (1)	5 (2)	0 (0)	3 (1)		
Not reported	6 (1)	5 (2)	4 (2)	6 (2)	10 (3)	22 (3)		
Re-used another's syringe last month (%)								
None	87 (80)	146 (78)	353 (82)	227 (81)	156 (78)	226 (81)	257 (84)	193 (79)
Once	12 (11)	18 (9)	24 (6)	16 (6)	14 (7)	20 (7)	13 (4)	14 (6)
Twice	6 (6)	7 (4)	15 (4)	16 (6)	8 (4)	11 (4)	11 (4)	14 (6)
3-5 times	4 (4)	9 (5)	19 (4)	8 (3)	10 (5)	7 (3)	6 (2)	7 (3)
>5 times	0 (0)	8 (4)	6 (1)	9 (3)	6 (3)	4 (1)	3 (1)	5 (2)
Don't know	0 (0)	0 (0)	10 (2)	0 (0)	2 (1)	0 (0)	0 (0)	2 (<1)
Not reported	0 (0)	0 (0)	6 (1)	4 (1)	5 (2)	10 (4)	16 (5)	10 (4)
Number of people syringe was re-used after last month (%)								
None	87 (80)	146 (78)	353 (82)	227 (81)	156 (78)	226 (81)	257 (84)	193 (79)
One	11 (10)	19 (10)	67 (15)	45 (17)	34 (16)	38 (14)	17 (5)	28 (11)
Two	7 (6)	20 (10)	5 (1)	4 (1)	1 (1)	1 (<1)	3 (1)	2 (1)
Three to five	3 (3)	3 (2)	2 (1)	0 (0)	3 (1)	1 (<1)	2 (1)	1 (<1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (1)	2 (1)	1 (<1)
Don't know	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	4 (1)	1 (<1)
Not reported	0 (0)	0 (0)	6 (1)	4 (1)	5 (2)	10 (4)	21 (7)	19 (8)
Relationship to people syringe was re-used after last month (%)*								
Regular sex partner	42 (10)	35 (13)	24 (12)	25 (9)	20 (7)	16 (7)		
Casual sex partner	1 (<1)	3 (1)	2 (1)	3 (1)	3 (1)	2 (1)		
Close friend	22 (5)	9 (3)	8 (4)	9 (3)	11 (4)	9 (4)		
Acquaintance	5 (1)	3 (1)	5 (2)	4 (1)	7 (2)	4 (2)		
Other	5 (1)	1 (<1)	4 (2)	3 (1)	1 (<1)	2 (1)		
Equipment used after someone else last month (%)*								
Spoon			113 (56)	81 (29)	111 (36)	101 (41)		
Water			79 (39)	50 (18)	59 (19)	77 (31)		
Filter			70 (35)	36 (13)	53 (17)	74 (30)		
Tourniquet			28 (14)	30 (11)	37 (12)	39 (16)		
Drug mix			99 (49)	35 (13)	42 (14)	60 (24)		
Injected by someone else who'd already injected themselves or others last month (%)								
Yes			42 (8)	41 (8)	48 (15)	52 (21)		
No			156 (78)	225 (81)	244 (80)	183 (75)		
Not reported			3 (1)	11 (4)	14 (5)	10 (4)		

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 120	N = 195	N = 457	N = 288	N = 214	N = 293	N = 340	N = 265
Any treatment/therapy for drug use (%)								
No	47 (39)	56 (29)	129 (28)	76 (26)	44 (20)	44 (15)	72 (21)	41 (15)
Yes	73 (61)	137 (70)	328 (72)	212 (74)	168 (79)	247 (84)	266 (78)	224 (85)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)	2 (1)	2 (1)	0 (0)
History of methadone treatment (%)								
Currently	18 (15)	46 (24)	104 (23)	44 (15)	40 (19)	55 (19)	53 (16)	45 (17)
Previously	25 (21)	42 (22)	113 (25)	88 (31)	75 (35)	112 (38)	145 (43)	112 (42)
Never	77 (64)	105 (53)	240 (52)	156 (54)	97 (46)	124 (52)	138 (40)	107 (40)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	1 (<1)	2 (1)	4 (1)	1 (1)
History of other pharmacological therapy (%)								
Currently					4 (2)	9 (3)	27 (8)	65 (25)
Previously					28 (13)	48 (16)	53 (16)	60 (23)
Never					151 (71)	236 (81)	256 (75)	137 (51)
Not reported					31 (14)	0 (0)	4 (1)	3 (1)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 214	N = 293	N = 340	N = 265
From an NSP last month (%)								
Daily or almost daily					73 (34)	81 (28)	60 (18)	62 (24)
A couple of times each week					60 (28)	107 (37)	100 (29)	72 (27)
Less than weekly					42 (20)	65 (22)	76 (22)	67 (25)
Once last month					23 (11)	21 (7)	58 (17)	31 (12)
Not in the last month					14 (7)	17 (6)	38 (11)	27 (10)
Not reported					2 (1)	2 (1)	8 (2)	6 (2)
From a chemist last month (%)								
Daily or almost daily					10 (5)	11 (4)	11 (3)	11 (4)
A couple of times each week					17 (8)	28 (10)	28 (8)	22 (8)
Less than weekly					65 (31)	86 (29)	50 (15)	39 (15)
Once last month					39 (18)	38 (13)	72 (21)	59 (22)
Not in the last month					80 (38)	127 (43)	168 (50)	128 (49)
Not reported					2 (1)	3 (1)	11 (3)	6 (2)

VICTORIA

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 120	N = 195	N = 457	N = 288	N = 214	N = 293	N = 340	N = 265
Sex last month (%)								
Yes	86 (72)	147 (75)	306 (67)	204 (71)	134 (63)	188 (64)	251 (74)	190 (72)
No	31 (26)	45 (23)	150 (33)	84 (29)	76 (36)	100 (34)	85 (25)	74 (28)
Not reported	3 (3)	3 (2)	1 (<1)	0 (0)	4 (2)	5 (2)	4 (1)	1 (<1)
Condom use last sex (%)								
Yes	27 (23)	45 (23)	171 (37)	94 (33)	71 (33)	115 (39)	119 (35)	95 (36)
No	68 (57)	99 (51)	284 (62)	184 (64)	137 (64)	166 (57)	209 (61)	166 (62)
Not reported	25 (21)	51 (26)	2 (<1)	10 (3)	6 (3)	12 (4)	12 (4)	4 (2)
Condom use with regular sex partner(s) last month (%)*								
No	96 (71)	195 (69)	106 (70)	77 (66)	93 (66)	125 (69)	85 (68)	
Sometimes	12 (9)	37 (13)	20 (13)	16 (14)	16 (11)	25 (14)	13 (10)	
Always	28 (20)	50 (18)	26 (17)	24 (20)	32 (23)	31 (17)	28 (22)	
Condom use with new sex partner(s) last month (%)*								
No	13 (27)	35 (30)	9 (36)	7 (23)	13 (25)	40 (31)	38 (41)	
Sometimes	4 (8)	11 (10)	3 (12)	2 (6)	5 (9)	21 (16)	12 (13)	
Always	31 (65)	69 (60)	13 (52)	22 (71)	35 (66)	68 (53)	42 (46)	
Condom use with casual sex partner(s) last month (%)*								
No		23 (37)	16 (29)	22 (26)	38 (35)	36 (40)		
Sometimes		10 (16)	6 (11)	9 (11)	15 (14)	9 (10)		
Always		29 (47)	33 (60)	54 (63)	55 (51)	44 (50)		
Duration of regular sexual relationship (%)**								
One month					14 (8)	13 (9)		
2 - 6 months					28 (17)	14 (10)		
6 - 12 months					29 (17)	17 (12)		
>12 months					97 (58)	94 (69)		
Sex work last month (%)								
Yes	7 (6)	17 (9)	35 (8)	17 (6)	20 (9)	50 (17)	45 (13)	37 (14)
No	104 (87)	163 (84)	419 (92)	264 (92)	188 (88)	237 (81)	283 (83)	223 (84)
Not reported	9 (8)	15 (8)	3 (1)	7 (2)	5 (3)	6 (2)	12 (4)	5 (2)
Condom use last sex work last month (%)**								
Yes	6 (100)	16 (94)	26 (90)	14 (88)	17 (94)	47 (98)	40 (95)	33 (89)

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1996-2002).

** Percentages exclude missing data.

Table 6: Number and (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 120	N = 195	N = 457	N = 288	N = 214	N = 293	N = 340	N = 265
Previous HIV test (%)								
Yes, last year	76 (63)	109 (56)	298 (65)	189 (66)	134 (63)	209 (71)	219 (64)	184 (69)
> 1 year ago	25 (21)	50 (26)	95 (21)	59 (20)	50 (23)	58 (20)	79 (23)	58 (22)
Never tested	15 (13)	33 (17)	4 (1)	1 (<1)	27 (13)	26 (9)	36 (11)	22 (8)
Not reported	4 (3)	3 (2)	60 (13)	39 (14)	3 (1)	0 (0)	6 (2)	1 (1)
Self report HBV infection (%)								
Yes	26 (22)	46 (24)	71 (16)	38 (19)	34 (16)	43 (15)	53 (16)	51 (19)
No	92 (77)	147 (75)	344 (75)	239 (83)	166 (78)	235 (80)	246 (72)	176 (67)
Don't know	0 (0)	0 (0)	40 (9)	9 (3)	13 (6)	12 (4)	36 (11)	35 (13)
Not reported	2 (2)	2 (1)	2 (<1)	2 (1)	1 (<1)	3 (1)	5 (1)	3 (1)
Self report HBV vaccination (%)*								
Yes	31 (33)	50 (34)	121 (31)	86 (34)	64 (35)	115 (46)	140 (49)	103 (48)
No	62 (66)	95 (64)	227 (59)	146 (58)	106 (59)	110 (45)	109 (38)	87 (41)
Don't know	0 (0)	0 (0)	36 (9)	17 (7)	9 (5)	21 (8)	25 (9)	24 (11)
Not reported	1 (1)	4 (2)	2 (1)	1 (1)	1 (1)	3 (1)	13 (4)	0 (0)
Previous HCV test (%)								
Yes ever	87 (73)	144 (75)	---	---	---	---	---	---
Yes, last year	---	---	294 (63)	202 (70)	140 (65)	208 (71)	227 (67)	187 (71)
> 1 year ago	---	---	85 (19)	50 (17)	51 (24)	63 (22)	85 (25)	59 (22)
Never tested	29 (24)	46 (24)	76 (16)	36 (13)	22 (10)	19 (6)	24 (7)	19 (7)
Not reported	4 (3)	1 (1)	2 (<1)	0 (0)	0 (0)	3 (1)	4 (1)	0 (0)
Any treatment for HCV (%)								
No treatment						N = 92	N = 139	N = 167
Interferon						88 (96)	130 (94)	147 (88)
Interferon+Ribavarin						1 (1)	2 (1)	4 (2)
Other						0 (0)	1 (1)	2 (1)
Not reported						2 (2)	3 (2)	8 (5)
Current treatment for HCV								
Interferon					N = 1	N = 3	N = 4	N = 2
Interferon+Ribavarin					0	0	1	1
Other					0	0	1	0
					1	3	2	1

* Number (percentage) among participants not reporting HBV infection.

VICTORIA

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995	77	1 (1.3)	41	0 (0.0)	118	1 (0.9)
1996	131	3 (2.3)	63	1 (1.6)	195	4 (2.1)
1997	294	4 (1.4)	141	1 (0.7)	436	5 (1.2)
1998	193	0 (0.0)	90	0 (0.0)	283	0 (0.0)
1999	137	2 (1.5)	69	0 (0.0)	207	2 (1.0)
2000	177	1 (0.6)	115	0 (0.0)	293	1 (0.3)
2001	214	2 (0.9)	117	0 (0.0)	333	2 (0.6)
2002	151	1 (0.7)	91	0 (0.0)	244	1 (0.4)
χ^2 trend p value		0.3		0.1		0.1

Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.

Sexual identity	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Heterosexual	64	0 (0.0)	---	---	94	0 (0.0)
Bisexual	8	1 (12.5)	---	---	15	1 (6.7)
Homosexual	5	0 (0.0)	---	---	9	0 (0.0)
p value		0.01				0.03
1996						
Heterosexual	118	3 (2.5)	41	1 (2.4)	159	4 (2.5)
Bisexual	6	0 (0.0)	15	0 (0.0)	21	0 (0.0)
Homosexual	6	0 (0.0)	5	0 (0.0)	11	0 (0.0)
p value		0.9		0.8		0.7
1997						
Heterosexual	261	1 (0.4)	86	1 (1.2)	348	2 (0.6)
Bisexual	17	2 (11.8)	37	0 (0.0)	54	2 (3.7)
Homosexual	10	1 (10.0)	15	0 (0.0)	25	1 (4.0)
p value		<0.001		0.7		0.06
1998						
Heterosexual	---	---	---	---	---	---
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p value						
1999						
Heterosexual	118	0 (0.0)	---	---	167	0 (0.0)
Bisexual	11	0 (0.0)	---	---	29	0 (0.0)
Homosexual	5	2 (40.0)	---	---	7	2 (28.6)
p value		<0.001				<0.001
2000						
Heterosexual	162	0 (0.0)	---	---	239	0 (0.0)
Bisexual	8	0 (0.0)	---	---	39	0 (0.0)
Homosexual	5	1 (20.0)	---	---	10	1 (10.0)
p value		<0.001				<0.001
2001						
Heterosexual	177	1 (0.6)	---	---	260	1 (0.4)
Bisexual	10	0 (0.0)	---	---	34	0 (0.0)
Homosexual	10	1 (10.0)	---	---	15	1 (6.7)
p value		0.01				0.01
2002						
Heterosexual	---	---	---	---	---	---
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p value						

* Total includes people whose sex was not reported or reported as transgender.

Table 9: HIV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
< 20 years	6	0 (0.0)	---	---	11	0 (0.0)
20 – 24	10	0 (0.0)	---	---	26	0 (0.0)
25 – 29	21	0 (0.0)	---	---	29	0 (0.0)
30 + years	40	1 (2.5)	---	---	52	1 (1.9)
p value		0.8				0.7
1996						
< 20 years	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)
20 – 24	23	0 (0.0)	21	0 (0.0)	44	0 (0.0)
25 – 29	30	1 (3.3)	19	1 (5.3)	50	2 (4.0)
30 + years	64	2 (3.1)	17	0 (0.0)	81	2 (2.5)
p value		0.8		0.5		0.5
1997						
< 20 years	29	0 (0.0)	26	0 (0.0)	55	0 (0.0)
20 – 24	73	0 (0.0)	42	0 (0.0)	115	0 (0.0)
25 – 29	73	2 (2.7)	41	1 (2.4)	114	3 (2.6)
30 + years	119	2 (1.7)	32	0 (0.0)	152	2 (1.3)
p value		0.5		0.5		0.2
1998						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	---	---	---	---
25 – 29	---	---	---	---	---	---
30 + years	---	---	---	---	---	---
p value						
1999						
< 20 years	8	0 (0.0)	---	---	23	0 (0.0)
20 – 24	39	0 (0.0)	---	---	64	0 (0.0)
25 – 29	43	0 (0.0)	---	---	54	0 (0.0)
30 + years	46	2 (4.4)	---	---	64	2 (3.1)
p value		0.3				0.2
2000						
< 20 years	5	0 (0.0)	---	---	20	0 (0.0)
20 – 24	41	0 (0.0)	---	---	81	0 (0.0)
25 – 29	61	1 (1.6)	---	---	91	1 (1.1)
30 + years	70	0 (0.0)	---	---	101	0 (0.0)
p value		0.6				0.5
2001						
< 20 years	12	0 (0.0)	---	---	24	0 (0.0)
20 – 24	48	0 (0.0)	---	---	84	0 (0.0)
25 – 29	57	1 (1.8)	---	---	80	1 (1.3)
30 + years	97	1 (1.0)	---	---	145	1 (0.7)
p value		0.8				0.7
2002						
< 20 years	4	0 (0.0)	---	---	12	0 (0.0)
20 – 24	31	0 (0.0)	---	---	53	0 (0.0)
25 – 29	34	0 (0.0)	---	---	63	0 (0.0)
30 + years	82	1 (1.2)	---	---	116	1 (0.9)
p value		0.8				0.8

* Total includes people whose sex was not reported or reported as transgender.

VICTORIA
HIV ANTIBODY

Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
<1 to 2 years	14	0 (0.0)	---	---	21	0 (0.0)
3 to 5 years	14	0 (0.0)	---	---	28	0 (0.0)
6 to 10 years	13	0 (0.0)	---	---	29	0 (0.0)
10 + years	36	1 (2.8)	---	---	40	1 (2.5)
p value		0.8				0.6
1996						
<1 to 2 years	23	0 (0.0)	11	0 (0.0)	34	0 (0.0)
3 to 5 years	24	0 (0.0)	15	0 (0.0)	39	0 (0.0)
6 to 10 years	30	1 (3.3)	14	1 (7.1)	45	2 (4.4)
10 + years	51	2 (3.9)	22	0 (0.0)	73	2 (2.7)
p value		0.6		0.3		0.4
1997						
<1 to 2 years	47	0 (0.0)	35	0 (0.0)	82	0 (0.0)
3 to 5 years	67	0 (0.0)	37	0 (0.0)	104	0 (0.0)
6 to 10 years	67	1 (1.5)	35	1 (2.9)	102	2 (2.0)
10 + years	108	2 (1.9)	34	0 (0.0)	143	2 (1.4)
p value		0.6		0.4		0.4
1998						
<1 to 2 years	---	---	---	---	---	---
3 to 5 years	---	---	---	---	---	---
6 to 10 years	---	---	---	---	---	---
10 + years	---	---	---	---	---	---
p value						
1999						
<1 to 2 years	21	0 (0.0)	---	---	41	0 (0.0)
3 to 5 years	31	0 (0.0)	---	---	47	0 (0.0)
6 to 10 years	37	1 (2.7)	---	---	57	1 (1.8)
10 + years	47	1 (2.1)	---	---	60	1 (1.7)
p value		0.7				0.7
2000						
<1 to 2 years	19	1 (5.3)	---	---	35	1 (2.9)
3 to 5 years	39	0 (0.0)	---	---	75	0 (0.0)
6 to 10 years	52	0 (0.0)	---	---	82	0 (0.0)
10 + years	67	0 (0.0)	---	---	99	0 (0.0)
p value		0.04				0.06
2001						
<1 to 2 years	19	0 (0.0)	---	---	31	0 (0.0)
3 to 5 years	43	2 (4.7)	---	---	68	2 (2.9)
6 to 10 years	63	0 (0.0)	---	---	105	0 (0.0)
10 + years	84	0 (0.0)	---	---	121	0 (0.0)
p value		0.05				0.06
2002						
<1 to 2 years	8	0 (0.0)	---	---	14	0 (0.0)
3 to 5 years	25	0 (0.0)	---	---	45	0 (0.0)
6 to 10 years	39	0 (0.0)	---	---	68	0 (0.0)
10 + years	75	1 (1.3)	---	---	112	1 (0.9)
p value		0.8				0.8

* Total includes people whose sex was not reported or reported as transgender.

Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex.

Last drug injected	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Amphetamine	26	0 (0.0)	---	---	36	0 (0.0)
Heroin	44	1 (2.3)	---	---	74	1 (1.4)
More than one	1	0 (0.0)	---	---	1	0 (0.0)
Other/not reported	6	0 (0.0)	---	---	7	0 (0.0)
p value		0.9				0.9
1996						
Amphetamine	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
Heroin	105	1 (1.0)	54	1 (1.9)	159	2 (1.3)
More than one	3	0 (0.0)	3	0 (0.0)	7	0 (0.0)
Other/not reported	10	2 (20.0)	1	0 (0.0)	11	2 (18.2)
p value		0.002		>0.9		0.002
1997						
Amphetamine	22	0 (0.0)	12	0 (0.0)	34	0 (0.0)
Heroin	250	4 (1.6)	124	1 (0.8)	374	5 (1.3)
More than one	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)
Other/not reported	12	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		0.9		>0.9		0.8
1998						
Amphetamine	---	---	---	---	---	---
Heroin	---	---	---	---	---	---
More than one	---	---	---	---	---	---
Other/not reported	---	---	---	---	---	---
p value						
1999						
Amphetamine	8	0 (0.0)	---	---	15	0 (0.0)
Heroin	121	2 (1.7)	---	---	179	2 (1.1)
More than one	0	---	---	---	0	---
Other/not reported	8	0 (0.0)	---	---	13	0 (0.0)
p value		0.9				0.9
2000						
Amphetamine	13	0 (0.0)	---	---	19	0 (0.0)
Heroin	156	1 (0.6)	---	---	255	1 (0.4)
More than one	6	0 (0.0)	---	---	11	0 (0.0)
Other/not reported	2	0 (0.0)	---	---	8	0 (0.0)
p value		>0.9				>0.9
2001						
Amphetamine	61	1 (1.6)	---	---	80	1 (1.3)
Heroin	116	1 (0.9)	---	---	197	1 (0.5)
More than one	17	0 (0.0)	---	---	32	0 (0.0)
Other/not reported	20	0 (0.0)	---	---	24	0 (0.0)
P value		0.9				0.8
2002						
Amphetamine	40	1 (2.5)	---	---	53	1 (1.9)
Heroin	81	0 (0.0)	---	---	144	0 (0.0)
More than one	17	0 (0.0)	---	---	24	0 (0.0)
Other/not reported	13	0 (0.0)	---	---	23	0 (0.0)
p value		0.4				0.3

* Total includes people whose sex was not reported or reported as transgender.

VICTORIA
HIV ANTIBODY

Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.

Frequency of drug injection last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
Not last month	8	0 (0.0)	---	---	11	0 (0.0)
Less than weekly	15	0 (0.0)	---	---	23	0 (0.0)
Weekly not daily	25	0 (0.0)	---	---	40	0 (0.0)
Daily or more	29	1 (3.5)	---	---	44	1 (2.3)
p value		0.6				0.6
1996						
Not last month	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
Less than weekly	18	0 (0.0)	9	0 (0.0)	27	0 (0.0)
Weekly not daily	42	1 (2.4)	26	0 (0.0)	68	1 (1.5)
Daily or more	67	2 (3.0)	25	1 (4.0)	93	3 (3.2)
p value		0.9		0.7		0.7
1997						
Not last month	16	0 (0.0)	5	1 (20.0)	21	1 (4.8)
Less than weekly	66	1 (1.5)	26	0 (0.0)	92	1 (1.1)
Weekly not daily	44	0 (0.0)	27	0 (0.0)	72	0 (0.0)
Daily or more	168	3 (1.8)	83	0 (0.0)	251	3 (1.2)
p value		0.8		<0.001		0.4
1998						
Not last month	---	---	---	---	---	---
Less than weekly	---	---	---	---	---	---
Weekly not daily	---	---	---	---	---	---
Daily or more	---	---	---	---	---	---
p value						
1999						
Not last month	10	0 (0.0)	---	---	12	0 (0.0)
Less than weekly	12	0 (0.0)	---	---	25	0 (0.0)
Weekly not daily	30	1 (3.3)	---	---	40	1 (2.5)
Daily or more	85	1 (1.2)	---	---	129	1 (0.8)
p value		0.8				0.7
2000						
Not last month	8	0 (0.0)	---	---	13	0 (0.0)
Less than weekly	23	0 (0.0)	---	---	32	0 (0.0)
Weekly not daily	38	1 (2.6)	---	---	60	1 (1.7)
Daily or more	108	0 (0.0)	---	---	186	0 (0.0)
p value		0.3				0.3
2001						
Not last month	18	1 (5.6)	---	---	26	1 (3.9)
Less than weekly	39	1 (2.6)	---	---	57	1 (1.8)
Weekly not daily	54	0 (0.0)	---	---	77	0 (0.0)
Daily or more	100	0 (0.0)	---	---	166	0 (0.0)
p value		0.09				0.07
2002						
Not last month	11	0 (0.0)	---	---	15	0 (0.0)
Less than weekly	28	0 (0.0)	---	---	39	0 (0.0)
Weekly not daily	334	0 (0.0)	---	---	53	0 (0.0)
Daily or more	77	1 (1.3)	---	---	134	1 (0.8)
p value		0.08				0.8

* Total includes people whose sex was not reported or reported as transgender.

Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.

Reused someone else's syringe last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	59	1 (1.7)	---	---	85	1 (1.2)
Yes	10	0 (0.0)	---	---	22	0 (0.0)
p value		0.7				0.6
1996						
No	105	3 (2.9)	40	1 (2.5)	146	4 (2.7)
Yes	22	0 (0.0)	20	0 (0.0)	42	0 (0.0)
p value		0.4		0.5		0.3
1997						
No	229	3 (1.3)	---	---	340	3 (0.9)
Yes	45	1 (2.2)	---	---	69	1 (1.5)
p value		0.6				0.7
1998						
No	---	---	---	---	---	---
Yes	---	---	---	---	---	---
p value						
1999						
No	96	2 (2.1)	---	---	150	2 (1.3)
Yes	27	0 (0.0)	---	---	39	0 (0.0)
p value		0.5				0.5
2000						
No	144	1 (0.7)	---	---	226	1 (0.4)
Yes	21	0 (0.0)	---	---	42	0 (0.0)
p value		0.7				0.7
2001						
No	162	1 (0.6)	---	---	251	1 (0.4)
Yes	21	0 (0.0)	---	---	33	0 (0.0)
p value		0.7				0.7
2002						
No	---	---	---	---	---	---
Yes	---	---	---	---	---	---

* Total includes people whose sex was not reported or reported as transgender.

VICTORIA
HIV ANITBODY

Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.

Imprisonment last year	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	62	1 (1.6)	---	---	101	1 (1.0)
Yes	15	0 (0.0)	---	---	17	0 (0.0)
p value		0.6				0.7
1996						
No	113	3 (2.7)	56	1 (1.8)	169	4 (2.4)
Yes	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		0.5		0.8		0.5
1997						
No	244	3 (1.2)	131	1 (0.8)	376	4 (1.1)
Yes	49	1 (2.0)	10	0 (0.0)	59	1 (1.7)
p value		0.7		0.8		0.7
1998						
No	---	---	---	---	---	---
Yes	---	---	---	---	---	---
p value						
1999						
No	105	2 (1.9)	---	---	165	2 (1.2)
Yes	32	0 (0.0)	---	---	40	0 (0.0)
p value		0.4				0.5
2000						
No	129	1 (0.8)	---	---	228	1 (0.4)
Yes	40	0 (0.0)	---	---	54	0 (0.0)
p value		0.6				0.6
2001						
No	159	1 (0.6)	---	---	254	1 (0.4)
Yes	47	1 (2.1)	---	---	67	1 (1.5)
p value		0.4				0.3
2002						
No	119	1 (0.8)	---	---	191	1 (0.5)
Yes	30	0 (0.0)	---	---	51	0 (0.0)
p value		0.6				

* Total includes people whose sex was not reported or reported as transgender.

Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.

Condom use last sex	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	45	1 (2.2)	---	---	67	1 (1.5)
Yes	17	0 (0.0)	---	---	27	0 (0.0)
p value		0.5				0.5
1996						
No	60	0 (0.0)	---	---	99	0 (0.0)
Yes	30	1 (3.3)	---	---	45	1 (2.2)
p value		0.2				0.1
1997						
No	174	0 (0.0)	98	0 (0.0)	273	0 (0.0)
Yes	118	4 (3.4)	43	1 (2.3)	161	5 (3.1)
p value		0.01		0.1		0.003
1998						
No	---	---	---	---	---	---
Yes	---	---	---	---	---	---
p value						
1999						
No	85	0 (0.0)	---	---	130	0 (0.0)
Yes	48	2 (4.2)	---	---	71	2 (2.8)
p value		0.06				0.05
2000						
No	109	1 (0.9)	---	---	166	1 (0.6)
Yes	58	0 (0.0)	---	---	115	0 (0.0)
p value		0.5				0.4
2001						
No	131	1 (0.8)	---	---	205	1 (0.5)
Yes	76	1 (1.3)	---	---	116	1 (0.9)
p value		0.7				0.7
2002						
No	101	1 (1.0)	---	---	153	1 (1.7)
Yes	49	0 (0.0)	---	---	88	0 (0.0)
p value		0.8				0.7

* Total includes people whose sex was not reported or reported as transgender.

VICTORIA
HIV ANTIBODY

Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.

Sex work last month	Male		Female		Total *	
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)
1995						
No	69	1 (1.5)	---	---	102	1 (1.0)
Yes	0	---	---	---	7	0 (0.0)
p value						0.8
1996						
No	120	2 (1.7)	42	0 (0.0)	163	2 (1.2)
Yes	1	0 (0.0)	16	1 (6.3)	17	1 (5.9)
p value		0.9		0.1		0.2
1997						
No	286	3 (1.1)	113	1 (0.9)	400	4 (1.0)
Yes	5	1 (20.0)	28	0 (0.0)	33	1 (3.0)
p value		<0.001		0.6		0.3
1998						
No	---	---	---	---	---	---
Yes	---	---	---	---	---	---
p value						
1999						
No	132	2 (1.5)	---	---	182	2 (1.1)
Yes	2	0 (0.0)	---	---	20	0 (0.0)
p value		0.9				0.6
2000						
No	167	1 (0.6)	---	---	237	1 (0.4)
Yes	5	0 (0.0)	---	---	50	0 (0.0)
p value		0.9				0.6
2001						
No	195	2 (1.0)	---	---	277	2 (0.7)
Yes	10	0 (0.0)	---	---	44	0 (0.0)
p value		0.7				0.6
2002						
No	144	1 (0.7)	---	---	205	1 (0.5)
Yes	4	0 (0.0)	---	---	36	0 (0.0)
p value		0.9				0.7

* Total includes people whose sex was not reported or reported as transgender.

HCV antibody prevalence

Table 17: HCV antibody prevalence according to year of survey and sex.

Year of survey	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	77	43 (56)	41	20 (49)	118	63 (53)
1996	127	56 (44)	62	35 (56)	190	92 (48)
1997	294	140 (48)	141	81 (57)	436	221 (51)
1998	193	104 (54)	90	48 (53)	283	152 (54)
1999	135	81 (60)	69	40 (58)	205	122 (60)
2000	177	114 (64)	115	68 (59)	293	183 (62)
2001	218	150 (69)	119	87 (73)	339	237 (70)
2002	152	84 (55)	91	57 (63)	245	143 (58)
		χ² trend p value	<0.001		0.008	<0.001

Table 18: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
< 20 years	6	1 (17)	5	0 (0)	11	1 (9)
20 – 24	10	5 (50)	16	9 (56)	26	14 (54)
25 – 29	21	10 (48)	8	4 (50)	29	14 (48)
30 + years	40	27 (68)	12	7 (58)	52	34 (65)
p value		0.08		0.1		0.007
1996						
< 20 years	13	3 (23)	6	2 (33)	19	4 (21)
20 – 24	22	3 (14)	21	5 (24)	43	8 (19)
25 – 29	30	10 (33)	19	15 (79)	50	26 (52)
30 + years	62	41 (66)	16	13 (81)	78	54 (69)
p value		<0.001		<0.001		<0.001
1997						
< 20 years	29	6 (21)	26	11 (42)	55	17 (31)
20 – 24	73	15 (21)	42	13 (31)	115	28 (24)
25 – 29	73	32 (44)	41	31 (76)	114	63 (55)
30 + years	119	87 (73)	32	26 (81)	152	113 (74)
p value		<0.001		<0.001		<0.001
1998						
< 20 years	15	8 (53)	20	7 (35)	35	15 (43)
20 – 24	53	24 (45)	31	10 (32)	84	34 (40)
25 – 29	52	21 (40)	17	9 (53)	69	30 (43)
30 + years	73	51 (70)	22	22 (100)	95	73 (77)
p value		0.005		<0.001		<0.001
1999						
< 20 years	8	3 (38)	15	9 (60)	23	12 (52)
20 – 24	39	19 (49)	25	11 (44)	64	30 (47)
25 – 29	42	23 (55)	11	5 (45)	53	28 (53)
30 + years	45	35 (78)	18	15 (83)	63	50 (79)
p value		0.02		0.06		0.001
2000						
< 20 years	5	2 (40)	15	7 (47)	20	9 (45)
20 – 24	41	21 (51)	40	25 (63)	81	46 (57)
25 – 29	61	39 (64)	30	14 (47)	91	53 (58)
30 + years	70	52 (74)	30	22 (73)	101	75 (74)
p value		0.06		0.1		0.02
2001						
< 20 years	12	7 (58)	12	9 (75)	24	16 (67)
20 – 24	49	26 (53)	35	20 (57)	86	46 (53)
25 – 29	57	38 (67)	24	19 (79)	81	57 (70)
30 + years	100	79 (79)	48	39 (81)	148	118 (80)
p value		0.01		0.09		<0.001
2002						
< 20 years	4	3 (75)	8	2 (25)	12	5 (42)
20 – 24	31	16 (52)	21	17 (81)	53	34 (64)
25 – 29	34	15 (44)	28	15 (54)	63	31 (49)
30 + years	83	50 (60)	34	23 (68)	117	117 (62)
p value		0.3		0.03		0.2

* Total includes people whose sex was not reported or reported as transgender.

VICTORIA
HCV ANTIBODY

Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
<1 to 2 years	14	2 (14)	7	2 (29)	21	4 (19)
3 to 5 years	14	5 (36)	14	4 (29)	28	9 (32)
6 to 10 years	13	5 (38)	16	11 (69)	29	16 (55)
10 + years	36	31 (86)	4	3 (75)	40	34 (85)
p value		<0.001		0.07		<0.001
1996						
<1 to 2 years	21	2 (10)	11	3 (27)	32	5 (16)
3 to 5 years	24	5 (21)	15	6 (40)	39	11 (28)
6 to 10 years	29	11 (38)	14	7 (50)	44	19 (43)
10 + years	50	38 (76)	21	18 (86)	71	56 (79)
p value		<0.001		0.005		<0.001
1997						
<1 to 2 years	47	6 (13)	35	9 (26)	82	15 (18)
3 to 5 years	67	15 (22)	37	16 (43)	104	31 (30)
6 to 10 years	67	27 (40)	35	25 (71)	102	52 (51)
10 + years	108	90 (83)	34	31 (91)	143	121 (85)
p value		<0.001		<0.001		<0.001
1998						
<1 to 2 years	49	22 (45)	23	6 (26)	72	28 (39)
3 to 5 years	28	11 (39)	23	10 (43)	51	21 (41)
6 to 10 years	42	16 (38)	21	10 (48)	63	26 (41)
10 + years	73	55 (75)	21	20 (95)	94	75 (80)
p value		<0.001		<0.001		<0.001
1999						
<1 to 2 years	21	6 (29)	20	8 (40)	41	14 (34)
3 to 5 years	31	16 (52)	16	8 (50)	47	24 (51)
6 to 10 years	36	24 (67)	20	13 (65)	56	37 (66)
10 + years	46	34 (74)	13	11 (85)	59	45 (76)
p value		0.003		0.06		<0.001
2000						
<1 to 2 years	19	8 (42)	16	7 (44)	35	15 (43)
3 to 5 years	39	23 (59)	36	22 (61)	75	45 (60)
6 to 10 years	52	35 (67)	30	14 (47)	82	49 (60)
10 + years	67	48 (72)	31	24 (77)	99	73 (74)
p value		0.1		0.05		0.009
2001						
<1 to 2 years	19	3 (16)	12	6 (50)	32	9 (28)
3 to 5 years	44	21 (48)	24	19 (79)	69	40 (58)
6 to 10 years	63	46 (73)	43	32 (74)	106	78 (74)
10 + years	87	76 (87)	37	29 (78)	124	105 (85)
p value		<0.001		0.2		<0.001
2002						
<1 to 2 years	8	2 (25)	6	1 (17)	14	3 (21)
3 to 5 years	26	14 (54)	20	9 (45)	46	23 (50)
6 to 10 years	39	15 (38)	28	20 (71)	68	36 (53)
10 + years	75	52 (69)	36	26 (72)	112	79 (71)
p value		0.004		0.02		0.002

* Total includes people whose sex was not reported or reported as transgender.

Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995						
Amphetamine	9	0 (0)	27	7 (26)	36	7 (19)
Heroin	9	4 (44)	65	50 (77)	74	54 (73)
More than one	0	---	1	1 (100)	1	1 (100)
Other/not reported	3	0 (0)	4	1 (25)	7	1 (14)
p value		0.04		<0.001		<0.001
1996						
Amphetamine	3	1 (33)	15	3 (20)	18	3 (16)
Heroin	28	5 (18)	124	78 (63)	155	85 (55)
More than one	0	---	7	4 (57)	7	4 (57)
Other/not reported	1	0 (0)	8	1 (13)	10	1 (10)
p value		0.7		0.001		0.001
1997						
Amphetamine	10	1 (10)	24	6 (25)	34	7 (21)
Heroin	66	14 (21)	304	185 (61)	374	200 (53)
More than one	2	0 (0)	10	6 (60)	12	6 (50)
Other/not reported	4	0 (0)	11	7 (64)	16	8 (50)
p value		0.5		0.008		0.004
1998						
Amphetamine	4	0 (0)	8	3 (38)	12	3 (25)
Heroin	63	25 (40)	190	113 (59)	255	139 (55)
More than one	4	2 (50)	6	4 (67)	10	6 (60)
Other/not reported	1	1 (100)	4	2 (50)	6	4 (67)
p value		0.2		0.6		0.2
1999						
Amphetamine	1	0 (0)	14	10 (71)	15	10 (67)
Heroin	39	14 (36)	137	88 (64)	177	103 (58)
More than one	0	---	0	---	0	---
Other/not reported	1	0 (0)	11	8 (73)	13	9 (69)
p value		0.6		0.8		0.6
2000						
Amphetamine	2	1 (50)	17	9 (53)	19	10 (53)
Heroin	30	12 (40)	224	148 (66)	255	161 (63)
More than one	2	1 (50)	9	6 (67)	11	7 (64)
Other/not reported	1	1 (100)	6	4 (67)	8	5 (63)
p value		0.7		0.7		0.8
2001						
Amphetamine	13	3 (23)	70	43 (61)	84	47 (56)
Heroin	16	6 (38)	180	142 (79)	197	149 (76)
More than one	1	0 (0)	31	24 (77)	33	25 (76)
Other/not reported	2	0 (0)	18	14 (78)	25	16 (64)
p value		0.6		0.04		0.008
2002						
Amphetamine	3	0 (0)	49	14 (29)	54	15 (28)
Heroin	8	2 (25)	134	93 (69)	144	96 (67)
More than one	3	1 (33)	21	17 (81)	24	18 (75)
Other/not reported	0	0 (0)	22	14 (64)	23	14 (61)
p value		0.6		<0.001		<0.001

* Total includes people who did not report duration of drug injection.

VICTORIA
HCV ANTIBODY

Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995 -1996						
Less than daily	34	5 (15)	120	62 (52)	156	68 (44)
Daily or more	15	2 (13)	118	78 (66)	134	81 (60)
p value		0.9		0.02		0.005
1997-1998						
Less than daily	56	12 (21)	190	92 (48)	247	105 (43)
Daily or more	93	31 (33)	344	222 (65)	443	256 (58)
p value		0.1		<0.001		<0.001
1999-2000						
Less than daily	21	9 (41)	136	83 (61)	157	92 (59)
Daily or more	52	20 (39)	259	174 (67)	313	196 (63)
p value		0.7		0.2		0.4
2001-2002						
Less than daily	22	7 (32)	207	132 (64)	230	140 (61)
Daily or more	19	5 (26)	278	205 (74)	302	213 (71)
p value		0.7		0.02		0.02
All years						
Less than daily	133	33 (25)	653	372 (57)	790	408 (52)
Daily or more	79	59 (33)	999	681 (68)	1192	749 (63)
p value		0.1		<0.001		<0.001

Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month and duration of drug injection.

Reused someone else's syringe last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995 -1996						
No	35	5 (14)	190	111 (58)	228	118 (52)
Yes	14	2 (14)	48	29 (60)	62	31 (50)
p value		>0.9		0.8		0.8
1997-1998						
No	126	35 (28)	430	64 (59)	562	292 (52)
Yes	22	7 (32)	952	20 (55)	118	62 (53)
p value		0.7		0.9		0.9
1999-2000						
No	64	24 (38)	309	199 (64)	375	225 (60)
Yes	8	4 (50)	72	48 (67)	80	52 (65)
p value		0.5		0.7		0.4
2001-*2002						
No	34	9 (26)	421	290 (69)	463	301(65)
Yes	6	3 (50)	64	47 (73)	71	51 72)
p value		0.4		0.5		0.3

* Total includes people who did not report duration of drug injection.

Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection.

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1995						
No	50	9 (20)	212	114	265	124 (47)
Yes	3	0 (0)	33	27	37	28 (76)
p value		0.8		0.02		0.008
1997-1998						
No	139	34 (24)	469	261 (56)	616	299 (49)
Yes	12	8 (67)	87	64 (74)	99	72 (73)
p value		0.002		0.002		<0.001
1999-2000						
No	65	20 (31)	324	198 (61)	392	220 (56)
Yes	8	7 (88)	85	68 (80)	93	75 (81)
p value		0.002		0.001		<0.001
2001-2002						
No	42	11 (26)	397	263 (66)	450	279 (62)
Yes	3	0 (0)	116	88 (76)	119	88 (74)
p value		0.3		0.05		0.02

Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection.

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1996						
No	49	9 (18)	207	116 (56)	260	127 (49)
Yes	0	---	24	14 (58)	24	14 (58)
p value				0.8		0.4
1997-1998						
No	148	37 (26)	505	286 (57)	660	328 (50)
Yes	5	3 (60)	44	34 (77)	50	38 (76)
p value		>0.09		0.008		<0.001
1999-2000						
No	65	23 (35)	349	229 (66)	417	254 (61)
Yes	9	5 (56)	61	40 (66)	70	45 (64)
p value		0.2		>0.9		0.6
2001-2002						
No	40	8 (20)	436	292 (67)	488	306 (63)
Yes	6	4 (67)	74	61 (82)	81	66 (81)
p value		0.02		0.008		0.001

* Total includes people who did not report duration of drug injection.

WESTERN AUSTRALIA
1995-2002

Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.

Demographic characteristics	1995	1996	1997	1998	1999	2000	2001	2002
Number of sites	1	1	1	2	2	2	3	3
Response								
Nº surveyed	N = 30	N = 83	N = 48	N = 161	N = 86	N = 143	N = 164	N = 127
% response	29%	51%	28%	40%	43%	68%	57%	73 %
Sex (%)								
Males	18 (60)	51 (62)	26 (54)	97 (60)	53 (62)	101 (71)	100 (60)	90 (71)
Females	12 (40)	30 (36)	22 (46)	62 (38)	33 (38)	42 (29)	62 (38)	37 (29)
Transgender	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	2 (2)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Sexual identity (%)								
Heterosexual	23 (77)	68 (82)	38 (79)	123 (77)	65 (76)	105 (74)	131 (80)	99 (78)
Bisexual	5 (17)	9 (11)	7 (15)	18 (11)	11 (13)	14 (10)	11 (7)	11 (9)
Gay/lesbian	2 (6)	5 (6)	3 (6)	15 (9)	6 (7)	15 (10)	8 (5)	7 (6)
Not reported	0 (0)	1 (1)	0 (0)	5 (3)	4 (4)	9 (6)	14 (8)	10 (8)
Age and duration of injection (years)								
Median age	27.5	27.5	27	28	28	28	29	33
Age range	16 – 43	16 – 43	20 – 51	15 – 54	17 – 51	16 – 49	15 – 55	14 – 53
Not reported	0	1	0	0	0	2	0	0
Median age 1st IDU	17	18	18	18	18	18	17	18
Age range	14 – 34	12 – 33	12 – 36	7 – 44	11 – 42	9 – 42	12 – 43	12 – 46
Not reported	0	4	0	6	2	12	7	5
Median years IDU	10.5	7	7	8	8	8	10	11
Range	<1 – 23	1 – 29	2 – 32	<1 – 27	<1 – 28	<1 – 28	<1 – 35	<1 – 35
Not reported	0	6	0	6	2	14	7	7
Aboriginal and Torres Strait Islander Origin (%)								
Yes	0 (0)	2 (2)	3 (6)	14 (9)	6 (7)	10 (7)	10 (6)	1 (1)
No	30 (100)	80 (97)	45 (94)	143 (89)	78 (91)	128 (90)	154 (94)	123 (97)
Not reported	0 (0)	1 (1)	0 (0)	4 (2)	2 (2)	5 (3)	0 (0)	3 (2)
Imprisonment last year (%)								
Yes	3 (10)	12 (14)	7 (15)	24 (15)	11 (13)	25 (18)	26 (16)	13 (10)
No	25 (83)	68 (82)	39 (81)	133 (83)	75 (87)	116 (81)	133 (81)	113 (89)
Not reported	2 (7)	3 (4)	2 (4)	4 (2)	0 (0)	2 (1)	5 (3)	1 (1)
Injected in prison (%)								
Yes	2 (67)	4 (33)	3 (43)	8 (33)	2 (18)	10 (40)	14 (54)	4 (31)
Frequency of injection last month (%)								
Not last month	1 (3)	10 (12)	1 (2)	16 (10)	5 (6)	7 (5)	9 (5)	5 (12)
Less than weekly	4 (13)	16 (19)	9 (19)	24 (15)	13 (15)	12 (9)	24 (15)	25 (20)
Weekly not daily	13 (44)	25 (30)	5 (10)	34 (21)	16 (19)	36 (25)	40 (25)	29 (23)
Daily or more	12 (40)	31 (38)	33 (69)	85 (53)	52 (60)	79 (55)	87 (53)	56 (43)
Not reported	0 (0)	1 (1)	0 (0)	2 (1)	0 (0)	9 (6)	4 (2)	2 (2)
Last drug injected (%)								
Amphetamine	10 (33)	12 (14)	6 (13)	35 (22)	16 (19)	33 (23)	92 (56)	50 (39)
Anabolic steroids	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	2 (2)
Benzos	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)	2 (1)	1 (1)
Buprenorphine	---	---	---	---	---	---	---	5 (4)
Cocaine	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	2 (1)	0 (0)
Heroin	13 (43)	56 (68)	32 (67)	101 (62)	57 (66)	71 (49)	24 (15)	25 (19)
Heroin + Cocaine	2 (7)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Methadone	0 (0)	0 (0)	2 (4)	0 (0)	2 (2)	3 (2)	4 (2)	6 (5)
Morphine	4 (13)	7 (8)	3 (6)	9 (5)	6 (7)	7 (5)	19 (12)	10 (8)
More than one	0 (0)	3 (4)	2 (4)	11 (7)	5 (6)	16 (11)	14 (9)	14 (11)
Other	1 (3)	3 (4)	2 (4)	1 (1)	0 (0)	1 (1)	3 (2)	9 (7)
Not reported	0 (0)	0 (0)	0 (0)	3 (2)	0 (0)	10 (7)	4 (2)	4 (3)

WESTERN AUSTRALIA

Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.

Injecting behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº injected last month	N = 29	N = 72	N = 47	N = 143	N = 81	N = 127	N = 151	N = 110
Places injected last month (%)*								
Own home	41 (87)	116 (81)	66 (81)	102 (80)	124 (82)	93 (85)		
Friend's home	28 (60)	78 (55)	39 (48)	70 (55)	75 (50)	42 (38)		
Dealer's home	15 (32)	41 (29)	26 (32)	28 (22)	49 (32)	21 (19)		
Street, park, beach	14 (30)	41 (29)	27 (33)	46 (36)	50 (33)	21 (19)		
Car	1 (2)	49 (34)	33 (41)	61 (48)	58 (38)	38 (35)		
Public toilet	17 (36)	45 (31)	24 (30)	41 (32)	41 (27)	27 (25)		
"Shooting" room	5 (11)	1 (1)	0 (0)	2 (2)	0 (0)	0 (0)		
Squat			6 (7)	10 (8)	14 (9)	5 (5)		
Use of new sterile needles & syringes last month (%)								
All injections	32 (68)	79 (55)	35 (43)	66 (52)	84 (55)	69 (63)		
Most of the time	14 (30)	42 (29)	32 (40)	45 (36)	50 (33)	31 (28)		
Half of the time	0 (0)	10 (7)	8 (10)	8 (6)	6 (4)	7 (6)		
Some of the time	1 (2)	7 (5)	3 (4)	3 (2)	6 (4)	2 (2)		
Not last month	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)		
Not reported	0 (0)	5 (4)	2 (2)	5 (4)	4 (3)	1 (1)		
Re-used another's syringe last month (%)								
None	20 (69)	57 (78)	37 (79)	106 (75)	55 (68)	83 (65)	108 (72)	91 (82)
One	3 (10)	4 (6)	4 (9)	6 (4)	1 (1)	13 (10)	11 (7)	5 (5)
Twice	2 (7)	4 (6)	2 (4)	13 (9)	10 (13)	8 (6)	15 (10)	5 (5)
3-5 times	2 (7)	3 (4)	3 (6)	6 (4)	6 (7)	9 (7)	8 (5)	4 (4)
>5 times	2 (7)	4 (6)	1 (2)	6 (4)	7 (9)	10 (8)	4 (3)	3 (3)
Not reported	0 (0)	0 (0)	0 (0)	6 (4)	2 (2)	4 (3)	5 (3)	2 (2)
Number of people syringe was re-used after last month (%)								
None	20 (69)	57 (79)	37 (79)	106 (75)	55 (68)	83 (65)	108 (72)	91 (82)
One	4 (14)	8 (11)	8 (17)	25 (16)	11 (14)	27 (22)	22 (14)	10 (9)
Two	4 (14)	6 (8)	2 (4)	4 (3)	6 (8)	5 (4)	5 (3)	2 (2)
Three to five	1 (3)	1 (2)	0 (0)	1 (1)	2 (2)	2 (2)	4 (3)	1 (1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	3 (4)	3 (2)	1 (1)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	3 (2)	4 (3)	3 (3)
Not reported	0 (0)	0 (11)	0 (0)	6 (4)	2 (2)	4 (3)	7 (4)	3 (3)
Relationship to people syringe was re-used after last month (%)*								
Regular sex partner	5 (11)	20 (14)	16 (20)	22 (17)	17 (11)	7 (6)		
Casual sex partner	1 (2)	1 (1)	0 (0)	2 (2)	2 (1)	0 (0)		
Close friend	2 (4)	12 (8)	8 (10)	11 (9)	15 (10)	6 (5)		
Acquaintance	1 (2)	1 (2)	7 (9)	4 (3)	9 (6)	3 (3)		
Other	1 (4)	0 (0)	6 (7)	4 (3)	1 (1)	1 (1)		
Equipment used after someone else last month (%)*								
Spoon		39 (48)	46 (36)	53 (35)	25 (23)			
Water		22 (27)	31 (25)	40 (26)	22 (20)			
Filter		21 (26)	30 (24)	36 (24)	19 (17)			
Tourniquet		22 (27)	20 (16)	25 (17)	21 (19)			
Drug mix		14 (17)	17 (13)	35 (23)	13 (12)			
Injected by someone else who'd already injected themselves or others last month (%)								
Yes		17 (21)	31 (25)	31 (20)	20 (19)			
No		62 (77)	90 (71)	114 (76)	86 (78)			
Not reported		2 (2)	5 (4)	6 (4)	3 (3)			

* More than one option could be selected.

Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.

Treatment for drug use	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 30	N = 83	N = 48	N = 161	N = 86	N = 143	N = 164	N = 127
Any treatment/therapy for drug use (%)								
No	13 (43)	37 (45)	13 (27)	57 (35)	26 (30)	48 (34)	53 (32)	39 (31)
Yes	17 (57)	46 (55)	33 (69)	102 (64)	60 (70)	93 (65)	111 (68)	87 (68)
Not reported	0 (0)	0 (0)	2 (4)	2 (1)	0 (0)	2 (1)	0 (0)	1 (1)
History of methadone treatment (%)								
Currently	11 (37)	20 (24)	20 (42)	35 (22)	36 (30)	28 (20)	37 (22)	22 (17)
Previously	5 (17)	15 (18)	4 (8)	23 (14)	13 (15)	29 (20)	39 (24)	37 (29)
Never	14 (47)	48 (58)	22 (46)	101 (63)	47 (55)	84 (59)	88 (54)	67 (53)
Not reported	0 (0)	0 (0)	2 (4)	2 (1)	0 (0)	2 (1)	0 (0)	1 (1)
History of other pharmacological therapy (%)								
Currently				16 (10)	4 (5)	9 (6)	17 (10)	22 (17)
Previously				9 (6)	9 (10)	36 (25)	30 (18)	23 (18)
Never				131 (81)	58 (68)	93 (65)	116 (71)	80 (63)
Not reported				5 (3)	15 (17)	5 (4)	1 (1)	2 (2)

Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.

Syringe acquisition	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed					N = 86	N = 143	N = 164	N = 127
From an NSP last month (%)								
Daily or almost daily				15 (18)	16 (11)	10 (6)	6 (5)	
A couple of times each week				21 (24)	45 (32)	44 (27)	38 (30)	
Less than weekly				20 (23)	35 (24)	45 (28)	32 (25)	
Once last month				15 (18)	15 (11)	38 (23)	27 (21)	
Not in the last month				14 (16)	23 (16)	25 (15)	21 (17)	
Not reported				1 (1)	9 (6)	2 (1)	3 (2)	
From a chemist last month (%)								
Daily or almost daily				5 (6)	5 (4)	7 (4)	3 (2)	
A couple of times each week				20 (23)	25 (17)	22 (13)	10 (8)	
Less than weekly				23 (27)	26 (18)	24 (15)	19 (15)	
Once last month				13 (15)	31 (22)	40 (25)	28 (220)	
Not in the last month				25 (29)	51 (35)	69 (42)	64 (50)	
Not reported				0 (0)	5 (4)	2 (1)	3 (2)	

WESTERN AUSTRALIA

Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.

Sexual behaviour	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 30	N = 83	N = 48	N = 161	N = 86	N = 143	N = 164	N = 127
Sex last month (%)								
No	11 (37)	31 (37)	16 (33)	42 (26)	26 (30)	44 (31)	45 (27)	33 (26)
Yes	19 (63)	50 (61)	30 (63)	116 (72)	59 (69)	98 (68)	118 (72)	89 (70)
Not reported	0 (0)	2 (2)	2 (4)	3 (2)	1 (1)	1 (1)	1 (1)	5 (4)
Condoms last sex (%)								
No	13 (43)	31 (37)	29 (61)	94 (58)	64 (74)	84 (59)	122 (75)	89 (70)
Yes	8 (27)	20 (24)	17 (35)	63 (39)	22 (26)	53 (37)	38 (23)	36 (28)
Not reported	9 (30)	32 (39)	2 (4)	4 (3)	0 (0)	6 (4)	4 (2)	2 (2)
Condom use with regular sex partner(s) last month (%)*								
No	27 (57)	13 (48)	58 (62)	39 (76)	52 (64)	53 (70)	44 (73)	
Sometimes	6 (13)	6 (22)	15 (16)	4 (8)	10 (12)	8 (10)	7 (12)	
Always	14 (30)	8 (30)	20 (22)	8 (16)	20 (24)	15 (20)	9 (15)	
Condom use with new sex partner(s) last month (%)*								
No	6 (35)	4 (31)	13 (33)	7 (35)	10 (28)	33 (53)	20 (51)	
Sometimes	0 (0)	1 (8)	9 (22)	3 (15)	7 (19)	9 (15)	8 (21)	
Always	11 (65)	8 (61)	18 (45)	10 (50)	19 (53)	20 (32)	11 (28)	
Condom use with casual sex partner(s) last month (%)*								
No		17 (38)	7 (32)	9 (23)	28 (47)	19 (51)		
Sometimes		7 (16)	1 (4)	9 (23)	12 (20)	5 (14)		
Always		21 (46)	14 (64)	21 (54)	20 (33)	13 (35)		
Duration of regular sexual relationship (%)**								
One month					5 (6)	4 (6)		
2 - 6 months					14 (17)	11 (17)		
6 - 12 months					10 (12)	7 (11)		
>12 months					53 (65)	44 (66)		
Sex work last month (%)								
No	26 (86)	76 (92)	36 (75)	136 (85)	78 (91)	126 (88)	152 (93)	115 (91)
Yes	2 (7)	7 (8)	8 (17)	20 (12)	8 (9)	15 (11)	8 (5)	8 (6)
Not reported	2 (7)	0 (0)	4 (8)	5 (3)	0 (0)	2 (1)	4 (2)	4 (3)
Condom use last sex work last month (%)**								
Yes	1 (100)	5 (71)	7 (88)	17 (89)	7 (88)	12 (92)	6 (86)	6 (75)

* Percentages exclude missing data (1996-2002) and participants reporting no regular, new or casual sex partner respectively in the previous month (1999-2002).

** Percentages exclude missing data.

Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.

	1995	1996	1997	1998	1999	2000	2001	2002
Nº surveyed	N = 30	N = 83	N = 48	N = 161	N = 86	N = 143	N = 164	N = 127
Previous HIV test (%)								
Yes, last year	13 (43)	62 (75)	35 (73)	107 (66)	62 (72)	104 (73)	100 (61)	75 (59)
> 1 year ago	11 (37)	8 (10)	11 (23)	34 (21)	19 (22)	23 (16)	46 (28)	37 (29)
Never tested	2 (7)	1 (1)	0 (0)	18 (11)	5 (6)	16 (11)	17 (10)	15 (12)
Not reported	4 (13)	12 (14)	2 (4)	2 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Self report HBV infection (%)								
Yes	6 (20)	18 (22)	12 (25)	27 (17)	16 (19)	19 (13)	25 (15)	26 (21)
No	23 (77)	65 (78)	32 (67)	112 (70)	59 (69)	115 (81)	118 (72)	85 (67)
Don't know	0 (0)	0 (0)	4 (8)	19 (12)	8 (9)	9 (6)	19 (12)	13 (10)
Not reported	1 (3)	0 (0)	0 (0)	3 (1)	3 (3)	0 (0)	2 (1)	3 (2)
Self report HBV vaccination (%)*								
Yes	12 (50)	24 (37)	11 (31)	58 (44)	36 (51)	63 (51)	71 (51)	53 (52)
No	11 (46)	40 (60)	20 (55)	48 (36)	27 (39)	52 (41)	46 (33)	39 (39)
Don't know	0 (0)	0 (0)	5 (14)	22 (16)	5 (7)	7 (6)	19 (14)	6 (6)
Not reported	1 (4)	1 (2)	0 (0)	6 (4)	2 (3)	2 (2)	3 (2)	3 (3)
Previous HCV test (%)								
Yes ever	25 (83)	63 (76)	---	---	---	---	---	---
Yes, last year	---	---	34 (71)	117 (73)	61 (71)	112 (78)	115 (70)	81 (70)
> 1 year ago	---	---	10 (21)	23 (14)	20 (23)	16 (11)	34 (21)	29 (21)
Never tested	3 (10)	17 (20)	2 (4)	18 (11)	5 (6)	14 (10)	15 (9)	17 (13)
Not reported	2 (7)	3 (4)	2 (4)	3 (2)	0 (0)	1 (1)	0 (0)	0 (0)
Any treatment for HCV (%)								
Interferon					N = 28	N = 49	N = 60	N = 38
Interferon+Ribavarin					2 (7)	1 (2)	5 (8)	1 (3)
Other					1 (4)	0 (0)	2 (3)	1 (3)
No treatment					0 (0)	3 (6)	2 (3)	1 (3)
Not reported					25 (89)	43 (88)	50 (84)	35 (91)
Current treatment for HCV								
Interferon					N = 1	N = 2	N = 2	N = 1
Interferon+Ribavarin					0	0	1	0
Other					1	0	1	0
					0 (0)	2 (4)	1 (2)	0 (0)

* Number (percentage) among participants not reporting HBV infection.

WESTERN AUSTRALIA

HIV antibody prevalence

Table 7: HIV antibody prevalence according to year of survey and sex.

Year of survey	Males		Females		Nº tested	Total
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)		
1995	14	2 (14.3)	10	0 (0.0)	24	2 (8.3)
1996	51	1 (2.0)	30	0 (0.0)	83	1 (1.2)
1997	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
1998	76	1 (1.3)	48	1 (2.1)	126	2 (1.6)
1999	53	0 (0.0)	32	0 (0.0)	85	0 (0.0)
2000	56	0 (0.0)	19	0 (0.0)	75	0 (0.0)
2001*	83	0 (0.0)	49	0 (0.0)	134	0 (0.0)
2002	87	0 (0.0)	36	0 (0.0)	123	0 (0.0)

* One female respondent self reported HIV infection, was antibody positive on ELIZA test but there was insufficient sample for confirmatory testing

Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.

Sexual identity	Males		Females		Nº tested	Total
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)		
1995-1998						
Heterosexual	129	1 (0.8)	66	1 (1.5)	197	2 (1.0)
Bisexual	9	0 (0.0)	17	0 (0.0)	27	0 (0.0)
Homosexual	12	3 (25.0)	11	0 (0.0)	23	3 (13.4)
p value		<0.001		0.8		<0.001
1999-2002						
Heterosexual	---	---	---	---	---	---
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---

Table 9: HIV antibody prevalence according to year of survey, age group and sex.

Age group	Males		Females		Nº tested	Total
	Nº tested	Nº with HIV (%)	Nº tested	Nº with HIV (%)		
1995-1998						
<25 years	46	0 (0.0)	45	1 (2.2)	91	1 (1.1)
25 + years	106	4 (3.8)	50	0 (0.0)	160	4 (2.5)
p value		0.2		0.3		0.4
1999-2002						
<25 years	---	---	---	---	---	---
25 + years	---	---	---	---	---	---
p value	---	---	---	---	---	---

HCV antibody prevalence

Table 10: HCV antibody prevalence according to year of survey and sex.

Year of survey	Males		Females		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995	13	6 (46)	10	5 (50)	23	11 (48)
1996	47	17 (37)	30	13 (42)	78	32 (41)
1997	12	6 (50)	7	3 (43)	19	9 (47)
1998	76	32 (42)	48	19 (40)	126	52 (41)
1999	53	28 (53)	32	15 (47)	85	43 (51)
2000	57	27 (47)	21	5 (24)	78	32 (41)
2001	84	49 (58)	51	24 (47)	137	75 (55)
2002	87	34 (39)	37	19 (51)	124	53 (43)
χ^2 trend p value		0.5		0.5		0.4

Table 11: HCV antibody prevalence according to year of survey, age group and sex.

Age group	Male		Female		Total *	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1998						
< 25 years	44	6 (14)	45	11 (24)	89	17 (19)
25 + years	103	55 (53)	50	29 (58)	157	86 (55)
Total	147	61 (42)	95	40 (42)	246	103 (42)
p value		<0.001		0.001		<0.001
1999-2000						
< 25 years	27	9 (33)	18	3 (17)	45	12 (27)
25 + years	83	46 (55)	35	17 (49)	118	63 (53)
Total	110	55 (50)	53	20 (38)	163	75 (46)
p value		0.05		0.02		0.002
2001-2002						
< 25 years	39	11 (28)	26	4 (15)	65	15 (23)
25 + years	132	72 (55)	62	39 (63)	196	113 (58)
Total	171	83 (49)	88	43 (49)	261	128 (49)
p value		0.004		<0.001		<0.001

Table 12: HCV antibody prevalence according to year of survey, duration of drug injection and sex.

Duration of drug injection	Male		Female		Total ¹	
	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)
1995-1998						
< 3 years	17	1 (6)	22	5 (23)	30	6 (20)
3 to 5 years	22	5 (23)	18	3 (17)	40	8 (20)
6 to 10 years	52	15 (29)	19	8 (42)	73	24 (33)
10 + years	52	38 (73)	34	24 (71)	76	52 (68)
p value		<0.001		<0.001		<0.001
1999-2000						
< 3 years	8	2 (25)	9	0 (0)	17	2 (12)
3 to 5 years	23	6 (26)	12	5 (42)	35	11 (31)
6 to 10 years	31	11 (35)	14	4 (29)	45	15 (33)
10 + years	46	36 (78)	16	10 (63)	62	46 (74)
p value		<0.001		0.02		<0.001
2001-2002						
< 3 years	12	2 (17)	10	3 (30)	22	5 (23)
3 to 5 years	21	7 (33)	15	1 (7)	36	8 (22)
6 to 10 years	43	16 (37)	25	15 (60)	68	31 (46)
10 + years	89	58 (65)	34	24 (71)	125	84 (67)
p value		<0.001		<0.001		<0.001

* Total includes people whose sex was not reported or reported as transgender.

WESTERN AUSTRALIA
HCV ANTIBODY

Table 13: HCV antibody prevalence according to year of survey, and sexual identity.

Sexual identity	Nº tested	Nº with HCV (%)
1995-1998		
Heterosexual	194	82 (42)
Bisexual	27	10 (37)
Homosexual	22	10 (45)
p value		0.8
1999-2000		
Heterosexual	124	61 (49)
Bisexual	18	5 (28)
Homosexual	14	6 (43)
p value		0.2
2001-2002		
Heterosexual	206	105 (51)
Bisexual	23	7 (30)
Homosexual	13	5 (38)
p value		0.1

Table 14: HCV antibody prevalence according to year of survey and last drug injected.

Last drug injected	Nº tested	Nº with HCV (%)
1995-1998		
Amphetamine	51	11 (22)
Heroin	157	77 (49)
More than one	12	5 (42)
Other/not reported	27	10 (37)
p value		0.007
1999-2000		
Amphetamine	33	10 (30)
Heroin	99	52 (52)
More than one	13	3 (23)
Other/not reported	18	10 (56)
p value		0.04
2001-2002		
Amphetamine	124	57 (46)
Heroin	47	30 (64)
More than one	23	12 (52)
Other/not reported	67	29 (43)
p value		0.1

Table 15: HCV antibody prevalence according to year of survey and frequency of drug injection last month.

Frequency of drug injection last month	Nº tested	Nº with HCV (%)
1995-1998		
Less than daily	108	39 (36)
Daily or more	112	55 (49)
p value		0.05
1999-2000		
Less than daily	55	25 (45)
Daily or more	99	46 (46)
p value		0.9
2001-2002		
Less than daily	106	50 (47)
Daily or more	128	73 (57)
p value		0.1

Table 16: HCV antibody prevalence according to year of survey and re-use of someone else's syringe last month.

Re-used someone else's syringe last month	Nº tested	Nº with HCV (%)
1995-1998		
Yes	49	20 (41)
No	168	71 (42)
p value		0.9
1999-2000		
Yes	48	27 (56)
No	101	40 (40)
p value		0.06
2001-2002		
Yes	49	27 (55)
No	187	92 (49)
p value		0.5

Table 17: HCV antibody prevalence according to year of survey and imprisonment last year.

Imprisonment last year	Nº tested	Nº with HCV (%)
1995-1998		
Yes	38	18 (47)
No	202	80 (40)
p value		0.4
1999-2000		
Yes	22	14 (64)
No	141	61 (43)
p value		0.08
2001-2002		
Yes	35	25 (71)
No	221	102 (46)
p value		

Table 18: HCV antibody prevalence according to year of survey and sex work last month.

Sex work last month	Nº tested	Nº with HCV (%)
1995-1998		
Yes	23	15 (65)
No	215	85 (40)
p value		0.02
1999-2000		
Yes	19	10 (53)
No	142	65 (46)
p value		0.6
2001-2002		
Yes	15	9 (60)
No	239	114 (48)
p value		0.4

Methodological Notes

All clients attending Needle and Syringe Program (NSP) sites during one week in March 1995 (21 sites), June 1996 (20 sites), and October 1997 (22 sites), 1998 (32 sites), 1999 (34 sites), 2000 (35 sites), 2001 (38 sites) and 2002 (46 sites) were asked to complete a brief, self-administered questionnaire and provide a finger prick blood sample for HIV and hepatitis C antibody testing.

NSP sites were selected for large numbers of clients and representing all jurisdictions. NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey week to assess response rate and representativeness of the survey sample. Some clients visited the site more than once during the survey week. Consequently, it was also necessary to record whether each attendance at the NSP was the first that week for each client so that only one attendance per person was included in the response rate denominator. Information on sexual behaviour, history of injecting drug use and HIV and hepatitis C testing history was obtained in the questionnaire.

Capillary blood was obtained by finger prick using disposable lancet devices and cotton-fibre paper cards. The dried blood samples were kept at room temperature at survey sites and then couriered to a central laboratory every second or third day. HIV antibody was detected using Genetic Systems HIV-1 ELISA tests, and if reactive twice, Western blot confirmatory testing. A modified third generation enzyme immunoassay (Abbott HCV 3.0, Chicago II) was used to test for HCV antibody. A cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for anti-HCV if the optical density to cut off ratio was greater or equal to one on initial and subsequent test.

Further information is available in:

National Centre in HIV Epidemiology and Clinical Research (NCHECR) (2002). Annual Surveillance Report 2000: HIV/AIDS, hepatitis C and sexually transmissible infections in Australia.
www.med.unsw.edu.au/nchecr

MacDonald MA, Wodak AD, Dolan KA, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. *Med J Aust* 2000;172(2): 57-61.

MacDonald M & the Collaboration of Australian Needle Exchanges. HIV prevalence and incidence among injecting drug users attending needle and syringe exchanges in Australia, 1995-1997. *Australian HIV Surveillance Report* January 1998.

MacDonald M, Wodak A, Ali R, et al. HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Med J Aust* 1997; 166: 237-240.

NSP survey questionnaire



CONFIDENTIAL

NATIONAL NEEDLE EXCHANGE SURVEY

INSTRUCTIONS (please ask if you need help)

FOR THE QUESTIONNAIRE: Fill in this questionnaire and return it to the open section of the plastic bag.

FOR THE BLOOD SPOTS:



1. Push and set the orange cap on the grey lancet
2. Twist and remove the cap

3. Wash your hands. Shake your hand, squeeze the tip of your index finger and milk the finger to increase the blood flow to the tip of your finger. Repeat the hand shaking and finger squeezing a few times.


4. Clean your index finger with the alcohol swab.

5. Place your finger (back of hand down) onto a hard surface.

6. Prick the finger with the grey plastic lancet (this won't hurt too much!)



7. Place the first blotting paper circle against your finger **and completely fill the first circle with blood**. The blood will soak through the paper (do not place on table). Then, fill the other circles.



Handy hint: it is easier if someone else holds the card against the blood drops for you while you gently milk your finger with your other hand.

8. Put the blotting paper into the sealed section of the plastic bag and place the used lancet in the sharps container.

Thank you for your help.

*This is a national study, endorsed by AIVL and local user groups.
Study sites are in Adelaide, Alice Springs, Brisbane, Cairns, Canberra
Darwin, Gold Coast, Hobart, Melbourne, Nimbin,
Perth, Sydney, Sunshine Coast and Toowoomba.*

1. Are you	<input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Transgender	6b. How often did you use a NEW sterile needle and syringe last month ?
2. Do you identify as	<input type="checkbox"/> Gay/lesbian <input type="checkbox"/> Bisexual <input type="checkbox"/> Heterosexual	<input type="checkbox"/> All injections <input type="checkbox"/> Most of the time <input type="checkbox"/> Half of the time <input type="checkbox"/> Some of the time <input type="checkbox"/> Not last month
3. How old are you?	<input type="text"/> / <input type="text"/>	6c. Tick any equipment that you used after anyone else last month ?
4. How old were you when you first injected drugs?	<input type="text"/> / <input type="text"/>	<input type="checkbox"/> Spoon <input type="checkbox"/> Tourniquet <input type="checkbox"/> Water <input type="checkbox"/> Drug solution / mix <input type="checkbox"/> Filter
5. What was the last drug you injected?	<input type="checkbox"/> Heroin <input type="checkbox"/> Heroin+Cocaine together <input type="checkbox"/> Cocaine <input type="checkbox"/> Speed <input type="checkbox"/> Methadone <input type="checkbox"/> Morphine <input type="checkbox"/> Anabolic steroids <input type="checkbox"/> Other, specify _____	6d. How many TIMES last month did someone else inject you after injecting themselves or others?
6. How often did you inject last month ?	<input type="checkbox"/> More than 3 times most days <input type="checkbox"/> 2 to 3 times most days <input type="checkbox"/> Once a day <input type="checkbox"/> More than weekly, not daily <input type="checkbox"/> Less than weekly (on 1 to 6 days) <input type="checkbox"/> Not in the last month	<input type="checkbox"/> More than 10 times <input type="checkbox"/> 6 to 10 times <input type="checkbox"/> 3 to 5 times <input type="checkbox"/> Once or twice <input type="checkbox"/> None
<i>If you did NOT inject last month, skip the next column and go to Q7. If you did inject last month, please continue.</i>		6e. How many TIMES last month did you reuse a needle & syringe after someone else had used it, including your sex partner (even if it was cleaned)?
6a. Tick all the places where you injected last month .	<input type="checkbox"/> Own home <input type="checkbox"/> Friend's home <input type="checkbox"/> Dealer's home <input type="checkbox"/> Street, park or beach <input type="checkbox"/> Car <input type="checkbox"/> Public toilet <input type="checkbox"/> Commercial "shooting" room <input type="checkbox"/> Squat <input type="checkbox"/> Other, specify _____	<input type="checkbox"/> More than 5 times <input type="checkbox"/> 3 to 5 times <input type="checkbox"/> Twice <input type="checkbox"/> Once <input type="checkbox"/> None
		6f. How many PEOPLE , including your sex partner, did you re- use a needle & syringe after last month (even if cleaned)?
		<input type="checkbox"/> More than 5 people <input type="checkbox"/> 3 to 5 people <input type="checkbox"/> 2 people <input type="checkbox"/> 1 person <input type="checkbox"/> No one <input type="checkbox"/> Don't know how many
		6g. Who were these people?
		<input type="checkbox"/> Regular sex partner <input type="checkbox"/> Casual sex partner <input type="checkbox"/> Close friend <input type="checkbox"/> Acquaintance <input type="checkbox"/> No one <input type="checkbox"/> Other, please specify _____

7. Have you ever been on a methadone program?
- Yes, am on it now
 Yes, in the past
 No, never
8. Have you ever been on other drug substitution programs such as naltrexone, buprenorphine or LAAM?
- Yes, am on it now
 Yes, in the past
 No, never
9. Have you ever had any other therapies for your drug use such as detox, counselling, or N.A.?
- Yes No
10. Were you in prison in 1999?
- Yes No
- If YES, did you inject drugs in prison?
- Yes No
11. How would you describe your sexual activity **last month**?
- None
 Casual sex only
 Regular relationship
 Regular and casual sex
- If NO SEX last month, go to next column Q12*
- 11a. If **SEX LAST MONTH**, how many of your sex partners last month
- were female?
- were male?
- were new partners?
- 11b. Did you use condoms in the **last month** with your:
- Regular** sex partner(s)?
- No Every time
 Sometimes No Regular partner
- Casual** sex partner(s)?
- No Every time
 Sometimes No Casual partner
- New** sex partner(s)?
- No Every time
 Sometimes No New partner

12. Did you use condoms the **last time** you had sex?
- Yes No
13. Have you been paid for sex in the **last month**?
- Yes No
- If YES, did you use condoms the **last time** you were paid for sex?
- Yes No
14. Have you ever been tested for HIV?
- Yes, in the last year
 Yes, more than a year ago
 Never tested
- If YES, what was the result of your last HIV test?
- Did not have HIV
 I have HIV infection
 Don't know result
15. Have you been tested for hepatitis C?
- Yes, in the last year
 Yes, more than a year ago
 Never tested
- If YES, what was the result of your last hep C test?
- Did not have hep C
 I have hep C
 Don't know result
- If you have hep C, answer questions 16a & 16b below. If you do not have hep C go to the next page Q17.*
- 16a. If you have hep C, what year did you find out?
- 16b. If you have hep C, have you had any treatment for your hep C?
- No
 Yes, interferon
 Yes, interferon + ribavirin
 Other, specify
- If YES, are you on treatment now?
- No
 Yes, interferon
 Yes, interferon + ribavirin
 Other

17. Have you ever had hep B infection?

- Yes
- No
- Not sure

18. Have you ever had hep B vaccination?

- Yes
- No
- Not sure

19. Do you have any tattoos?

- Yes
- No

If YES, were any done

In the last 12 months? Yes No

If tattooed in the last 12 months,
where did you get the tattoo done?
(more than one may be ticked)

- Parlour / professional
- Friend
- Prison
- Other, specify

20. Do you have any body/ear piercings?

- Yes
- No

If YES, were any done

In the last 12 months? Yes No

If piercings in the last 12 months,
where did you get them done?
(more than one may be ticked)

- Parlour / professional
- Friend
- Prison
- Other, please specify

If NOT by parlour / professional, had
anyone else used the needle before
you? Yes No

21. Have you been living in this city/town for at
least the last 6 months?

- Yes
- No

22. What was the main language spoken at home
by your parents?

23. In which country were you borne?

- Australia
- Other, please specify

24. When were you born? _____ / _____
month year

25. Are you of Aboriginal or Torres Strait
Islander origin? Yes No

26. How many TIMES last month did you get
needles & syringes from a chemist ?

- Daily or almost daily
- A couple of times each week
- Less than weekly (2 to 5 times)
- Once last month
- Not in the last month

27. How many TIMES last month did you get
needles & syringes at a needle exchange?

- Daily or almost daily
- A couple of times each week
- Less than weekly (2 to 5 times)
- Once last month
- Not in the last month

28. Have you been in this survey before?

- Yes
- No

29. What are the first two
letters of your first
name?

--	--

30. What are the first two
letters of your last name?

--	--

Thank you for doing
the survey

All questions are voluntary. The name code is included because the survey is repeated each year to see how drug use changes over time. We cannot identify you from the code. If you have been in the survey before, please use the same code. If you use initials other than your own, please use a code you will remember for next time.

Participating sites

		95	96	97	98	99	00	01	02
Australian Capital Territory									
ACT IV League		✓	✓						
Drug Referral Information Centre				✓	✓	✓	✓	✓	✓
New South Wales									
Albury	Base Hospital								✓
	Community Health Centre								✓
Cabramatta	Drug Intervention Services				✓	✓	✓	✓	✓
	Street Youth Program (ICON)				✓		✓	✓	✓
Canterbury REP IDU				✓	✓			✓	✓
Kings Cross	K2		✓	✓	✓	✓	✓	✓	✓
	Kirketon Road Centre	✓	✓	✓	✓	✓	✓	✓	✓
Kogarah NSP		✓	✓	✓	✓	✓	✓	✓	✓
Manly Exchange						✓	✓	✓	✓
Mt Druitt	West Area Adolescent Team								✓
Newcastle	Royal Newcastle Hospital								✓
Northern Rivers Health Service			✓	✓	✓	✓	✓	✓	✓
Port Kembla	First Step Program								✓
Redfern REP IDU			✓	✓	✓	✓	✓	✓	✓
Ryde Exchange					✓	✓	✓	✓	✓
Sydney Sexual Health									✓
Wentworth HIV & Sexual Health Service					✓	✓	✓	✓	✓
Western Sydney	Auburn					✓	✓	✓	✓
	Blacktown	✓	✓	✓	✓	✓	✓	✓	✓
	Parramatta	✓	✓	✓	✓	✓	✓	✓	✓
Northern Territory									
Alice Springs Life Choices Inc		✓	✓	✓	✓	✓	✓	✓	✓
Darwin HINT		✓	✓	✓	✓	✓	✓	✓	✓
Queensland									
Brisbane	Biala	✓	✓	✓	✓	✓	✓	✓	✓
	Bodyline	✓							
	QuIVAA	✓	✓	✓	✓		✓	✓	✓
Cairns	Base Hospital	✓	✓	✓	✓	✓	✓	✓	✓
Gold Coast	Dune (GAIN) Hospital	✓	✓	✓	✓	✓	✓	✓	✓
Ipswich Sexual Health									✓
Mackay Sexual Health									✓
Logan Youth									✓
Sunshine Coast SCIVAA						✓	✓	✓	✓
Toowoomba		✓	✓	✓	✓	✓	✓	✓	✓
South Australia									
Clovelly Park		✓							
Hindmarsh Centre							✓	✓	✓
Lyell McEwin									✓
Noarlunga Community Health Service					✓	✓	✓	✓	✓
Northern Metropolitan CHS & Shopfront		✓	✓	✓	✓	✓	✓	✓	✓
Parks CHS					✓	✓	✓	✓	✓
Port Adelaide CHS					✓	✓	✓	✓	✓
SAVIVE		✓	✓	✓	✓	✓	✓	✓	✓
Warinella Clinic					✓	✓	✓		
Tasmania									
Glenorchy NuFIT									✓
Launceston Sexual Health									✓
TasCAHRD		✓	✓	✓	✓	✓	✓	✓	✓
The Link (Youth Health Service, Hobart)									✓
User's Health Support League						✓			
Victoria									
Ballarat CHS		✓							
Dandenong Alcohol & Drug Service									✓
Geelong CHS		✓							
Melbourne Inner Needle Exchange		✓	✓	✓	✓	✓	✓	✓	✓
St Kilda NSP		✓	✓	✓	✓	✓	✓	✓	✓
SHARPS, Frankston		✓	✓	✓	✓				
Western Region WRAP				✓	✓	✓	✓	✓	✓
WA									
AIDS Council		✓	✓	✓	✓	✓	✓	✓	✓
User's Association	Bunbury							✓	✓
	Perth				✓	✓	✓	✓	✓

Acknowledgements

We would like to acknowledge the people who helped in the development and conduct of the NSP surveys, the clients who participated, the staff at the survey sites, and the laboratory staff at the Centre for Immunology, in particular Phillip Cunningham, Claire Harris and Brian Seckold. Thanks are also due to the project investigators and steering committee members: Jude Byrne; Nick Crofts; Kate Dolan; John Kaldor; Margaret Kelaher; Wendy Loxley; Tim Moore; Paul Sullivan; Ingrid van Beek and Alex Wodak.

Ethics approval was obtained from institutional Ethics Committees associated with investigators and with each NSP site. The NCHECR and the Australian NSP surveys are funded by the Commonwealth Department of Health and Ageing. Site expansion in New South Wales and Queensland was funded by the respective State Health Departments.

List of tables

NATIONAL	9
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.	9
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.	10
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.	11
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.	11
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.	12
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.	13
Table 7: HIV antibody prevalence according to year of survey and sex.	14
Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.	14
Table 9: HIV antibody prevalence according to year of survey, age group and sex.	15
Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.	16
Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex.	17
Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.	18
Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.	19
Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.	20
Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.	21
Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.	22
Table 17: HCV antibody prevalence according to year of survey and sex.	23
Table 18: HCV antibody prevalence according to year of survey, age group and sex.	23
Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.	24
Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.	25
Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.	26
Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month and duration of drug injection.	27
Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection.	28
Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection.	29

AUSTRALIAN CAPITAL TERRITORY	31
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.	31
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.....	32
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.	33
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.....	33
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.....	34
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.	35
Table 7: HIV antibody prevalence according to year of survey and sex.....	36
Table 8: HIV antibody prevalence according to sexual identity, 1995-2002.....	36
Table 9: HIV antibody prevalence according to age group, 1995-2002.	36
Table 10: HIV antibody prevalence according to duration of drug injection, 1995-2002.	36
Table 11: HIV antibody prevalence according to last drug injected, 1995-2002.	36
Table 12: HIV antibody prevalence according to frequency of drug injection last month, 1995-2002.	36
Table 13: HIV antibody prevalence according to reuse of someone else's syringe last month, 1995-2002.	36
Table 14: HIV antibody prevalence according to imprisonment last year, 1995-2002.	36
Table 15: HIV antibody prevalence according to condom use last sex, 1995-2002.....	36
Table 16: HIV antibody prevalence according to sex work last month, 1995-2002.....	36
Table 17: HCV antibody prevalence according to year of survey and sex.	37
Table 18: HCV antibody prevalence according to year of survey, age group and sex.....	37
Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.	38
Table 20: HCV antibody prevalence according to year of survey and last drug injected.....	39
Table 21: HCV antibody prevalence according to year of survey and frequency of drug injection last month.....	39
Table 22: HCV antibody prevalence according to year of survey and re-use of someone else's syringe last month.....	39
Table 23: HCV antibody prevalence according to year of survey and imprisonment last year.....	39
Table 24: HCV antibody prevalence according to year of survey and sex work last month.....	40

NEW SOUTH WALES	41
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey	41
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey	42
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey	43
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey	43
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey	44
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey	45
Table 7: HIV antibody prevalence according to year of survey and sex	46
Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex	46
Table 9: HIV antibody prevalence according to year of survey, age group and sex	47
Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex	48
Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex	49
Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex	50
Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex	51
Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex	52
Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex	53
Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex	54
Table 17: HCV antibody prevalence according to year of survey and sex	55
Table 18: HCV antibody prevalence according to year of survey, age group and sex	56
Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex	57
Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection	58
Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection	59
Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month and duration of drug injection	60
Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection	61
Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection	62

NORTHERN TERRITORY.....	63
Table 1: Number (percent) and age of respondents according to demographic characteristics and year of survey.....	63
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.....	64
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.....	65
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.....	65
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.....	66
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.....	67
Table 7: HIV antibody prevalence according to year of survey and sex.....	68
Table 8: HIV antibody prevalence according to sexual identity among males, 1995-2002.....	68
Table 9: HIV antibody prevalence according to age group among males, 1995-2002.....	68
Table 10: HIV antibody prevalence according to duration of drug injection among males, 1995-2002.....	68
Table 11: HIV antibody prevalence according to last drug injected among males, 1995-2002.....	68
Table 12: HIV antibody prevalence according to frequency of drug injection last month among males, 1995-2002.....	68
Table 13: HIV antibody prevalence according to reuse of someone else's syringe last month among males, 1995-2002.....	68
Table 14: HIV antibody prevalence according to imprisonment last year among males, 1995-2002.....	68
Table 15: HIV antibody prevalence according to condom use last sex among males, 1995-2002.....	68
Table 16: HCV antibody prevalence according to year of survey and sex.....	69
Table 17: HCV antibody prevalence according to year of survey, age group and sex.....	69
Table 18: HCV antibody prevalence according to year of survey, duration of drug injection and sex.....	70
Table 19: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.....	70
Table 20: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.....	71
Table 21: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month.....	71
Table 22: HCV antibody prevalence according to year of survey, imprisonment last year.....	71
Table 23: HCV antibody prevalence according to year of survey, sex work last month.....	71

QUEENSLAND	73
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey	73
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey	74
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey	75
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey	75
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey	76
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey	77
Table 7: HIV antibody prevalence according to year of survey and sex	78
Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex	78
Table 9: HIV antibody prevalence according to year of survey, age group and sex	79
Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex	80
Table 11: HIV antibody prevalence according to year of survey, type of drug last injected and sex	81
Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex	82
Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex	83
Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex	84
Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex	85
Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex	86
Table 17: HCV antibody prevalence according to year of survey and sex	87
Table 18: HCV antibody prevalence according to year of survey, age group and sex	88
Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex	89
Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection	90
Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection	91
Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe and last month and duration of drug injection	92
Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection	93
Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection	94

SOUTH AUSTRALIA	95
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey	95
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.....	96
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey	97
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.....	97
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.....	98
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.....	99
Table 7: HIV antibody prevalence according to year of survey and sex.....	100
Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.....	100
Table 9: HIV antibody prevalence according to year of survey, age group and sex.	101
Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.....	102
Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex.....	103
Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.	104
Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.	104
Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.	105
Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.	105
Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.	106
Table 17: HCV antibody prevalence according to year of survey and sex.	107
Table 18: HCV antibody prevalence according to year of survey, age group and sex.....	107
Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.....	108
Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.....	109
Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month.	110
Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month.	110
Table 23: HCV antibody prevalence according to year of survey, imprisonment last year.....	111
Table 24: HCV antibody prevalence according to year of survey, sex work last month.....	111

TASMANIA	113
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.	113
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.	114
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.	115
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.	115
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.	116
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.	117
Table 7: HIV antibody prevalence according to year of survey.	118
Table 8: HIV antibody prevalence according to sex and sexual identity, 1995-2002.....	118
Table 9: HCV antibody prevalence according to year of survey and sex.....	118
Table 10: HCV antibody prevalence according to age group and duration of drug injection, 1995-2002.	118
Table 11: HCV antibody prevalence according to frequency of drug injection last month, re-use of someone else's syringe last month, sex work last month and imprisonment last year, 1995-2002.	118

VICTORIA	119
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey	119
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.....	120
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey	121
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.....	121
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.....	122
Table 6: Number and (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.....	123
Table 7: HIV antibody prevalence according to year of survey and sex.....	124
Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.....	124
Table 9: HIV antibody prevalence according to year of survey, age group and sex.	125
Table 10: HIV antibody prevalence according to year of survey, duration of drug injection and sex.....	126
Table 11: HIV antibody prevalence according to year of survey, last drug injected and sex.....	127
Table 12: HIV antibody prevalence according to year of survey, frequency of drug injection last month and sex.	128
Table 13: HIV antibody prevalence according to year of survey, reuse of someone else's syringe last month and sex.	129
Table 14: HIV antibody prevalence according to year of survey, imprisonment last year and sex.	130
Table 15: HIV antibody prevalence according to year of survey, condom use last sex and sex.	131
Table 16: HIV antibody prevalence according to year of survey, sex work last month and sex.....	132
Table 17: HCV antibody prevalence according to year of survey and sex.	133
Table 18: HCV antibody prevalence according to year of survey, age group and sex.....	133
Table 19: HCV antibody prevalence according to year of survey, duration of drug injection and sex.	134
Table 20: HCV antibody prevalence according to year of survey, last drug injected and duration of drug injection.....	135
Table 21: HCV antibody prevalence according to year of survey, frequency of injection last month and duration of drug injection.....	136
Table 22: HCV antibody prevalence according to year of survey, reuse of someone else's syringe last month and duration of drug injection.	136
Table 23: HCV antibody prevalence according to year of survey, imprisonment last year and duration of drug injection.	137
Table 24: HCV antibody prevalence according to year of survey, sex work last month and duration of drug injection.	137

WESTERN AUSTRALIA 1995-2002.....	139
Table 1: Number (percentage) of respondents according to demographic characteristics and year of survey.....	139
Table 2: Number (percentage) of respondents according to injecting behaviour in the month before survey and year of survey.....	140
Table 3: Number (percentage) of respondents according to treatment for drug use and year of survey.....	141
Table 4: Number (percentage) of respondents according to site of syringe acquisition last month and year of survey.....	141
Table 5: Number (percentage) of respondents according to sexual behaviour in the month before survey and year of survey.....	142
Table 6: Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and treatment for HCV according to year of survey.....	143
Table 7: HIV antibody prevalence according to year of survey and sex.....	144
Table 8: HIV antibody prevalence according to year of survey, sexual identity and sex.....	144
Table 9: HIV antibody prevalence according to year of survey, age group and sex.....	144
Table 10: HCV antibody prevalence according to year of survey and sex.....	145
Table 11: HCV antibody prevalence according to year of survey, age group and sex.....	145
Table 12: HCV antibody prevalence according to year of survey, duration of drug injection and sex.....	145
Table 13: HCV antibody prevalence according to year of survey, and sexual identity.....	146
Table 14: HCV antibody prevalence according to year of survey and last drug injected.....	146
Table 15: HCV antibody prevalence according to year of survey and frequency of drug injection last month.....	146
Table 16: HCV antibody prevalence according to year of survey and re-use of someone else's syringe last month.....	146
Table 17: HCV antibody prevalence according to year of survey and imprisonment last year.....	147
Table 18: HCV antibody prevalence according to year of survey and sex work last month.....	147